WO2012088420A1 - Histone acetyltransferase modulators and usese thereof - Google Patents

Histone acetyltransferase modulators and usese thereof Download PDF

Info

Publication number
WO2012088420A1
WO2012088420A1 PCT/US2011/066851 US2011066851W WO2012088420A1 WO 2012088420 A1 WO2012088420 A1 WO 2012088420A1 US 2011066851 W US2011066851 W US 2011066851W WO 2012088420 A1 WO2012088420 A1 WO 2012088420A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
disease
cycloalkyl
body weight
Prior art date
Application number
PCT/US2011/066851
Other languages
French (fr)
Inventor
Yitshak Francis
Mauro Fa
Ottavio Arancio
Jole FIORITO
Shixian Deng
Donald W. Landry
Michal LUZAC
Yan Feng
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Priority to JP2013546423A priority Critical patent/JP6616057B2/en
Priority to CN201180066968.9A priority patent/CN103347392B/en
Priority to CA2822621A priority patent/CA2822621C/en
Priority to EP11850544.5A priority patent/EP2654428B1/en
Priority to US13/996,483 priority patent/US9969677B2/en
Priority to EP17207865.1A priority patent/EP3323813B1/en
Publication of WO2012088420A1 publication Critical patent/WO2012088420A1/en
Priority to US15/968,524 priority patent/US20180244603A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • Cognitive neurodegenerative disorders are characterized by synaptic dysfunction, cognitive abnormalities, and/or the presence of inclusion bodies throughout the CNS containing, for example, but not limited to native beta-amyloid fragments, native and phosphorylated Tau, native and phosphorylated alpha-synuclein, lipofuscin, cleaved
  • TARDBP TARDBP (TDB-43), in various percentages and in relation to the specific disease.
  • AD Alzheimer's disease
  • ⁇ amyloid ⁇ -peptides
  • ⁇ 42 amyloid-P-peptide 1-42
  • AD Alzheimer's disease
  • Cholinesterase inhibitors such as Razadyne® (galantamine), Exelon® (rivastigmine), Aricept® (donepezil), and Cognex® (tacrine) have been prescribed for early stages of Alzheimer's disease, and may temporarily delay or prevent progression of symptoms related to AD.
  • Razadyne® galantamine
  • Exelon® rivastigmine
  • Aricept® donepezil
  • Cognex® tacrine
  • Namenda® memantine
  • N-methyl D-aspartate (NMD A) antagonist is also prescribed to treat moderate to severe Alzheimer's disease; however only temporary benefits are realized.
  • Histone Acetyltransferases are involved in histone acetylation (leading to gene activation), chromosome decondensation, DNA repair and non-histone substrate modification.
  • the invention is directed to a compound of formula (I), wherein,
  • R a is H, Ci-Ce-alkyl, Ci-Ce-haloalkyl, O-(Ci-Ce-alkyl), 0-(Ci-C 6 -haloalkyl), halogen, CN, or
  • R b is H, Ci-Ce-alkyl, C 2 -C 6 -alkenyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -heteroalkyl, C 3 -C 8 - heterocycloalkyl, aryl, heteroaryl, 0-(Ci-C 6 -alkyl), 0-(C 3 -C8-cycloalkyl), 0-(C 2 -C6-alkenyl), 0-(C 3 -C 8 -heterocycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), N(R 10 )-(C 3 -C 8 -cycloalkyl), S-(Ci-C 6 - alkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , O-(C 3 -C 8 -cycloalkyl)-N(R 10 ) 2 , N(
  • R d is H, OH, -(Ci-Ce-alkyl), 0-(C 3 -C 8 -cycloalkyl), 0-(C 3 -C 8 -heterocycloalkyl), 0-(C 2 -C 6 - alkenyl), 0-(Ci-C 6 -alkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-R 3 , 0-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , -N(R 10 )-(Ci-C 6 -alkyl), -N(R 10 )-(C 2 -C 6 -alkenyl), -N(R 10 )-(C 3 -C 8 - cycloalkyl), -N(R 10 )-
  • W and Z are independently N or CR 1 ;
  • Y is N or CR 2 ;
  • R 1 is H, halogen, 0-(Ci-C 6 -alkyl), O-(C 2 -C 6 -alkyl)N(R 10 ) 2 ;
  • R 2 is H, Ci-Ce-alkyl, Ci-C 6 -haloalkyl, 0-(Ci-C 6 -alkyl), 0-(Ci-C 6 -haloalkyl), halogen, CN, or N0 2 ;
  • R 3 is cycloalkylamino, optionally containing a heteroatom selected from N(R 10 ), O and S;
  • R 10 is independently H, -(Ci-C 4 -alkyl), -(Ci-C 4 -haloalkyl), -(C 3 -C 8 -cycloalkyl), -(C 3 -C 8 - heterocycloalkyl), aryl or heteroaryl;
  • each n is independently an integer from 1-3, or a pharmaceutically acceptable salt or hydrate
  • R a is H, halogen, or haloalkyl
  • Y is CH, C-halogen, or C-CN
  • R b is H, 0-(Ci-C 2 -alkyl), S-(Ci-C 2 -alkyl), O-cyclopentyl, OCH 2 CH 2 N(CH 3 ) 2 , or
  • R d is H, Ci-C 5 -alkyl, OH, O-alkyl, OCH 2 CH 2 N(CH 3 ) 2 , CH 2 CH 2 CH 2 N(CH 3 ) 2 ,
  • W and Z are each CH, R b is ethoxy, R c is hydrogen, and R d is
  • W is C-OCH 2 CH 2 N(CH 3 ) 2 , Z is CH, R b is hydrogen, R c is hydrogen, and R d is hydrogen; or
  • W and Z are each CH, R b is cyclopentyloxy, R c is hydrogen, and R d is
  • W and Z are each CH, R b is -OCH 2 CH 2 N(CH 3 ) 2 , R c is -C(0)NH-(3-CF 3 , 4-Cl- phenyl), and R d is -OCH 2 CH 2 N(CH 3 ) 2 ; or
  • W is CH, Z is C-ethoxy, R b is ethoxy, R c is -C(0)NH-(3-CF 3 , 4-Cl-phenyl), and R d is hydrogen; or
  • W and Z are each CH, R b is -CH 2 CH 2 CH 2 N(CH 3 ) 2 , R c is -C(0)NH-(3-CF 3 , 4-Cl- phenyl), and R d is -CH 2 CH 2 CH 2 N(CH 3 ) 2 or hydrogen; or
  • W and Z are each CH, R b is ethoxy, R c is -C(0)NH-(3-CF 3 , 4-Cl-phenyl), and R d is hydrogen or -OCH 2 CH 2 N(CH 3 ) 2 ; or
  • W and Z are nitrogen, R b is ethoxy, R c is hydrogen, and R d is-OCH 2 CH 2 N(CH 3 ) 2 ; or when is Ar is not wherein R b is ethoxy, or Ar is
  • W and Z are each CH, R b is -Sethyl, R c is hydrogen, and R d is n- pentyl; or
  • R b is hydrogen, R c is hydrogen, and R a is -OCH 2 CH 2 N(CH 3 ) 2 ; or
  • R D is ethoxy, R c is hydrogen, and R d is -OCH 2 CH 2 N(CH 3 ) 2 ; or
  • W and Z are each CH, R b is -OCH 2 C(0)OR wherein R is H or alkyl, R c is hydrogen, and R d is -Sethyl; or when , Ar is not wherein W and Z are each CH, R b is -OCH 2 C(0)OR wherein R is H or alkyl, R c is hydrogen, and R d is -Sethyl; or when , Ar is not wherein W and Z are each CH, R b is -OCH 2 C(0)OR wherein R is H or alkyl, R c is hydrogen, and R d is -Sethyl; or when , Ar is not wherein W and Z are each CH, R b is -OCH 2 C(0)OR wherein R is H or alkyl, R c is hydrogen, and R d is -Sethyl; or when , Ar is not wherein W and Z are each CH, R b is -OCH 2 C(0)OR wherein R is H or alkyl, R
  • R b is ethoxy
  • R c is hydrogen
  • R d is -SCH 2 CH 2 N(CH 3 )2.
  • Ar is ;
  • R a is H, halogen, or haloalkyl
  • R b is H, 0-(Ci-C 6 -alkyl), 0-(C 3 -C 8 -cycloalkyl), 0-(C 2 -C 6 -alkenyl), 0-(C 3 -C 8 - heterocycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), N(R 10 )-(C 3 -C 8 -cycloalkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , O-(C 3 -C 8 -cycloalkyl)-N(R 10 ) 2 , N(R 10 )-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alky
  • R c is H, -(Ci-Ce-alkyl), or 0-(Ci-C 6 -alkyl);
  • R d is H, OH, Ci-Ce-alkyl, 0-(C 3 -C 8 -cycloalkyl), 0-(C 3 -C 8 -heterocycloalkyl), 0-(Ci-C 6 - alkyl), -0-(C 2 -C 6 -alkenyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-R 3 , 0-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , -N(R 10 )-(Ci-C 6 -alkyl), -N(R 10 )-(C 3 -C 8 -cycloalkyl), -N(R 10 )-(C 3 -C 8 -cycloalkyl), -N(R 10 )-(C 3
  • W and Z are CR 1 ;
  • Y is CR 2 ;
  • R 1 is H, halogen, 0-(Ci-C 6 -alkyl), O-(C 2 -C 6 -alkyl)N(R 10 ) 2 ;
  • R 2 is halogen or haloalkyl
  • R 3 is cycloalkylamino, optionally containing a heteroatom selected from N(R 10 ), O and S;
  • R 10 is independently H, -(Ci-C 4 -alkyl), -(Ci-C 4 -haloalkyl), -(C 3 -C 8 -cycloalkyl), -(C 3 -C 8 - heterocycloalkyl), aryl or heteroaryl;
  • n is an integer from 1-3, or a pharmaceutically acceptable salt thereof.
  • compounds of formula (I) have histone acetyltransferase (HAT) activity.
  • the compounds of formula (I) are HAT modulators.
  • the compounds of formula (I) are HAT activators.
  • the compounds of formula (I) are HAT inhibitors.
  • the compounds of formula (I) exhibit high selectivity for HAT and blood-brain-barrier (BBB) permeability.
  • the compounds of formula (I) exhibit high selectivity for HAT.
  • the compounds of formula (I) exhibit blood-brain-barrier (BBB) permeability.
  • Another aspect of the invention provides a method for screening compounds of formula (I) to treat conditions associated with accumulated amyloid-beta peptide deposits.
  • the method comprises (a) administering a compound of formula (I) to an animal model of amyloid-beta peptide deposit accumulation; and (b) selecting a compound of formula (I) that can modulate histone acetylation after administration in an animal model of amyloid-beta peptide deposit accumulation.
  • Another aspect of the invention provides a method for reducing amyloid beta ( ⁇ ) protein deposits in a subject wherein the method comprises administering to the subject an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I) thereby decreasing ⁇ protein deposits in the subject.
  • a compound of formula (I) is administered.
  • a composition comprising a compound of formula (I) is administered.
  • the subject exhibits abnormally elevated levels of amyloid beta plaques.
  • the subject is afflicted with Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy.
  • the ⁇ protein deposit comprises an ⁇ 40 isomer, an ⁇ 42 isomer, or a combination of isomers.
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight.
  • the composition crosses the blood brain barrier.
  • the compound is a compound of formula (I).
  • the compound is compounds 1-26, or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • Another aspect of the invention provides a method for treating Alzheimer's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I).
  • a compound of formula (I) is administered.
  • a composition comprising a compound of formula (I) is administered.
  • composition crosses the blood brain barrier.
  • the compound is a compound of formula (I).
  • the compound is compounds 1-26, or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • Another aspect of the invention provides a method for treating Alzheimer's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I).
  • a compound of formula (I) is administered.
  • a composition comprising a compound of formula (I) is administered.
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the
  • the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • Another aspect of the invention provides a method for increasing memory retention in a subject afflicted with a neurodegenerative disease, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I).
  • a compound of formula (I) is administered.
  • a composition comprising a compound of formula (I) is administered.
  • the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV- associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia,
  • ALD Adrenoleukodystrophy
  • Alcoholism Alexander's disease
  • Alper's disease Alzheimer's disease
  • Alper's disease Alzheimer's disease
  • Amyotrophic lateral sclerosis (Lou Gehrig's Disease)
  • Neuroborreliosis Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele- Richardson-Olszewski disease, Tabes dorsalis, or Toxic encephalopathy.
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some combination, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg
  • the composition crosses the blood brain barrier.
  • the compound is a compound of formula (I).
  • the compound is any of compounds 1-26 or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • Another aspect of the invention provides a method for increasing synaptic plasticity in a subject afflicted with a neurodegenerative disease, the method comprising administering to a subject a therapeutic amount of a composition that increases histone acetylation in the subject, wherein the composition comprises a compound of formula (I).
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some combination, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg
  • the composition crosses the blood brain barrier.
  • the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism,
  • Alexander's disease Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt- Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy,
  • synaptic plasticity comprises learning, memory, or a combination thereof.
  • synaptic plasticity comprises long term potentiation (LTP).
  • the compound is a compound of formula (I).
  • the compound is any of compounds 1-26 or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • Another aspect of the invention provides a method for ameliorating symptoms of Parkinson's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I).
  • a compound of formula (I) is administered.
  • a composition comprising a compound of formula (I) is administered.
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some combination, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg
  • the composition crosses the blood brain barrier.
  • the compound is any of compounds 1-26 or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • the symptoms of Parkinson's Disease comprise tremor, bradykinesia, dyskinesia, rigidity, postural instability, dystonia, akathisia, dementia, impaired gross motor coordination, or a combination of the listed symptoms.
  • the postural instability comprises impaired imbalance, impaired coordination, or a combination thereof.
  • Another aspect of the invention also provides a method for treating cancer in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered.
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight.
  • the composition crosses the blood brain barrier.
  • the cancer comprises B cell lymphoma, colon cancer, lung cancer, renal cancer, bladder cancer, T cell lymphoma, myeloma, leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic
  • lymphocytic leukemia acute lymphocytic leukemia, hematopoietic neoplasias, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, uterine cancer, renal cell carcinoma, hepatoma, adenocarcinoma, breast cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, ovarian cancer, primary or metastatic melanoma, squamous cell carcinoma, basal cell carcinoma, brain cancer, angiosarcoma, hemangiosarcoma, bone sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma
  • lymphangioendotheliosarcoma synovioma, testicular cancer, uterine cancer, cervical cancer, gastrointestinal cancer, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia, papillary adenocarcinomas, cystadenocarcinoma, bronchogenic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, lung carcinoma, epithelial carcinoma, cervical cancer, testicular tumor, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma,
  • the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof.
  • Another aspect of the invention provides a method for treating Huntington's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered.
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the
  • composition crosses the blood brain barrier.
  • the compound is any of compounds 1-26 or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • Another aspect of the invention provides for a method of treating a neurodegenerative disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I).
  • a compound of formula (I) is administered.
  • a composition comprising a compound of formula (I) is administered.
  • the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the
  • the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome,
  • ALD Adrenoleukodystrophy
  • Alcoholism Alexander's disease
  • Alper's disease Alzheimer's disease
  • Amyotrophic lateral sclerosis Lou Gehrig's Disease
  • Ataxia telangiectasia Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome
  • BSE Bovine spongiform encephalopathy
  • Frontotemporal lobar degeneration Huntington's disease, HIV-associated dementia,
  • Kennedy's disease Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren- Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, or Toxic encephalopathy.
  • synaptic plasticity comprises learning, memory, or a combination thereof.
  • synaptic plasticity comprises long term potentiation (LTP).
  • the compound is a compound of formula (I).
  • the compound is any of compounds 1-26 or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • Another aspect of the invention provides for a method of decreasing inclusion bodies in a subject afflicted with a neurodegenerative disorder, the method comprising administering to the subject an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I).
  • a compound of formula (I) is
  • composition comprising a compound of formula (I) is administered.
  • the inclusion bodies comprise beta-amyloid peptides, native and phosphorylated Tau proteins, native and phosphorylated alpha-synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof.
  • the subject exhibits abnormally elevated levels of amyloid beta plaques.
  • the composition crosses the blood brain barrier.
  • the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV- associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia,
  • Neuroborreliosis Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele- Richardson-Olszewski disease, Tabes dorsalis, or Toxic encephalopathy.
  • synaptic plasticity comprises learning, memory, or a combination thereof.
  • synaptic plasticity comprises long term potentiation (LTP).
  • the compound is a compound of formula (I).
  • the compound is any of compounds 1-26 or any combination thereof.
  • the compound increases histone acetylation.
  • histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.
  • histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
  • FIG. 1 is a schematic showing that CBP is recruited to act as a bridge between DNA- bound phosphorylated CREB and the basal transcription machinery located at the start site of transcription.
  • CBP acts as a HAT, making the chromatin more accessible and increasing the transcription of memory associated genes.
  • HDACs remove an acetyl group from histones, thus restricting access of the transcriptional machinery to the DNA (figure was modified from Lodish H., B.A., Zipursky LS., Matsudaira P., Baltimore D., Darnell J., Molecular Cell Biology. 4 ed. 2000, New York: W. H. Freeman and Company).
  • FIG. 2 is a schematic of histone acetylation and the role of HATs.
  • FIG. 3 is a schematic showing the role of a HDAC inhibitor (HDACi; e.g., TSA) in histone acetylation and deacetylation.
  • HDACi HDAC inhibitor
  • FIG. 4 is a schematic of the compound D/CTPB/CTB (FIG. 4A) and nemorosone (FIG. 4B) scaffolds.
  • FIG. 5 is an exemplary synthetic scheme for compounds (I-g). Modifications at C2, where Yis OH, or NH 2 . Modifications at C2 for compounds (I-g), where Y is O, or NH; R is alkyl, cycloalkyl, alkenyl, heterocycle, aryl, heteroaryl, alkylamino, or cycloalkylamino.
  • FIG. 6 is an exemplary synthetic scheme for compounds (I-h). Modifications at C6, where R is alkyl, cycloalkyl, alkenyl, heterocycle, aryl, heteroaryl, alkylamino, or
  • FIG. 7 are exemplary structures showing modifications at linker between I and II rings.
  • X is CO, R is H, alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, or substituted aryl and heteroaryl;
  • X is CH 2 , R is H;
  • X is CH 2 CO, R is H, Y is 0-3;
  • X is CO, R is H, Y is 1-3.
  • FIG. 8 is an exemplary structure showing modifications at the II ring, where R is a substituted aryl and heteroaryl for compound (1-1).
  • FIG. 9 is an exemplary structure showing modifications at the I ring.
  • R 2 is ethoxyl, R 3 is H, R 4 is methyl, R 5 is H;
  • R 2 is ethoxyl, R 3 is CI, R 4 is H, R 5 is CI;
  • R 2 is H, R 3 is ethoxyl, R 4 is H, R 5 is H;
  • R 2 is H, R 3 is H, R 4 is ethoxyl, R 5 is H.
  • FIG. 10 are drawings of molecular structures that are constrained, where Y is O, or NH; and where R is ethyl, or 2-(dimethylamino)ethyl.
  • FIG. 11 is a synthetic scheme for compound 5.
  • FIG. 12 shows the synthetic scheme for (I-d) compounds 3-alkyloxyphthalimide (FIG. 12A) and 3-aminophthalimide derivatives (FIG. 12B).
  • FIG. 13 shows in vitro measurements of HAT enzymatic activity for selected compounds.
  • the invention is directed to a compound of formula (I).
  • R a is H, Ci-Ce-alkyl, Ci-C 6 -haloalkyl, 0-(Ci-C 6 -alkyl), 0-(Ci-C 6 -haloalkyl), halogen, CN, or N0 2 ;
  • R b is H, Ci-Ce-alkyl, C 2 -C 6 -alkenyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -heteroalkyl, C 3 -C 8 - heterocycloalkyl, aryl, heteroaryl, 0-(Ci-C 6 -alkyl), 0-(C 3 -C8-cycloalkyl), 0-(C 2 -C6-alkenyl), 0-(C 3 -C 8 -heterocycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), N(R 10 )-(C 3 -C 8 -cycloalkyl), S-(Ci-C 6 - alkyl), 0-(C 2 -C 6 -alkyl)-N(R lu ) 2 , 0-(C 3 -C 8 -cycloalkyl)-N(R lu ) 2
  • R d is H, OH, -(Ci-Ce-alkyl), 0-(C 3 -C 8 -cycloalkyl), 0-(C 3 -C 8 -heterocycloalkyl), 0-(C 2 -C 6 - alkenyl), 0-(Ci-C 6 -alkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-R 3 , 0-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , -N(R 10 )-(Ci-C 6 -alkyl), -N(R 10 )-(C 2 -C 6 -alkenyl), -N(R 10 )-(C 3 -C 8 - cycloalkyl), -N(R 10 )-
  • W and Z are independently N or CR 1 ;
  • Y is N or CR 2 ;
  • R 1 is H, halogen, 0-(Ci-C 6 -alkyl), O-(C 2 -C 6 -alkyl)N(R 10 ) 2 ;
  • R 2 is H, Ci-Ce-alkyl, Ci-C 6 -haloalkyl, 0-(Ci-C 6 -alkyl), 0-(Ci-C 6 -haloalkyl), halogen, CN, or N0 2 ;
  • R 3 is cycloalkylamino, optionally containing a heteroatom selected from N(R 10 ), O and S;
  • R 10 is independently H, -(Ci-C 4 -alkyl), -(Ci-C 4 -haloalkyl), -(C 3 -C 8 -cycloalkyl), -(C 3 -C 8 - heterocycloalkyl), aryl or heteroaryl; and
  • R a is H, halogen, or haloalkyl
  • R b is H, Ci-Ce-alkyl, C 2 -C 6 -alkenyl, C 3 -C 8 -cycloalkyl, C 2 -C 6 -heteroalkyl, C 3 -C 8 - heterocycloalkyl, aryl, heteroaryl, 0-(Ci-C 6 -alkyl), 0-(C 3 -C 8 -cycloalkyl), 0-(C 2 -C6-alkenyl), 0-(C 3 -C 8 -heterocycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), N(R 10 )-(C 3 -C 8 -cycloalkyl), S-(Ci-C 6 - alkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , O-(C 3 -C 8 -cycloalkyl)-N(R 10 ) 2 , N
  • R d is H, OH, Ci-Ce-alkyl, 0-(C 3 -C 8 -cycloalkyl), 0-(C 3 -C 8 -heterocycloalkyl), 0-(C 2 -C 6 - alkenyl), 0-(Ci-C 6 -alkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-R 3 , 0-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , -N(R 10 )-(Ci-C 6 -alkyl), -N(R 10 )-(C 2 -C 6 -alkenyl), -N(R 10 )-(C 3 -C 8 - cycloalkyl), -N(R 10 )-(C 3
  • W and Z are independently N or CR 1 ;
  • Y is N or CR 2 ;
  • R 1 is H, halogen, 0-(Ci-C 6 -alkyl), O-(C 2 -C 6 -alkyl)N(R 10 ) 2 ;
  • R 2 is H, halogen, haloalkyl, -N0 2 or CN;
  • R 3 is cycloalkylamino, optionally containing a heteroatom selected from N(R 10 ), O and S;
  • R 10 is independently H, -(Ci-C 4 -alkyl), -(Ci-C 4 -haloalkyl), -(C 3 -C 8 -cycloalkyl), -(C 3 -C 8 - heterocycloalkyl), aryl or heteroaryl;
  • n is an integer from 1-3, or a pharmaceutically acceptable salt thereof; with the proviso that
  • R a is H, halogen, or haloalkyl
  • Y is CH, C-halogen, or C-CN
  • R b is H, 0-(Ci-C 2 -alkyl), S-(Ci-C 2 -alkyl), O-cyclopentyl, OCH 2 CH 2 N(CH 3 ) 2 , or
  • R d is H, Ci-Cs-alkyl, OH, O-alkyl, OCH 2 CH 2 N(CH 3 )2, CH 2 CH 2 CH 2 N(CH 3 ) 2 ,
  • Z is CH, C-0-(Ci-C 2 -alkyl), C-OCH 2 CH 2 N(CH 3 ) 2 ;
  • W and Z are each CH, R b is cyclopentyloxy, R c is hydrogen, and R d is
  • W and Z are each CH, R b is -OCH 2 CH 2 N(CH 3 ) 2 , R c is -C(0)NH-(3-CF 3 , 4-C1- phenyl), and R d is -OCH 2 CH 2 N(CH 3 ) 2 ; or
  • W is CH, Z is C-ethoxy, R b is ethoxy, R c is -C(0)NH-(3-CF 3 , 4-Cl-phenyl), and R d is hydrogen; or
  • W and Z are each CH, R b is -CH 2 CH 2 CH 2 N(CH 3 ) 2 , R c is -C(0)NH-(3-CF 3 , 4-Cl- phenyl), and R d is -CH 2 CH 2 CH 2 N(CH 3 ) 2 or hydrogen; or
  • W and Z are each CH, R b is ethoxy, R c is -C(0)NH-(3-CF 3 , 4-Cl-phenyl), and R d is hydrogen or -OCH 2 CH 2 N(CH 3 ) 2 ; or wherein W and Z are nitrogen, R b is ethoxy, R c is hydrogen, and R d is-OCH 2 CH 2 N(CH3) 2 ; or
  • R b not R c A Z A R d wherein W and Z are each CH, R b is -Sethyl, R c is hydrogen, and R d is n- pentyl; or
  • Ar is not wherein W is nitrogen, R b is -SCH 3 , R c is hydrogen, and R d is n-pentyl; or
  • R b is hydrogen, R c is hydrogen, and R d is -OCH 2 CH 2 N(CH 3 ) 2 ; or
  • R b is ethoxy, R c is hydrogen, and R d is -OCH 2 CH 2 N(CH 3 ) 2 ; or
  • W and Z are each CH, R b is methoxy, R c is hydrogen, and R d is -SCH 2 CH 2 N(CH 3 ) 2 ; or when wherein W and Z are each CH, R b is -OCH 2 C(0)OR wherein R is H or alkyl, R c is hydrogen, and R d is -Sethyl; or
  • R b is ethoxy
  • R c is hydrogen
  • R d is -SCH 2 CH 2 N(CH3)2.
  • the compound of formula (I) is not selected from the
  • R is H or alkyl
  • Ar is ;
  • R a is H, halogen, or haloalkyl
  • R b is H, 0-(Ci-C 6 -alkyl), 0-(C 3 -C 8 -cycloalkyl), 0-(C 2 -C 6 -alkenyl), 0-(C 3 -C 8 - heterocycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), N(R 10 )-(C 3 -C 8 -cycloalkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , O-(C 3 -C 8 -cycloalkyl)-N(R 10 ) 2 , N(R 10 )-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alky
  • R c is H, -(Ci-Ce-alkyl), or 0-(Ci-C 6 -alkyl);
  • R d is H, OH, Ci-Ce-alkyl, 0-(C 3 -C 8 -cycloalkyl), 0-(C 3 -C 8 -heterocycloalkyl), 0-(Ci-C 6 - alkyl), -0-(C 2 -C 6 -alkenyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-R 3 , 0-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , -N(R 10 )-(Ci-C 6 -alkyl), -N(R 10 )-(C 3 -C 8 -cycloalkyl), -N(R 10 )-(C 3 -C 8 -cycloalkyl), -N(R 10 )-(C 3
  • W and Z are CR 1 ;
  • Y is CR 2 ;
  • R 1 is H, halogen, 0-(d-C 6 -alkyl), O-(C 2 -C 6 -alkyl)N(R 10 ) 2 ;
  • R 3 is cycloalkylamino, optionally containing a heteroatom selected from N(R 10 ), O and S;
  • R 10 is independently H, -(Ci-C 4 -alkyl), -(Ci-C 4 -haloalkyl), -(C 3 -C 8 -cycloalkyl), -(C 3 -C 8 - heterocycloalkyl), aryl or heteroaryl;
  • n is an integer from 1-3, or a pharmaceutically acceptable salt thereof.
  • Ar is .
  • Ar is N-[0045]
  • R a is H, Ci-C 6 -alkyl, Ci-C 6 -haloalkyl, 0-(Ci-C 6 -alkyl), 0-(C C 6 -haloalkyl), halogen, CN, or N0 2 .
  • R a is Ci-C 6 -alkyl, Ci-C 6 - haloalkyl, 0-(Ci-C 6 -alkyl), 0-(Ci-C 6 -haloalkyl), halogen, CN, or N0 2 .
  • R a is Ci-C 3 -alkyl, Ci-C 3 -haloalkyl, 0-(Ci-C 3 -haloalkyl), halogen, CN, or N0 2 .
  • R a is H, halogen, or Ci-C 6 -haloalkyl.
  • R a is H, halogen, or Ci-C 3 -haloalkyl.
  • R a is halogen or Ci-C6-haloalkyl.
  • R a is halogen or Ci-C 3 -haloalkyl.
  • R a is Ci-C 6 - haloalkyl.
  • R a is Ci-C 3 -haloalkyl.
  • R a is CF 3 .
  • R b is H, 0-(C 2 -C 6 -alkyl), S-(C 2 -C 6 -alkyl), 0-(C 3 -C 8 - cycloalkyl), 0-(C 2 -C 6 -alkenyl), 0-(C 3 -C 8 -heterocycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), N(R 10 )- (C 3 -C 8 -cycloalkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , O-(C 3 -C 8 -cycloalkyl)-N(R 10 ) 2 , N(R 10 )-(C 2 -C 6 - alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-N(
  • R b is H, 0-(C 2 -C 6 -alkyl), S-(C 2 -C 6 -alkyl), 0-(C 3 -C 8 -cycloalkyl), 0-(C 2 -C 6 -alkenyl), 0-(C 3 -C 8 - heterocycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), N(R 10 )-(C 3 -C 8 -cycloalkyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , O-aryl, or O-heteroaryl.
  • R b is H, 0-(C 2 -C 6 -alkyl), S-(C 2 -C 6 -alkyl), O- (C 3 -C 8 -cycloalkyl), N(R 10 )-(Ci-C 6 -alkyl), or N(R 10 )-(C 3 -C 8 -cycloalkyl).
  • R b is H, 0-(C 2 -C 4 -alkyl), or N(R 10 )-(Ci-C 6 -alkyl).
  • R b is H or 0-(C 2 -C6-alkyl).
  • R b is H or 0-(C 2 -C 4 -alkyl). In some embodiments, R b is 0-(C 2 -C 4 -alkyl) or S-(C 2 -C 4 -alkyl). In some embodiments, R b is 0-(C 2 - C 4 -alkyl). In some embodiments, R b is O-ethyl, O-propyl, O-butyl, O-cyclopropyl, or O- cyclobutyl. In some embodiments, R b is O-ethyl, O-propyl, or O-butyl. In some
  • R b is O-ethyl
  • R c is H, -(Ci-C 6 -alkyl), or 0-(C 2 -C 6 -alkyl). In some embodiments, R c is H or -(Ci-C 6 -alkyl). In some embodiments, R c is H, or 0-(C 2 -C 6 -alkyl). In some embodiments, R c is H.
  • R d is H, OH, Ci-C 6 -alkyl, 0-(C 3 -C 8 -cycloalkyl), 0-(C 3 -C 8 - heterocycloalkyl), 0-(Ci-C 6 -alkyl), -0-(C 2 -C 6 -alkenyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 - alkyl)-R 3 , 0-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , -N(R 10 )-(Ci-C 6 -alkyl), -N(R 10 )-(C 3 - C 8 -cycloalkyl), -N(R 10 )-(C 3 -C 8 -heterocycloalkyl), -N(R 10 )-(
  • R d is 0-(C 3 -C 8 -cycloalkyl), 0-(C 3 -C 8 -heterocycloalkyl), 0-(Ci-C 6 - alkyl), -0-(C 2 -C 6 -alkenyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(C C 6 -alkyl)-R 3 , 0-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , -N(R 10 )-(Ci-C 6 -alkyl), -N(R 10 )-(C 3 -C 8 -cycloalkyl), -N(R 10 )-(C 3 -C 8 heterocycloalkyl), -N(R 10 )-(C 2 -C 6 -alkenyl), N(
  • R d is 0-(Ci C 6 -alkyl), -0-(C 2 -C 6 -alkenyl), O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(Ci-C 6 -alkyl)-R 3 , 0-(Ci-C 6 -alkyl)- R 3 , N(R 10 )-(C 1 -C 6 -alkyl)-R 3 , N(R 10 )-(C 2 -C 6 -alkyl)-N(R 10 ) 2 , -(C C 6 -alkyl )-N(R 10 ) 2 , O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl.
  • R d is O-(C 2 -C 6 -alkyl)-N(R 10 ) 2 -(Ci-C 6 -alkyl)-R 3 , 0-(C C 6 -alkyl)-R 3 , N(R 10 )-(Ci-C 6 -alkyl)-R 3 , N(R 10 )-(C 2 -C 6 -alkyl)- N(R 10 ) 2 , or -(Ci-C 6 -alkyl )-N(R 10 ) 2 .
  • R d is O-(C 2 -C 4 -alkyl)-N(R 10 ) 2 , (Ci-C 4 -alkyl)-R 3 , 0-(Ci-C 4 -alkyl)-R 3 , N(R 10 )-(Ci-C 4 -alkyl)-R 3 , N(R 10 )-(C 2 -C 4 -alkyl)- N(R 10 ) 2 , or -(Ci-C 4 -alkyl )-N(R 10 ) 2 .
  • R d is O-(C 2 -C 4 -alkyl)-N(R 10 ) 2 or 0-(Ci-C 4 -alkyl)-R 3 .
  • W and Z are independently N or CR 1 .
  • W is N.
  • Z is N.
  • W is CR 1 .
  • Z is CR 1 .
  • W and Z are both CR 1 .
  • W and Z are both N.
  • Ar and X together form
  • Ar and X together form
  • Ar and X together form
  • the compound of formul a (I) is
  • the compound of formula (I) is or
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-phenyl
  • the compound of formula (I) is, X
  • the compound of formula (I) is X
  • Y is N or CR 2 . In some embodiments, Y is CR 2 . In some embodiments, Y is N. [0063] In some embodiments, R 1 is H, halogen, 0-(Ci-C 6 -alkyl), or O-(C 2 -C 6 -alkyl)N(R 10 ) 2 . In some embodiments, R 1 is H or halogen. In some embodiments, R 1 is H. In some embodiments, R 1 is halogen. In some embodiments, R 1 is CI or F.
  • R 2 is H, Ci-C 6 -alkyl, Ci-C 6 -haloalkyl, 0-(Ci-C 6 -alkyl), 0-(Ci- C 6 -haloalkyl), halogen, CN, or N0 2 .
  • R 2 is H, Ci-C 6 -alkyl, Ci-C 6 - haloalkyl, 0-(Ci-C 6 -alkyl), 0-(Ci-C 6 -haloalkyl), halogen, CN, or N0 2 .
  • R 2 is H, Ci-C 6 -alkyl, Ci-C 6 -haloalkyl, 0-(Ci-C 6 -alkyl), 0-(Ci-C 6 -haloalkyl), halogen, CN, or N0 2 .
  • R 2 is Ci-C 3 -alkyl, Ci-C 3 -haloalkyl, 0-(Ci-C 3 -haloalkyl), halogen, CN, or N0 2 .
  • R 2 is H, halogen, Ci-C 6 -haloalkyl, N0 2 or CN.
  • R 2 is H, halogen, or Ci-C 6 -haloalkyl.
  • R 2 is H, halogen, or C 1 -C 3 - haloalkyl.
  • R 2 is halogen or Ci-C 6 -haloalkyl.
  • R 2 is halogen or Ci-C 3 -haloalkyl. In some embodiments, R 2 is Ci-C 6 -haloalkyl. In some embodiments, R 2 is halogen. In some embodiments, R 2 is Ci-C 3 -haloalkyl. In some embodiments, R 2 is CI, F, or CF 3 .
  • R 3 is cycloalkylamino, optionally containing a heteroatom selected from N(R 10 ), O and S. In some embodiments, R 3 is C 3 -C 8 -cycloalkylamino, optionally containing a heteroatom selected from N(R 10 ), O and S. In some embodiments, R 3 is C 3 -C 8 -cycloalkylamino, morpolinyl, thiomorpholinyl, or N-alkylpiperazinyl. In some embodiments, R 3 is piperidinyl, or N-alkylpiperazinyl.
  • R 10 is independently H, -(Ci-C 4 -alkyl), -(Ci-C 4 -haloalkyl), - (C 3 -C 8 -cycloalkyl), aryl or heteroaryl.
  • R 10 is independently H, -(Ci- C 4 -alkyl), or -(Ci-C 4 -haloalkyl).
  • R 10 is independently H or -(Ci-C 4 - alkyl).
  • R 10 is independently H or -(Ci-C 2 -alkyl). In some
  • R 10 is independently H or methyl. In some embodiments, R 10 is H.
  • the compound of formula (I) is a compound of formula (I-a), s wherein,
  • R a is H, halogen, or haloalkyl
  • R b is 0-(Ci-C 6 )-alkyl or S-(Ci-C 6 )-alkyl;
  • R d is (Ci-C 6 )-alkyl or 0-(Ci-C 6 )-alkyl-N(CH 3 ) 2 ;
  • Y is haloalkyl, C-CN, C-N0 2 , or N;
  • W is CH or N
  • Z is CH or N, or a pharmaceutically acceptable salt or hydrate thereof.
  • the compound of formula (I) is a compound of formula (I-b),
  • R a is haloalkyl
  • R 2 is CN
  • R b is 0-(Ci-C 6 )-alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
  • the compound of formula (I) is a compound of formula (I-c),
  • R b is H, or ethoxyl
  • W and Z are independently CH, C-Cl, or C-OEt;
  • R c is H, ethoxyl, or methyl; or a pharmaceutically acceptable salt or hydrate thereof.
  • R b is ethoxyl, W and Z are each CH, and R c is methyl.
  • R b is ethoxyl, W and Z are each C-Cl, and R c is H.
  • R b is H, W is ethoxyl, R c is H, and Z is CH.
  • R b is H, W and Z are each CH, and R c is ethoxyl.
  • the compound of formula (I) is , or a pharmaceutically acceptable salt or hydrate thereof.
  • the compound of formula (I) is compound (I-d), (I-d) , wherein R b is -O-ethyl, -0-CH 2 CH 2 N(CH 3 )2, -NH-ethyl, or -NH-CH 2 CH 2 N(CH 3 ) 2 , or a pharmaceutically acceptable salt or hydrate thereof.
  • the compound of formula (I) is compound (I-e),
  • R b is -O-ethyl, -0-CH 2 CH 2 N(CH 3 ) 2 , -NH-ethyl, or
  • the compound of formula (I) is compound (I-f),
  • R b is -O-ethyl, -0-CH 2 CH 2 N(CH 3 )2, -NH-ethyl, or -NH-CH 2 CH 2 N(CH 3 ) 2 , or a pharmaceutically acceptable salt or hydrate thereof.
  • the compound of formula (I) is compound (I-g): ! " ⁇ ) , whereinR d is -0-(d-C 6 )-alkyl, -NH-(Ci-C 6 )-alkyl, -O-
  • (C 2 -C 6 )-alkenyl -NH-(C 2 -C 6 )-alkenyl, -0-(C 3 -C 8 )-cycloalkyl, -NH-(C 3 -C 8 )-cycloalkyl, - 0-(C 3 -C8)-heterocycloalkyl, -NH-(C 3 -C8)-heterocycloalkyl, -O-aryl, -N-aryl, -O-heteroaryl, -N-heteroaryl, -O-(Ci-C 6 )-alkyl-N(R 10 ) 2 , -NH-(Ci-C 6 )-alkyl-N(R 10 ) 2 , -0-(Ci-C 6 -alkyl)-R 3 , or -NH-(Ci-C 6 -alkyl)-R 3 .
  • the compound of formula (I) is compound (I-h):
  • R b is -0-(Ci-C 6 )-alkyl, -0-(C 2 -C 6 )-alkenyl, -0-(C 3
  • the compound of formula (I) is compound (I-i):
  • R 1U is H, -(d-C 4 -alkyl), -(Ci-C 4 -haloalkyl), -(C 3 -C 8 cycloalkyl), -(C 3 -C 8 -heterocycloalkyl), aryl or heteroaryl.
  • R is H, - (Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-Cg-cycloalkyl), or
  • R 10 is H, -(Ci-C4-alkyl), or -(Ci-C4-haloalkyl).
  • R 10 is H, or -(Ci-C4-alkyl).
  • R 10 is -(Ci-C4-alkyl).
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • the compound of formula (I) is -j) wherein X is CH 2 CONH(CH 2 ) n , and n is 0-3.
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • the compound of formula (I) is / N ⁇ .
  • the compound of formula (I) is a pharmaceutically acceptable salt. In some embodiments, the compound of formula (I) is a hydrate.
  • HAT modulator encompasses, for example, compound of formula (I) and subgenera and/or species thereof.
  • the HAT modulator compound is a compound of formula (I).
  • the HAT modulator compound is a compound of formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j), (I-k), (I-l), or any combination thereof.
  • the compound of formula (I) is a compound of formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j), (I-k), (I-l), or any combination thereof.
  • the compound is any of compounds 1-26, or any combination thereof.
  • the compound of formula (I) is any of compounds 1-26, or any combination thereof.
  • the HAT modulator is a HAT activator.
  • the HAT modulator is a HAT inhibitor.
  • HAT modulator may also apply as used elsewhere herein.
  • the compound of formula (I) is a compound of formula (I-a). In some embodiments, the compound of formula (I) is a compound of formula (I-b). In some embodiments, the compound of formula (I) is a compound of formula (I-c). In some embodiments, the compound of formula (I) is a compound of formula (I-d). In some embodiments, the compound of formula (I) is a compound of formula (I-e). In some embodiments, the compound of formula (I) is a compound of formula (I-f). In some embodiments, the compound of formula (I) is a compound of formula (I-g). In some embodiments, the compound of formula (I) is a compound of formula (I-h).
  • the compound of formula (I) is a compound of formula (I-i). In some embodiments, the compound of formula (I) is a compound of formula (I-j). In some embodiments, the compound of formula (I) is a compound of formula (I-k). In some embodiments, the compound of formula (I) is a compound of formula (1-1). Each of the embodiments of formula (I) may be combined with one or more other embodiments of formula (I) to generate further embodiments of formula (I).
  • AD Alzheimer's disease
  • ⁇ -amyloid a peptide that is present in high amounts in the disease
  • LTP long-term potentiation
  • Epigenetics is defined as the mechanism that changes gene expression by 'marking' DNA or its associated proteins, through processes such as DNA methylation and histone (H) modification, without changing the DNA sequence itself (Biochem J, 2001. 356(Pt 1): p. 1-10; herein incorporated by reference in its entirety). Modification of histones by, for example, the addition or removal of acetyl or methyl functional groups causes the chromatin structure to open or close, so that the information contained within the DNA is made more or less accessible to transcription factors. Deregulation of one of the epigenetic mechanisms may lead to memory disruption.
  • HDAC inhibitors have been shown to enhance memory in mice (Nature 459, 55-60 (7 May 2009); herein incorporated by reference in its entirety). Although clinical trials of several HDAC inhibitors are currently underway to try to prevent deacetylation, the alternative strategy of increasing histone acetylation by activating HAT has not been significantly explored.
  • Histone acetylation is discussed in, for example, U.S. Patent Publication Nos. 2010/0166781; 2010/0144885; 2009/0076155; Neuroscience 2011, 194, 272-281; and J. Phys. Chem B 2007, 111(17), 4527-4534 (each of which herein incorporated by reference in its entirety).
  • HAT activators represent a new class of compounds that may effectively counteract the disease progression. Recently, a novel HAT activator has been demonstrated to improve contextual learning in healthy mice (WO 2011/072243; herein incorporated by reference in its entirety).
  • the invention comprises compounds that show comparable positive effects, but have improved drug-like characteristics.
  • HDACs histone deacetylases
  • the pleiotropic effect of nonspecific HDAC inhibition can hamper the therapeutic potential of HDAC inhibitors (J Virol, 2001. 75(4): p. 1909-17; J Virol, 2003. 77(21): p. 11425-35; Biochemistry. 2008, Vanderbilt: Arlington, p. 167; PLoS One, 2009. 4(8): p. e6612; each of which herein incorporated by reference in its entirety).
  • new HAT activators will be designed and synthesized which can treat AD; compounds with high affinity and good selectivity for selective HAT activators will be identified that target specifically CBP and PCAF; HAT activators will be assessed as to whether they have a good pharmacokinetic (PK) profile and are safe; select HAT activators will be examined for their ability to rescue synaptic dysfunction in APP/PS1 mice; and HAT activators will be further screened to determine beneficial effects against cognitive abnormalities in APP/PS1 mice.
  • PK pharmacokinetic
  • HDAC inhibitors enhance LTP and contextual fear memory, a form of associative memory in which animals must associate a neutral stimulus with an aversive one ⁇ J Biol Chem, 2004. 279(39): p. 40545-59; hereby incorporated by reference in its entirety). Also, memory and LTP deficits of CBP +/ mice were reversed by HDAC inhibition ⁇ Neuron, 2004. 42(6): p. 947-59; hereby incorporated by reference in its entirety).
  • HDAC inhibitor TSA ameliorates LTP and contextual fear conditioning (FC) in the double Tg APP(K670M:N671L)/PS1(M146L, line 6.2) (APP/PS1) mouse model of amyloid deposition (J Alzheimer s Dis, 2009. 18(1): p. 131-9; hereby incorporated by reference in its entirety).
  • FC LTP and contextual fear conditioning
  • HATs can be divided in two main groups, the nuclear HATs and cytoplasmic HATs (Biochim Biophys Acta, 2009. 1789(1): p. 58-68; hereby incorporated by reference in its entirety.
  • Nuclear A-type HATs can be grouped into at least 4 different families based on sequence conservation within the HAT domain: Gcn5 and p300/CBP associated factor (PCAF), MYST (MOZ, Ybf2/ Sas3, Sas2 and Tip60), p300 and CBP (named for the two human paralogs p300 and CBP) and Rttl09.
  • HAT activators can be a viable approach to enhance histone acetylation.
  • Two scaffolds for HAT activators have been identified. The first one includes CTPB and its derivative CTB ⁇ JPhys Chem B, 2007. 111(17): p. 4527-34; J Biol Chem, 2003. 278(21): p. 19134-40; each hereby incorporated by reference in its entirety). The second one includes only one compound, nemorosone ⁇ Chembiochem. 11(6): p. 818-27; hereby incorporated by reference in its entirety).
  • CTPB/CTB were found to be insoluble and membrane -impermeable ⁇ JPhys Chem B, 2007. 111(17): p.
  • CTPB has unfavorable characteristics to be used in CNS diseases (such as, for example, MW equal to 553.29, clogP equal to 12.70) and the clogP of CTB is 5.13.
  • Nemorosone has a MW of 502 and a clogP of 8.42.
  • Compounds that target CBP and PCAF can be useful in treatment of CNS disorders such as, for example, AD, as their endogenous expression is reduced following ⁇ elevation.
  • HATs share a highly conserved motif containing an acetyl-CoA binding site. HATs can be involved in the pathology of cancer, asthma, neurodegenerative diseases and viral infection. HAT activators have been reported, but many compounds are neither soluble nor membrane permeant, which makes them poor drug candidates.
  • the invention provides for compounds with histone acetyltransferase activity.
  • the compounds are HAT activators.
  • the compounds are HAT inhibitors.
  • the compounds have good HAT activation potency, high selectivity, reasonable
  • these compounds can be used as therapy with decreased side effects for AD patients.
  • the compounds improve cognition or memory in AD and Alzheimer' s-like pathologies, as well as minimize the side effects for subjects afflicted with other neurodegenerative diseases.
  • the compounds of the invention can also be developed as anti-cancer therapies.
  • acylation of histone proteins increases gene expression in a subject resulting in enhanced memory and cognition.
  • the invention provides for the utilization of HAT agonists as memory enhancers in normal subjects (for example, a subject not afflicted with a
  • the invention provides for the utilization of HAT agonists as memory enhancers in aging subjects (for example, a subject that is greater than about 55 years old). In some embodiments, the invention provides for the utilization of HAT agonists as memory enhancers for other conditions associated with cognitive decrease/impairment.
  • conditions associated with cognitive decrease/impairment include a variety of syndromes associated with mental retardation and syndromes associated with learning disabilities, Parkinson's disease, Pick's disease, a Lewy body disease, amyotrophic lateral sclerosis, Huntington's disease,
  • Creutzfeld- Jakob disease Down syndrome, multiple system atrophy, neuronal degeneration with brain iron accumulation type I (Hallervorden-Spatz disease), pure autonomic failure, REM sleep behavior disorder, mild cognitive impairment (MCI), cerebral amyloid angiopathy (CAA), mild cognitive deficits, aging, vascular dementias mixed with
  • Alzheimer's disease a neurodegenerative disease characterized by abnormal amyloid deposition, and any combination thereof.
  • Eukaryotic DNA is highly organized and packaged into the nucleus.
  • the organization and packaging are achieved through the addition of proteins, including core histones H2A, H2B, H3 and H4, which form a complex structure, the chromatin, together with DNA (See, for example, WO 2011/072243 and references cited therein).
  • the modification of core histones is of fundamental importance to conformational changes of the chromatin.
  • the level of acetylation is related to transcription activity, and then the acetylation induces an open chromatin confirmation that allows the transcription machinery access to promoters.
  • Histone deacetylase HDAC
  • histone acetyltransferase HAT
  • Chromatin acetylation correlates with transcriptional activity (euchromatin)
  • deacetylation correlates with gene silencing.
  • acetylation of H3 in area CA1 of the hippocampus an area in the brain that plays an important role in long-tem memory
  • inhibiting HDAC may manipulate changes in the chromatin and enhance the formation of long-tem memory.
  • Deregulation of these mechanisms may lead to the disruption of memory-associated gene expression, resulting in a number of syndromes associated with mental retardation.
  • the DNA is firstly wrapped around an octamer complex of histones (H) to form nucleosomal units, giving the appearance of beads on a string ⁇ Nature, 2001. 409(6822): p. 860-921; herein incorporated by reference in its entirety).
  • these nucleosomal units fold into a higher-order chromatin fiber ⁇ Cell, 1999.
  • Each histone-octamer complex contains two copies of histones H3 and H4 bordered by two copies of histones 2A and 2B ⁇ Cell, 1999. 98(3): p.
  • HI and its avian variant H5 are linker histones that bind the nucleosome and both the entry and exit sites of the DNA, thus locking the DNA into place and allowing the formation of higher order structure. Every histone has a globular domain, which mediates histone-histone interactions, and an N-terminal 'tail' extension. The histone cores and in particular their tails, are targets for a considerable number of covalent modifications, such as acetylation, ubiquitination, sumoylation, phosphorylation,
  • Histone modifications associated with active gene transcription such as H3 Lys4 methylation and H3 Lys56 acetylation, were found to lead to gene expression.
  • histone modifications associated with the inactivation of gene transcription such as H3 Lys27 methylation and H2A Lysl 19 ubiquitination were found to cause gene silencing.
  • Histones 2B, 3 and 4 have been shown to be involved in memory processes ⁇ Nature, 2007. 447(7141): p. 178-82; Neuron, 2004.
  • Histone modifications and their combinations can be involved in gene regulation by modifying the chromatin accessibility and by acting as docking sites for transcription factors and modifying enzymes (Bioessays, 2005. 27(2): p. 164-75; Nature, 2000. 403(6765): p. 41-5; each herein incorporated by reference in its entirety).
  • One of the most studied histone modifications is the acetylation of the evolutionary-conserved lysine residues on the histone N-termini by histone acetyltransferase (HAT).
  • HDAC histone deacetylase
  • the GNAT family members include Gcn5, PCAF, Elp3, HATlm Hpa2 and Nutl .
  • the MYST family is named after the founding members of the family: Morf, Ybf2, Sas2 and Tip60 (J Biochem, 2005. 138(6): p. 647-62; herein incorporated by reference in its entirety).
  • other proteins including CBP/p300, Tafl and a number of nuclear receptor co-activators have been shown to possess intrinsic HAT activity. However, these proteins do not contain a consensus domain and therefore represent an Orphan class' of HAT enzymes (J Biochem, 2005. 138(6): p. 647-62; herein incorporated by reference in its entirety).
  • HDACs form repressor complexes with transcription activators and with other
  • HDACs (Biochem J, 2003. 370(Pt 3): p. 737-49; herein incorporated by reference in its entirety).
  • Mammalian HDACs can be divided into the classical and the silent information regulator 2 (Sir2)-related protein (sirtruin) families (Oncogene, 2007. 26(37): p. 5310-8; herein incorporated by reference in its entirety).
  • members of the classical family have another subdivision, which include class I, II and IV, that share sequence similarity and require Zn+ for deacetylase activity.
  • Class I HDACs HDACl-3, HDAC8 are related to the yeast gene repressor Rpd3p, and are subunits of at least two distinct co-repressor complexes, the Sin3 complex and the NuRD complex.
  • Class II HDACs HDAC4-7, 9 and 10 are similar to the yeast Hdalp HDAC, they act as gene repressors and have been implicated in various roles in cell differentiation and development.
  • Class IV comprises HDAC11, which has some features of both class I and II HDACs.
  • the sirtruin family includes class III HDACs (SIRT1- 7), which are similar to yeast Sir2.
  • Class III HDACs are biochemically and structurally distinct from the classical family and require NAD + as a cofactor. HDACs appear to be involved in gene silencing and heterochromatin formation at centromeres and telomeres (J Mol Biol, 2004. 338(1): p. 17-31; herein incorporated by reference in its entirety).
  • HATs Histone Acetyltransferases
  • HDAC Histone Deacetylases
  • HATs include, but are not limited to GCN5, GCN5L, PCAF, HAT1, ELP3, HPA2, ESA1, SAS2, SAS3, TIP60, HBOl, MOZ, MORF, MOF, SRC1, SRC3, TIF2, GRIP1, ATF-2 [see Lee and Workman (2007) Nat Rev Mol Cell Biol, 8(4):284-95, Marmorstein (2001) J Molec Biol. 311 : 433-444; and Kimura et al., (2005) J Biochem. 138(6): 647-662, which are each hereby incorporated by reference in their entireties].
  • the HAT modulator compound of the invention is directed to GCN5, GCN5L, HAT1, PCAF, or a combination thereof.
  • the HAT modulator compound of the invention is directed to proteins that possess intrinsic HAT activity, such as nuclear receptor co-activators (for example, CBP/p300 and Tafl).
  • nuclear receptor co-activators for example, CBP/p300 and Tafl.
  • the acetylation of H2, H3, and/or H4 histones is increased.
  • the HAT modulator compound is a compound of formula (I).
  • the HAT modulator compound is any of compounds 1-26 or any combination thereof.
  • HAT activator No HAT activator is currently in clinical trials, however several HDAC inhibitors are currently in clinical trials. Some of these HDAC inhibitors (HDACi) have shown therapeutic efficacy in preclinical trials. Without being bound by theory, HAT modulators may be useful therapeutic candidates with a role similar to HDACi. However, many HAT activators have little solubility and membrane permeability, making them unsuitable as drugs.
  • HDACi are in trials for cancer, some of which are, for example, 4SC-
  • HDAC inhibitors which include Vorinostat, Depsipeptide, and MGCD0103.
  • HDAC inhibitors in clinical use or development which include hydroxamic acid compounds (e.g., Vorinostat, Trichostatin A, LAQ824,
  • Panobinostat, Belinostat, and ITF2357 cyclic tetrapeptide compounds (e.g., Depsipeptide), benzamide compounds (e.g., Entinostat and MGCD0103), and short-chain aliphatic acid compounds (e.g., valproic acid, phenyl butyrate, and pivanex).
  • cyclic tetrapeptide compounds e.g., Depsipeptide
  • benzamide compounds e.g., Entinostat and MGCD0103
  • short-chain aliphatic acid compounds e.g., valproic acid, phenyl butyrate, and pivanex
  • HDACi are or were being developed for neurological diseases, such as an HDACi from Merck (Whitehouse Station, NJ) that is being used for the treatment of neurodegenerative diseases; and HDACi from TopoTarget (Rockaway, NJ) that was being used for the treatment of Huntington's disease, now discontinued; isovaleramide NPS-1776 (NPS Pharmaceutical, Bedminster, New Jersey) that was being used for bipolar disorder, epilepsy, and migraines, now discontinued; and a histone acetyltransferase inhibitor for cancer from TopoTarget A/S (Kobenhavn, Denmark), which was discontinued in the preclinical stage.
  • the synthesis of a new class of HAT modulators with improved solubility and membrane permeability are described.
  • the HAT modulators of formula (I) and/or compounds 1-26 may be used as adjuvant therapy in several cancers, psychiatric and neurodegenerative diseases and may improve efficacy and safety of treatment for these disorders.
  • the compounds of formula (I) and/or compounds 1-26 have improved solubility and membrane and Blood-brain-Barrier (BBB) permeability.
  • BBB Blood-brain-Barrier
  • a HAT modulator compound is used to treat a cancer in a subject in need thereof.
  • cancers include B cell lymphoma, colon cancer, lung cancer, renal cancer, bladder cancer, T cell lymphoma, myeloma, leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, hematopoietic neoplasias, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, uterine cancer, renal cell carcinoma, hepatoma, adenocarcinoma, breast cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, ovarian cancer, primary or metastatic melanoma, squamous cell carcinoma, basal cell carcinoma,
  • endotheliosarcoma lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, testicular cancer, uterine cancer, cervical cancer, gastrointestinal cancer, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia, papillary adenocarcinomas,
  • cystadenocarcinoma bronchogenic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, lung carcinoma, epithelial carcinoma, cervical cancer, testicular tumor, glioma, astrocytoma, meduUoblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, retinoblastoma, leukemia, melanoma, neuroblastoma, small cell lung carcinoma, bladder carcinoma, lymphoma, multiple myeloma, and medullary carcinoma.
  • a HAT modulator compound is used to treat a neurodegenerative disease in a subject in need thereof.
  • a neurodegenerative disease in a subject in need thereof.
  • neurodegenerative diseases include Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren- Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral s
  • a schematic representation of the processes involved in gene transcription and memory is shown, for example, WO 2011/072243 (herein incorporated by reference in its entirety).
  • CBP functions as a co-activator that facilitates interactions with the basal transcription machinery and through its HAT activity catalyzes acetylation of the histones, causing a loss in chromosomal repression and increase in the transcription of memory associated genes. Mutations in HAT domain CBP were found to cause LTM impairment. For instance, Korzus et a ⁇ .
  • HDAC inhibition can be beneficial in certain neurodegenerative disorders, such as Huntington's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, ischemia and Rubinstein-Taybi syndrome (Nature, 2007. 447(7141): p. 178-82; Neuron, 2004. 42(6): p. 947-59; Curr Drug Targets CNS Neurol Disord, 2005. 4(1): p. 41-50; Proc Natl Acad Sci US A, 2003. 100(4): p. 2041-6; each herein incorporated by reference in its entirety).
  • HDAC inhibitors can depend upon specific HDACs, as neuron-specific overexpression of HDAC2, but not that of HDAC 1, reduced dendritic spine density, synapse number, synaptic plasticity and memory formation (Nature, 2009. 459(7243): p. 55-60; herein incorporated by reference in its entirety). Conversely, HDAC2 deficiency increased synapse number and facilitated memory, similar to chronic treatment with HDAC inhibitors in mice (Nature, 2009. 459(7243): p. 55-60; herein incorporated by reference in its entirety). HDAC inhibition can provide a therapeutic avenue for memory impairment in neurodegenerative diseases characterized by cognitive disorders such as AD.
  • APP(K670N:M671L) transgenic animals showed a decrease in CREB phosphorylation at the downstream level of the ⁇ -7-nicotinic-receptor (a7-nAChR)/ERK/MAPK cascade (J Neurosci, 2001. 21(12): p. 4125-33; J Biol Chem, 2002. 277(25): p. 22768-80; each herein incorporated by reference in its entirety).
  • PSl and 2 conditional double knockout (PS cDKO) mice showed impaired memory and LTP that were amplified with age.
  • PS cDKO mice showed a reduction in CBP levels and in CRE-dependent gene expression in the cerebral cortex, which contributed to subsequent neuronal degeneration (Neuron, 2004. 42(1): p. 23- 36; herein incorporated by reference in its entirety).
  • WT wild-type
  • M146L AD associated mutant of PSl
  • AD Alzheimer's disease
  • LTM long-term memory
  • N-terminal tails of histone proteins are known to undergo post-translational modifications, such as histone acetylation, ubiquitination, sumoylation, phosphorylation, citrullination, ADP-ribosylation, and methylation that can dictate the transitions between transcriptionally active or transcriptionally silent chromatin states ⁇ Curr Biol, 2004. 14(14): p. R546-5; herein incorporated by reference in its entirety).
  • Deregulation of one of these mechanisms can lead to disruption of memory associated gene expression and cognitive disorders.
  • Studies of the mechanisms underlying synaptic and memory dysfunction in AD have indicated central roles for the transcription factor CREB (CRE binding protein) and the coactivator CREB binding protein (CBP).
  • AD Alzheimer's disease
  • LTP long- term-potentiation
  • NO nitric oxide
  • cGMP-analogs ⁇ J Neurosci 25, 6887-6897 (2005); herein incorporated by reference in its entirety.
  • NOS2 NO-synthase 2
  • APP mutated amyloid precursor protein
  • AD Alzheimer's disease
  • ⁇ -amyloid ⁇ has been found to inhibit memory ⁇ Proc Natl Acad Sci USA, 2006. 103:8852-7; Nat Neurosci, 2005. 8:79 84; each herein
  • LTP long-term potentiation
  • PS1 presenilin 1
  • PS2 presenilin 2
  • Presenilins are part of the ⁇ - secretase complex responsible for cleaving APP and producing the ⁇ 42 peptide (Neurosci Lett, 1999. 260: 121-4; herein incorporated by reference in its entirety).
  • AD is characterized neuropathologically by neuronal loss, extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFTs).
  • SPs extracellular senile plaques
  • NFTs intracellular neurofibrillary tangles
  • SPs are chiefly comprised of ⁇ aggregates.
  • the major component of NFTs is the microtubule binding protein tau.
  • AD Alzheimer's disease
  • An emerging view of the processes involved in synaptic impairment shows that the subtlety and variability of the earliest amnesic symptoms, occurring in the absence of any other clinical signs of brain injury, can be due to discrete changes in the function of a single synapse, produced at least in part, by ⁇ (Neuroreport, 1997. 8(15): p. 3213-7; Eur J Pharmacol, 1999. 382(3): p. 167-75; Proc Natl Acad Sci USA, 2002. 99(20): p. 13217-21; Nature, 2002. 416(6880): p. 535-9; herein incorporated by reference in its entirety).
  • a target for developing a causal therapy for Alzheimer's disease is represented by synapses.
  • Synaptic alterations are highly correlated with the severity of clinical dementia (Histol Histopathol, 1995. 10(2): p. 509-19; Science, 2002. 298(5594): p. 789-91; each herein incorporated by reference in its entirety), whereas other important variables such as senile plaques and neurofibrillary tangles are involved to a lesser extent (Histol Histopathol, 1995. 10(2): p. 509-19; herein incorporated by reference in its entirety).
  • the importance of synaptic alterations in AD has been confirmed by studies of transgenic (Tg) mouse models of AD (Neurochem Res, 2003.
  • L&M long-term potentiation
  • AD Alzheimer's disease
  • CRE binding protein transcription factor CREB
  • CBP coactivator CREB binding protein
  • LTP long-term potentiation
  • NO is a central molecule in cellular biochemical processes. This gas has been established as an important messenger molecule in various steps of brain physiology, from development to synaptic plasticity and learning and memory. In AD research, NO has been found to have a protective effect on ⁇ -induced damage of the nervous system (Med
  • drugs enhancing the NO-cascade can have a beneficial effect against AD (Curr Alzheimer Res, 2005. 2(2): p. 171-82; herein incorporated by reference in its entirety).
  • the compounds of the invention are HAT modulators.
  • a HAT modulator compound can be a compound that increases the activity and/or expression of a HAT molecule (e.g., GCN5, GCN5L, PCAF, or HATl) in vivo and/or in vitro.
  • HAT modulator compounds can be compounds that exert their effect on the activity of a HAT protein via the expression, via post-translational modifications, or by other means.
  • a HAT modulator compound increases HAT protein or mRNA expression, or acetyltransferase activity by at least about 10%, at least about 20%, at least about 30%), at least about 40%>, at least about 50%>, at least about 60%>, at least about 70%>, at least about 75%, at least about 80%>, at least about 85%, at least about 90%>, at least about 95%, at least about 97%, at least about 99%, or 100%.
  • Test compounds or agents that bind to a HAT molecule such as GCN5,
  • the assay can be a binding assay comprising direct or indirect measurement of the binding of a test compound or a known HAT ligand to the active site of a HAT protein.
  • the assay can also be an activity assay comprising direct or indirect measurement of the activity of a HAT molecule.
  • the assay can also be an expression assay comprising direct or indirect measurement of the expression of a HAT mRNA or protein.
  • the various screening assays can be combined with an in vivo assay comprising measuring the effect of the test compound on cognitive and synaptic function in an animal model for neurodegenerative disorders, such as, but not limited to, AD or
  • the inhibitors of the expression of a HAT molecule can be identified via contacting a HAT -positive cell or tissue with a test compound and determining the expression of a HAT protein or HAT mRNA in the cell.
  • the protein or mRNA expression level of a HAT molecule in the presence of the test compound can be compared to the protein or mRNA expression level of a HAT protein in the absence of the test compound.
  • the test compound can then be identified as an inhibitor of expression of a HAT protein (such as GCN5, GCN5L, PCAF, or HATl) based on this comparison.
  • the test compound can also be a HAT inhibitor compound (such as an antagonist).
  • Acivators of the expression of a HAT molecule can also be identified via contacting a HAT -positive cell or tissue with a test compound and determining the expression of a HAT protein or HAT mRNA in the cell.
  • the protein or mRNA expression level of a HAT molecule in the presence of the test compound can be compared to the protein or mRNA expression level of a HAT protein in the absence of the test compound.
  • the test compound can then be identified as an activator of expression of a HAT protein (such as GCN5, GCN5L, PCAF, or HATl) based on this comparison.
  • the compound when expression of HAT protein or mRNA is statistically or significantly more in the presence of the test compound than in its absence, the compound is identified as an activator of the expression of a HAT protein or mRNA.
  • the test compound can also be a HAT Activator compound (such as an agonist).
  • the expression level of a HAT protein or mRNA in cells can be determined by methods described herein.
  • BIA Bimolecular Interaction Analysis
  • the invention provides for compounds that bind to a
  • HAT activator protein such as GCN5, GCN5L, PCAF, or HATl . These compounds can be identified by the screening methods and assays described herein, and enhance the activity or expression of HAT activator proteins.
  • the compound of formula (I) is 8, 9, 10, 11, 12, 13, and/or 14.
  • the compound of formula (I) is 16 and/or 17.
  • the compound of formula (I) is 18, 19, 20, and/or 21.
  • the compound of formula (I) is 22, 23, and/or 24.
  • the compound of formula (I) is 25 and/or 26.
  • R a is H, halogen, or haloalkyl
  • Y is CH, C-halogen, or C-CN
  • R b is H, 0-(Ci-C 2 -alkyl), S-(d-C 2 -alkyl), O-cyclopentyl, OCH 2 CH 2 N(CH 3 ) 2 , or
  • R d is H, Ci-C 5 -alkyl, OH, O-alkyl, OCH 2 CH 2 N(CH 3 ) 2 , CH 2 CH 2 CH 2 N(CH ) 2 ,
  • Z is CH, C-0-(Ci-C 2 -alkyl), C-OCH 2 CH 2 N(CH 3 ) 2 ;
  • the compound of formula (I) is compound (I-g): 0-8) , wherein R d is -0-(Ci-C 6 )-alkyl, -NH-(Ci-C 6 )-alkyl, -O-
  • the compound of formula (I) is compound (I-h):
  • R b is -0-(d-C 6 )-alkyl, -0-(C 2 -C 6 )-alkenyl, -0-(C 3
  • the compound of formula (I) is compound (I-i):
  • R 1U is H, -(Ci-C 4 -alkyl), -(Ci-C 4 -haloalkyl), -(C 3 -C 8 cycloalkyl), -(C 3 -C8-heterocycloalkyl), aryl or heteroaryl, wherein aryl or heteroaryl.
  • the compound of formula (I) is
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • X is CH 2 CONH(CH 2 ) n
  • n is 0-3.
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • X is CONH(CH 2 ) n
  • n is 0-3.
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • R a is H, halogen, or haloalkyl
  • R b is 0-(Ci-C 6 )-alkyl or S-
  • R d is (Ci-C 6 )-alkyl or 0-(Ci-C 6 )-alkyl-N(CH 3 ) 2 ;
  • Y is haloalkyl, C-CN, C-N0 2 , or N;
  • W is CH or N; and
  • Z is CH or N, or a pharmaceutically acceptable salt or hydrate thereof.
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • R a is haloalkyl
  • R 2 is CN
  • R b is 0-(Ci-C 6 )-alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • W and Z are independently CH, C-
  • R c is H, ethoxyl, or methyl; or a pharmaceutically acceptable salt or hydrate thereof.
  • R b is ethoxyl, W and Z are each CH, and R c is methyl.
  • R b is ethoxyl, W and Z are each C- Cl, and R c is H.
  • R b is H, W is ethoxyl, R c is H, and Z is CH.
  • R b is H, W and Z are each CH, and R c is ethoxyl.
  • the compound of formula (I) is CH 3 , or a pharmaceutically acceptable salt or hydrate thereof.
  • Compound 5 can be synthesized according to the scheme depicted in FIG. 11.
  • the compound of formula (I) is , wherein R b is -O-ethyl, -0-CH 2 CH 2 N(CH 3 )2, -NH-ethyl, or -NH- CH 2 CH 2 N(CH 3 ) 2 , or a pharmaceutically acceptable salt or hydrate thereof.
  • Compounds (I-d) can be synthesized according to the scheme depicted in FIG. 12.
  • the compound of formula (I) is , wherein R b is -O-ethyl, -0-CH 2 CH 2 N(CH 3 ) 2 , -NH-ethyl, or -NH- CH 2 CH 2 N(CH 3 ) 2 , or a pharmaceutically acceptable salt or hydrate thereof.
  • Compounds (I-e) can be synthesized from commercially available 8-hydroxy-3,4-dihydro-lH-isochromen-l- one, which may be converted to the N-substituted 8-hydroxy-isochincolone via treatment with the corresponding amine in pyridine at reflux; followed by alkylation of the hydroxyl group.
  • the compound of formula (I) is
  • R b is -O-ethyl, -0-CH 2 CH 2 N(CH 3 ) 2 , -NH-ethyl, or -NH
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • R d is 2-(piperidin-l-yl) ethyloxy (8); 2- morpholinoethyloxy (9); 2-(piperaz-l-yl)-ethyloxy (10); 2-(4-methylpiperazin-l-yl)-ethyloxy (11); 2-(N,N-diethylamino)ethyloxy (12); 3-(N,N-dimethylamino)propyloxy (13), 3-(N,N- diethylamino)propyloxy (14); 3-methylbutyloxy (15).
  • the compounds 8-15 can be synthesized, for example, via Scheme 1.
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl
  • R 1 is ethoxyl and R c is H (18); or R 1 is H and R c is ethoxyl (19).
  • the compounds 18 and 19 can be synthesized, for example, via Scheme 4.
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe-N-[00160]
  • the compounds 20 and 21 can be synthesized, for example,
  • the compound of formula (I) is N-(00162]
  • the compound of formula (I) is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe-N-(2-a164]
  • R is ethoxy (23), or 2-(N, N-dimethyl)-ethoxy (24).
  • the compounds 23 and 24 can be synthesized, for example, via Scheme 7.
  • R ethyl
  • R 2-(N, N-dimethylamino)-ethyl.
  • a pharmaceutically acceptable salt of a compound of formula (I) is an acid addition salt, for example a hydrohalide (such as hydrochloride or hydrobromide), sulfate, or phosphate salt.
  • a pharmaceutically acceptable salt of a compound of formula (I) is a base addition salt, for example a sodium, potassium, calcium, or ammonium salt.
  • the base addition salt is a tetrafluoroboro salt.
  • the invention provides methods for reducing inclusion bodies (e.g., amyloid beta ( ⁇ ) protein deposits, native and phosphorylated Tau proteins, native and phosphorylated alpha-synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof) in a subject afflicted with a neurodegenerative disease (e.g., a AD, Huntington's Disease, or Parkinson's Disease) by administering any one of the HAT modulator compounds having formula (I).
  • a neurodegenerative disease e.g., a AD, Huntington's Disease, or Parkinson's Disease
  • the invention provides methods for treating a neurodegenerative disease in a subject by administering any one of the HAT modulator compounds having formula (I).
  • the invention further provides methods for treating cancer in a subject by administering any one of the HAT modulator compounds having formula (I).
  • the compound administered to a subject is any one of the compounds of formula (I).
  • the compound administered to a subject is any one of compounds any of compounds 1-26 or any combination thereof.
  • the methods comprise administering to the subject an effective amount of a composition comprising a HAT modulator compound.
  • the subject exhibits abnormally elevated amyloid beta plaques, or elevated Tau protein levels, or accumulations of alpha-synuclein, or accumulations of lipofuscin, or accumulation of cleaved TARDBP (TDB-43) levels, or a combination thereof.
  • the ⁇ protein deposit comprises an ⁇ 40 isomer, an ⁇ 42 isomer, or a combination thereof.
  • the subject is afflicted with Alzheimer's disease, Lewy body dementia, inclusion body myositis, Huntington's Disease, Parkinson's Disease, or cerebral amyloid angiopathy.
  • the subject is afflicted with cancer.
  • the dosage administered can be a therapeutically effective amount of the composition sufficient to result in amelioration of symptoms of a neurodegenerative disease such as, but not limited to reducing inclusion bodies (e.g., amyloid beta ( ⁇ ) protein deposits, native and phosphorylated Tau proteins, native and phosphorylated alpha-synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof), or reducing memory loss in a subject.
  • reducing inclusion bodies e.g., amyloid beta ( ⁇ ) protein deposits, native and phosphorylated Tau proteins, native and phosphorylated alpha-synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof
  • observing at least, about a 25% reduction, at least about a 30% reduction, at least about a 40% reduction, at least about a 50% reduction, at least about a 60% reduction, at least about a 70%> reduction, at least about a 80%> reduction, at least about a 85% reduction, at least about a 90%> reduction, at least about a 95% reduction, at least about a 97% reduction, at least about a 98% reduction, or a 100% reduction in inclusion bodies or memory loss in a subject is indicative of amelioration of symptoms of a neurodegenerative disease (for example, including, but not limited to, AD, Huntington's Disease, Parkinson's Disease).
  • This efficacy in reducing inclusion occurrence can be, for example, a meaure of ameliorating symptoms of a neurodegenerative disease.
  • the therapeutically effective amount is at least about
  • 0.1 mg/kg body weight at least about 0.25 mg/kg body weight, at least about 0.5 mg/kg body weight, at least about 0.75 mg/kg body weight, at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, at least about 100 mg/kg body weight, at least about 200 mg/kg body weight, at least about 250 mg/kg body weight, at least about 300 mg/kg body weight, at least about 3
  • a HAT modulator compound can be administered to the subject one time
  • a HAT modulator compound of the invention can be administered once or twice daily to a subject in need thereof for a period of from about 2 to about 28 days, or from about 7 to about 10 days, or from about 7 to about 15 days. It can also be administered once or twice daily to a subject for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 times per year, or a combination thereof.
  • the dosage administered can vary depending upon known factors such as the pharmacodynamic characteristics of the active ingredient and its mode and route of administration; time of administration of active ingredient; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired; and rate of excretion.
  • Toxicity and therapeutic efficacy of therapeutic compositions of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LO 50 /ED 50 .
  • Therapeutic agents that exhibit large therapeutic indices are useful.
  • Therapeutic compositions that exhibit some toxic side effects can also be used.
  • a therapeutically effective dose of a HAT modulator compound can depend upon a number of factors known to those of ordinary skill in the art.
  • a HAT modulator compound for example a compound of formula (I)
  • the dose(s) of a HAT modulator compound can vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the HAT modulator compound to have upon a HAT protein or a protein exhibiting intrinsic HAT activity.
  • these amounts can be readily determined by a skilled artisan.
  • HAT modulator compounds of the invention can be incorporated into pharmaceutical compositions suitable for administration.
  • Such compositions can comprise a HAT modulator compound (e.g., a compound of formula (I), or any of compounds 1-26 or any combination thereof) and a pharmaceutically acceptable carrier.
  • the compositions can be administered alone or in combination with at least one other agent, such as a stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water.
  • the compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.
  • a pharmaceutically acceptable carrier can comprise any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Any conventional media or agent that is compatible with the active compound can be used. Supplementary active compounds can also be incorporated into the compositions.
  • Any of the therapeutic applications described herein can be applied to any subject in need of such therapy, including, for example, a mammal such as a mouse, rat, dog, cat, cow, horse, rabbit, monkey, pig, sheep, goat, or human.
  • the subject is mouse, rat, monkey, dog or human.
  • the subject is a mouse, monkey or human.
  • the subject is a human.
  • a pharmaceutical composition of the invention can be formulated to be compatible with its intended route of administration.
  • Examplary routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following
  • a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor EMTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the injectable composition should be sterile and should be fluid to the extent that easy syringability exists. It should also be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a
  • polystyrene resin like glycerol, propylene glycol, liquid polyetheylene glycol, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the HAT modulator compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated herein.
  • examples of useful preparation methods are vacuum drying and freeze- drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier.
  • compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
  • compositions can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or sterotes
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • Compound D (MW 431, clogP 5.15, clogBB 0.17) is soluble, membrane permeable and BBB permeant, and is safe in acute toxicity tests.
  • Compound D is a N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2- (dimethyl-amino) ethoxy]-6-ethoxybenzamide. Its benzamide ring (I ring) has two substituents at C2 and C6, 2-dimethylamino ethoxy and ethoxy groups, respectively. The nitrogen atom of its amide group bears a substituted phenyl ring (II ring).
  • a strategy was employed to assess impact of structure on metabolic stability of D and explore the binding site through SAR analysis, and analysis of DCTPB/CTB and nemorosone.
  • An analysis of D/CTPB/CTB and nemorosone scaffolds shows that the two scaffolds consist of two ring-systems connected by a linker (FIG. 4).
  • two mono-cyclic rings (I and II ring) linked by a 2-nodes linker form the scaffold of
  • the lactone opening-ring of O-alkylated derivative and the amide bond formation can be carried out directly by using amine in the presence of reducing agent in pyridine (WO 2009/115707, PTC/FR2009/000233; each hereby incorporated by reference in its entirety). Such a reaction can be also performed without reducing agents (Eur. J. Org. Chem., 2008: p. 655-672; hereby incorporated by reference in its entirety). Then, Mitsunobu reaction can give amide (I-j). Compound 16 contains a methylene group in the linker, and was synthesized using 4-chloro-3- (trifluoromethyl)benzylamine in the second step of the synthetic scheme for D as shown above (Scheme 2). The reduction of D by using a reducing agent gave the imine 17 (Scheme 2).
  • Isoquinolinone (I-e) can be prepared in two steps from commercially available
  • N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide (EDC, 2.19 mL) was added to a solution of B (1.5 g) in methylene chloride (5 mL) at 0 °C, and then 4-chloro-3- (trifluoromethyl) aniline (1.61 g) was added. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was dissolved in AcOEt (100 mL) and the organic layer was washed with a solution of HC1 6N (3x50 mL) and a solution of NaOH 20% (3x50 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. Compound 25 (2.2 g) was obtained by crystallization from MeOH.
  • Diisopropyl azodicarboxylate (DIAD, 0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-(piperidin-l-yl) ethanol (0.096 mL) and triphenylphosphine (PPI13, 188.8 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H 2 0 (3x30 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. Purification by flash chromatography (10% MeOH in AcOEt) gave a colorless oil (145.0 mg).
  • Example 1-5 (Scheme 4) [00212] N-(4-chloro-3-(trifluoromethyl)phenyl)-5-ethoxy-2-hydroxybenzamide, G
  • EDC (0.437 mL) was slowly added to a solution of B (300.0 mg) and (4- chloro-3-(trifluoromethyl)phenyl)methanamine (0.243 mL) in DCM (5 mL) at 0 °C. The reaction was stirred at room temperature overnight. The solvent was evaporated and the residue was dissolved in AcOEt (100 mL) and washed with HC1 4N (3x80 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The desired product (371.0 mg) was obtained by crystallization from MeOH.
  • reaction was partitioned between AcOEt (30 mL) and H 2 0 (30 mL) and the organic layer was washed with H 2 0 (3x30 mL), dried over Na 2 S0 4 , filtered and evaporated.
  • DIAD (0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-
  • DIAD (0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-
  • LAH was added portionwise at 0 °C to a solution of C (200.0 mg) in 2 mL of
  • Example 2 Assays for HAT Affinity and Selectivity for CBP, PCAF, and P300
  • Compounds can be tested for HAT modulator activity using the HAT Assay kit from Active Motif (USA, CA).
  • the catalytic domain of human CBP, PCAF, p300 and GCN5 (Enzo Life Sci., USA) can be used.
  • the catalytic domains for the remaining HATs can be produced using New England Biolabs K. lactis Protein Expression Kit.
  • the candidate compounds can also be selective. When assayed against all other HATs, they can show a 50-fold greater potency towards CBP and/or PCAF.
  • compounds can be assayed in primary cultures and adult mice. Whether the compounds can increase specific histone acetylation in 10 day old cultured hippocampal neurons (prepared as described in Neuron, 2004. 42(1): p. 129-41; hereby incorporated by reference in its entirety) can also be determined. Media can be aspirated and replaced with 0.5 mL of PBS containing the HAT activator. After 30 min at 37°C, cells can be removed and lysed for WB analysis. Selected compounds can also be tested in adult mice, following an assessment of acute toxicity to determine the dose of compound to be administered to the animal (see “toxicity tests" below).
  • mice Testing in adult mice is useful as cell cultures do not mimic the whole body with complex cell-cell interactions and in vivo drug PK, BBB penetration, etc (see also Example 3 below).
  • Animals can be treated with the HAT compound, hippocampi can be collected 30 min after the i.p. injection, and lysed for WB analysis. Experiments can be performed in triplicate.
  • Pharmacokinetic assays can include the measurement of a) bioavailability and b) brain uptake. Mice can be i.p. injected with the compounds (for some compounds, PK tests can also be performed using p.o. and i.v. routes of administration). 5-6 mice/sex can be used for each time -point.
  • bioavailability concentration of compound in the blood as a function of time after administration
  • blood samples can be obtained from test animals following a single acute administration (collected at time intervals up to
  • Blood can be harvested by retro-orbital puncture, collected in heparanized tubes, and plasma obtained by centrifugation. Samples can be analyzed by LC- MS to measure the amounts of the candidate compound and metabolites. An indication of brain uptake and BBB penetration can be obtained by tissue extraction of the candidate compound from brain. Brain homogenates can be centrifuged 11,000 rpm for 10 min. An aliquot of the sample can be added to acetonitrile, then injected onto LC-MS/MS for analysis. Similar patterns of brain and plasma concentrations can be indicative of brain uptake as a reflection of concentration in the blood. A peak brain/blood concentration ratio >1 can indicate that brain uptake comparable with that of known CNS drugs in clinical use.
  • the brain/blood ratio for minaprine is >2 ⁇ Xenobiotica, 1985. 15(12): p. 1111-9; herein incorporated by refrence in its entirety).
  • Acute toxicity can also be evaluated. All clinical signs, time of onset, duration, reversibility of toxicity and mortalities can be recorded. Animals can be observed periodically during the first 24 hrs with continuous monitoring given to the first 4 hrs, then at least once a day for 14 days or until they die to check food and liquid intake, weight, as well as locomotion and exploratory behavior. Maximum tolerated dose (MTD) and chronic toxicity can also be evaluated. MTD can be computed as the maximum administered dose that does not produce any toxicity effect in terms of malaise or death (body weight will be monitored over time). Chronic toxicity can be assessed at the MTD. All clinical signs, time of onset, duration, reversibility of toxicity and mortalities can also be recorded.
  • An aspect of the drug screening protocol can include a measurement of the effect of compounds onto synaptic function.
  • the APP/PSl mouse presents an impairment of LTP by the age of 3 months (Ann Neurol, 2004. 55(6): p. 801-14; herein incorporated by refrence in its entirety), and therefore permits a relatively fast assessment of synaptic function without waiting a long time for mice aging.
  • LTP can be examined because it is a type of synaptic plasticity thought to underlie learning and memory. D rescues the ⁇ -induced reduction of LTP, and other compounds can also be screened to identify those that can re-establish normal LTP.
  • the compounds can be applied for 30 min.
  • Controls can be performed on slices from APP/PSl mice treated with vehicle, and WT mice treated with compound or vehicle. If the compounds re-establish normal LTP in APP/PSl slices, one can conclude that the compounds rescue impairment of synaptic plasticity in APP/PSl mice. Cognitive impairment can also be investigated (see Example 5).
  • mice can be obtained by crossing APP(K670M:N671L) with
  • PS1(M146L) (line 6.2) animals.
  • the genotype can be identified by PCR on tail samples
  • Electrophysiology can be performed on males (see description in Cell, 2006.
  • Example 5 Screening for Amelioration of Cognitive Abnormalities in APP/PSl Mice
  • Example 4 Treatment with a new HAT modulator indicated by Example 4 will study rescue of cognitive deficits in 3 and 6 month old APP/PSl mice.
  • the RAWM and contextual FC will be used, two types of tests that assess different types of memory (reference ad associative) that are affected in AD patients.
  • the treatment can be performed with the same timing (i.e. 30min before training for fear conditioning or before the 1 st and 2 nd group of tests for the RAWM).
  • Conditions to be tested can include: APP/PSl and WT treated with HAT activators, APP/PSl and WT treated with vehicle.
  • mice After behavioral testing, mice can be sacrificed and their blood and brains used for ⁇ level, Tau protein, TARDBP and TDB levels, and alpha-synuclein measurements.
  • hippocampal acetyl-H4 levels can be measured after administration of the compounds 30 min prior to training for fear conditioning and removal of the hippocampi lhr after the electric shock (APP/PSl mice have been shown to have a reduction of acetylated H4 after the electric shock (J Alzheimers Dis, 2009. 18(1): p. 131-9; hereby incoporated by reference in its entirety).
  • Further screening can include assays focusing on two areas that have resulted in the withdrawal of many drugs from the market: drug-drug interactions, hERG channel blockage (see Example 3).
  • Histone acetylation assay Western blot can be performed from snap-frozen in liquid nitrogen hippocampi. Tissue can be homogenized in RIPA buffer, then sonicated before centrifugation at 10,000 rpm for 5 min. Whole cell extracts can be electrophoresed on 10-20% gradient PAGE gel (Invitrogen) and then immunob lotted. Antibodies can be used at a 1 : 1,000 concentration for immunoblotting. All anti-histone antibodies can be purchased from Millipore. Immunoblot data can be quantified by measuring the band intensity using imaging software (NIH Image J). [00287] Determination of ⁇ levels can be performed on homogenates of frozen hemi- brains and plasma as previously described (Ann Neurol, 2004. 55(6): p. 801-14; hereby incorporated by reference in its entirety).
  • Determination of alpha-synuclein levels can be performed on homogenates of frozen hemi-brains using an a-Synuclein ELISA Kit (Catalog # NS400; Millipore, Billerica, MA) according to manufacturer's instructions.
  • TARDBP/TDP-43 levels can be performed on homogenates of frozen hemi-brains using a Human TAR DNA binding protein 43, TARDBP/TDP-43 ELISA Kit (Catalog # E1951h; Wuhan EIAab Science Co, Wuhan, China) according to manufacturer's instructions.
  • Determination of total Tau and phosphorylated Tau (Thr 231) levels can be performed on homogenates of frozen hemi-brains and plasma using assay and kits according to manufacturer's instructions available from MesoScale Discovery (Gaithersburg, MD) (see http://www.mesoscale.com catalogsystemweb/webroot/products/assays/alzheimers.aspx; hereby incorporated by reference in its entirety).
  • mice can be performed in blind. Results can be expressed as Standard Error Mean (SEM). Level of significance can be set for p ⁇ 0.05. Results can be analyzed with AN OVA with post-hoc correction with drug or genotype as main effect.
  • SEM Standard Error Mean
  • Example 6 Screening for Amelioration of Cognitive Abnormalities in Mouse Models for Huntington's Disease
  • Treatment with a HAT compound indicated by Example 13 to assess whether the compound can rescue the cognitive deficits in a mouse model of Huntington's Disease can be examined.
  • a mouse model of Huntington's Disease e.g., FVB-Tg(YAC128)53Hay/J and FVB/NJ-Tg(YAC72)251 IHay/J mice, available from the Jackson Laboratory, Bar Harbor ME
  • the RAWM and contextual FC can be employed, two types of tests assessing different types of memory (reference ad associative).
  • the treatment can be performed with the same timing (i.e. 30 min before training for fear conditioning or before the 1 st and 2 nd group of tests for the RAWM).
  • Conditions to be tested can include: Huntington's Disease mice and WT treated with HAT modulator, Huntington's Disease mice and WT treated with vehicle. After behavioral testing mice can be sacrificed and their blood and brains used for Huntingtin protein level measurement. As a control for effectiveness of HAT modulation, hippocampal acetyl-H4 levels can be measured after administration of the compounds 30 min prior to training for fear conditioning and removal of the hippocampi 1 hr after the electric shock. Assays focusing on two areas that have resulted in the withdrawal of many drugs from the market can also be employed: drug-drug interactions, hERG channel blockage (see Example 3).
  • Animals Mouse models of Huntington's Disease (e.g., FVB-1)
  • Tg(YAC128)53Hay/J [Stock no. 004938] and FVB/NJ-Tg(YAC72)251 lHay/J mice [Stock no. 003640]) can be obtained from the Jackson Laboratory (Bar Harbor ME). See also, Hodgson et al, (May 1999) Neuron, Vol. 23, 181-192; hereby incorporated by reference in its entirety.
  • Histone acetylation assay Western blot can be performed from snap-frozen in liquid nitrogen hippocampi. Tissue can be homogenized in RIPA buffer, then sonicated before centrifugation at 10,000 rpm for 5 min. Whole cell extracts can be electrophoresed on 10-20% gradient PAGE gel (Invitrogen) and then immunob lotted. Antibodies can be used at a 1 : 1 ,000 concentration for immunoblotting. All anti-histone antibodies can be purchased from Millipore. Immunoblot data can be quantified by measuring the band intensity using imaging software (NIH Image J).
  • Determination of huntingtin levels can be performed on homogenates of frozen hemi-brains and plasma using a Huntingtin (Htt) ELISA Kit (Catalog # ABIN423526; Antibodies-online, Atlanta, GA) according to manufacturer's instructions.
  • Htt Huntingtin
  • mice can be performed in blind. Results can be expressed as Standard Error Mean (SEM). Level of significance can be set for p ⁇ 0.05.
  • Results can be analyzed with AN OVA with post-hoc correction with drug or genotype as main effect.
  • Example 7 Screening for Amelioration of Cognitive Abnormalities in Mouse Modles for Parkinson's Disease
  • Parkinson's Disease is a degenerative disease with a neuronal death up to 75-95% of the dopamine neurons in the substantia nigra nucleus.
  • Treatment with a HAT modulator compound indicated by Example 4 to assess rescue of abnormal motor movements in a mouse model of PD e.g., see Parkinson's Disease mice models available from the Jackson Laboratory, Bar Harbor ME at http://jaxmice.jax.org/list/ ral594.html; see also Emborg, Journal of Neuroscience Methods 139 (2004) 121-143; Lane, Psychopharmacology (2008) 199:303-312; and Meredith et al, Acta Neuropathol (2008) 115:385-398; each hereby incorporated by reference in its entirety
  • a HAT modulator compound indicated by Example 4 to assess rescue of abnormal motor movements in a mouse model of PD
  • Behavioral tasks for example, dyskinesia, bradykinesia, tremor, and/or grip force for the evaluation of the compound's efficacy, can be examined at various stages of PD.
  • Conditions to be tested can include: PD mice and WT treated with HAT modulator, PD mice and WT treated with vehicle. After behavioral evaluation, mice can be sacrificed and their brains used for aggregated alpha-synuclein protein measurement. As a control for effectiveness of HAT modulation, hippocampal acetyl-H4 levels can be measured.
  • Histone acetylation assay Western blot can be performed from snap-frozen in liquid nitrogen hippocampi. Tissue can be homogenized in RIPA buffer, then sonicated before centrifugation at 10,000 rpm for 5 min. Whole cell extracts can be electrophoresed on 10-20% gradient PAGE gel (Invitrogen) and then immunob lotted. Antibodies can be used at a 1 : 1 ,000 concentration for immunoblotting. All anti-histone antibodies can be purchased from Millipore. Immunoblot data can be quantified by measuring the band intensity using imaging software (NIH Image J).
  • Determination of alpha-synuclein levels can be performed on homogenates of frozen hemi-brains using an a-Synuclein ELISA Kit (Catalog # NS400; Millipore, Billerica, MA) according to manufacturer's instructions or via standard neuropatho logical methods (brain tissue histology).
  • mice can be performed in blind. Results can be expressed as Standard Error Mean (SEM). Level of significance can be set for p ⁇ 0.05.
  • Results can be analyzed with AN OVA with post-hoc correction with drug or genotype as main effect.
  • the fluorescent signal was measured using a Tecan microplate reader (excitation: 380 nm, emission: 520 nm).
  • the assay methodology was adopted as it provided a 10-fold higher signal/background ratio and was more sensitive than other assays.
  • the EC 50 values of D for CBP (4.5 nM) and Tip60 (>200 ⁇ ) were established.
  • Initial screening revealed that compounds such as 8, 9, 12-14, and 19 behave as activators with respect to CBP and P300.
  • Compounds 16, 17, 18, 25 and 26 activated only CBP, whereas 11 inhibited P300 and had no effect on CBP.
  • Compound 10 had no effect with either P300 or CBP ( Figure 13).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

Description

HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF
[0001] This application claims priority to U.S. Provisional Application No. 61/426,033, filed on December 22, 2010, U.S. Provisional Application No. 61/539,697, filed on September 27, 2011, and U.S. Provisional Application No. 61/541,706, filed on September 30, 2011, each of which are incorporated herein by reference.
[0002] All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
[0003] This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights.
GOVERNMENT SUPPORT
[0004] This invention was made with government support under R01-NS049442 awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under POIAG 17490 awarded by the National Institute of Health (NIH), under U01 AG031294 awarded by the NIH, and under U01 AG 14351 awarded by the NIH. The government has certain rights in the invention.
BACKGROUND OF THE INVENTION
[0005] Cognitive neurodegenerative disorders are characterized by synaptic dysfunction, cognitive abnormalities, and/or the presence of inclusion bodies throughout the CNS containing, for example, but not limited to native beta-amyloid fragments, native and phosphorylated Tau, native and phosphorylated alpha-synuclein, lipofuscin, cleaved
TARDBP (TDB-43), in various percentages and in relation to the specific disease.
[0006] Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss, synaptic dysfunction and accumulation of amyloid β-peptides (Αβ). It is caused in part by increased levels of amyloid-P-peptide 1-42 (Αβ42). Although Alzheimer's Disease (AD) was described almost a century ago, the molecular mechanisms that lead to its development are still unknown. From a neuropatho logical point of view, Alzheimer's Disease is characterized by the presence of amyloid plaques and neurofibrillary tangles associated with neuronal degeneration; whereas the clinical hallmark is progressive memory loss associated with a number of neuropsychiatric symptoms.
[0007] Currently available therapies for AD are palliative and do not address the underlying cause of the disease. Cholinesterase inhibitors such as Razadyne® (galantamine), Exelon® (rivastigmine), Aricept® (donepezil), and Cognex® (tacrine) have been prescribed for early stages of Alzheimer's disease, and may temporarily delay or prevent progression of symptoms related to AD. However, as AD progresses, the brain loses less acetylcholine, thereby rendering cholinesterase inhibitors unproductive as treatment for AD. Namenda® (memantine), an N-methyl D-aspartate (NMD A) antagonist, is also prescribed to treat moderate to severe Alzheimer's disease; however only temporary benefits are realized.
[0008] Histone Acetyltransferases (HATs) are involved in histone acetylation (leading to gene activation), chromosome decondensation, DNA repair and non-histone substrate modification.
SUMMARY OF THE INVENTION
[0009] In one aspect, the invention is directed to a compound of formula (I),
Figure imgf000004_0001
wherein,
Figure imgf000005_0001
Ra is H, Ci-Ce-alkyl, Ci-Ce-haloalkyl, O-(Ci-Ce-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or
N02;
Rb is H, Ci-Ce-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-heteroalkyl, C3-C8- heterocycloalkyl, aryl, heteroaryl, 0-(Ci-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8-heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), S-(Ci-C6- alkyl), O-(C2-C6-alkyl)-N(R10)2, O-(C3-C8-cycloalkyl)-N(R10)2, N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, 0-(C3-C8-cylcoalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Ce-alkyl), O-(Ci-Ce-alkyl), C(=0)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl;
Rd is H, OH, -(Ci-Ce-alkyl), 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(C2-C6- alkenyl), 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C2-C6-alkenyl), -N(R10)-(C3-C8- cycloalkyl), -N(R10)-(C3-C8-heterocycloalkyl), N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-Ce-alkyl )- N(R10)2, S-(C2-C6-alkyl)-N(R10)2, OCH2C(0)0-alkyl, O-aryl, N-aryl, O-heteroaryl, or N- heteroaryl;
W and Z are independently N or CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nCON(R10)-, -(CH2)nCON(R10)( CH2)n-, - SON(R10)-, -SON(R10)(CH2)n-, -S02N(R10)-, -SO2N(R10)(CH2)n-, -N(R10)C(=O)N(R10)-, - N(R10)CO-, -N(R10)CO(CH2)n-, or -N(R10)CO(CH2)n-, -(CH2)nN(R10)-, -C=N-; or Ar and X together form
Figure imgf000006_0001
, or
Figure imgf000006_0002
Y is N or CR2;
R1 is H, halogen, 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
R2 is H, Ci-Ce-alkyl, Ci-C6-haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or N02;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S; R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3-C8- heterocycloalkyl), aryl or heteroaryl; and
each n is independently an integer from 1-3, or a pharmaceutically acceptable salt or hydrate
Figure imgf000006_0003
[0010] In some embodiments, Ra is H, halogen, or haloalkyl;
Y is CH, C-halogen, or C-CN;
Rb is H, 0-(Ci-C2-alkyl), S-(Ci-C2-alkyl), O-cyclopentyl, OCH2CH2N(CH3)2, or
CH2CH2CH2N(CH3)2;
Rc is H; C(=0)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl; Rd is H, Ci-C5-alkyl, OH, O-alkyl, OCH2CH2N(CH3)2, CH2CH2CH2N(CH3)2,
SCH2CH2N(CH3)2, or OCH2C(=0)0-alkyl;
Z is CH, C-0-(Ci-C2-alkyl), C-OCH2CH2N(CH3)2; and X is CONH, SONH, S02NH, NHC(=0)NH, or NHCO, or a pharmaceutically acceptable salt or hydrate thereof.
Figure imgf000007_0001
wherein W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is
OCH2CH2N(CH3)2 or OH; or
wherein W is C-OCH2CH2N(CH3)2, Z is CH, Rb is hydrogen, Rc is hydrogen, and Rd is hydrogen; or
wherein W and Z are each CH, Rb is cyclopentyloxy, Rc is hydrogen, and Rd is
OCH2CH2N(CH3)2; or
wherein W and Z are each CH, Rb is -OCH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-Cl- phenyl), and Rd is -OCH2CH2N(CH3)2; or
wherein W is CH, Z is C-ethoxy, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen; or
wherein W and Z are each CH, Rb is -CH2CH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-Cl- phenyl), and Rd is -CH2CH2CH2N(CH3)2 or hydrogen; or
wherein W and Z are each CH, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen or -OCH2CH2N(CH3)2; or
wherein W and Z are nitrogen, Rb is ethoxy, Rc is hydrogen, and Rd is-OCH2CH2N(CH3)2; or when
Figure imgf000008_0001
is Ar is not wherein Rb is ethoxy, or Ar is
not
Figure imgf000008_0002
wherein W and Z are each CH, Rb is -Sethyl, Rc is hydrogen, and Rd is n- pentyl; or
when X
Figure imgf000008_0003
Ar is not wherein W is CH, Z is nitrogen, Rb is -SCH3, Rc is hydrogen, and Rd d i ·s n-pentyl; or
when
Figure imgf000008_0004
wherein W and Z are each CH,
Rb is hydrogen, Rc is hydrogen, and Ra is -OCH2CH2N(CH3)2; or
when
Figure imgf000008_0005
wherein W and Z are each CH,
RD is ethoxy, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2; or
when X
Figure imgf000008_0006
wherein W and Z are each CH, Rb is methoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2; or
when
Figure imgf000008_0007
wherein W and Z are each CH, Rb is -OCH2C(0)OR wherein R is H or alkyl, Rc is hydrogen, and Rd is -Sethyl; or when
Figure imgf000009_0001
, Ar is not wherein W and Z are each
CH, Rb is ethoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2.
[0012] In some embodiments , Ar is
Figure imgf000009_0002
;
Ra is H, halogen, or haloalkyl;
Rb is H, 0-(Ci-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8- heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), O-(C2-C6-alkyl)-N(R10)2, O-(C3-C8-cycloalkyl)-N(R10)2, N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6- alkyl)-R3, 0-(Ci-C6-alkyl)-R3, 0-(C3-C8-cycloalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Ce-alkyl), or 0-(Ci-C6-alkyl);
Rd is H, OH, Ci-Ce-alkyl, 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(Ci-C6- alkyl), -0-(C2-C6-alkenyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C3-C8-cycloalkyl), -N(R10)-(C3-C8- heterocycloalkyl), -N(R10)-(C2-C6-alkenyl), N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-Ce-alkyl )- N(R10)2, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl;
W and Z are CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nN(R10)-, -C=N-; or Ar and X together form
Figure imgf000010_0001
, or
Figure imgf000010_0002
Y is CR2;
R1 is H, halogen, 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
R2 is halogen or haloalkyl;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S; R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3-C8- heterocycloalkyl), aryl or heteroaryl; and
n is an integer from 1-3, or a pharmaceutically acceptable salt thereof.
[0013] In some embodiments, compounds of formula (I) have histone acetyltransferase (HAT) activity. In some embodiments, the compounds of formula (I) are HAT modulators. In some embodiments, the compounds of formula (I) are HAT activators. In some embodiments, the compounds of formula (I) are HAT inhibitors. In some embodiments, the compounds of formula (I) exhibit high selectivity for HAT and blood-brain-barrier (BBB) permeability. In some embodiments, the compounds of formula (I) exhibit high selectivity for HAT. In some embodiments, the compounds of formula (I) exhibit blood-brain-barrier (BBB) permeability.
[0014] Another aspect of the invention provides a method for screening compounds of formula (I) to treat conditions associated with accumulated amyloid-beta peptide deposits. In some embodiments, the method comprises (a) administering a compound of formula (I) to an animal model of amyloid-beta peptide deposit accumulation; and (b) selecting a compound of formula (I) that can modulate histone acetylation after administration in an animal model of amyloid-beta peptide deposit accumulation.
[0015] Another aspect of the invention provides a method for reducing amyloid beta (Αβ) protein deposits in a subject wherein the method comprises administering to the subject an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I) thereby decreasing Αβ protein deposits in the subject. In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the subject exhibits abnormally elevated levels of amyloid beta plaques. In some embodiments, the subject is afflicted with Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy. In some embodiments, the Αβ protein deposit comprises an Αβ40 isomer, an Αβ42 isomer, or a combination of isomers. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the composition crosses the blood brain barrier. In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is compounds 1-26, or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
[0016] Another aspect of the invention provides a method for treating Alzheimer's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the
composition crosses the blood brain barrier. In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is compounds 1-26, or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
[0017] Another aspect of the invention provides a method for treating Alzheimer's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the
composition crosses the blood brain barrier. In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
[0018] Another aspect of the invention provides a method for increasing memory retention in a subject afflicted with a neurodegenerative disease, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV- associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia,
Neuroborreliosis, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele- Richardson-Olszewski disease, Tabes dorsalis, or Toxic encephalopathy. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some
embodiments, the composition crosses the blood brain barrier. In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
[0019] Another aspect of the invention provides a method for increasing synaptic plasticity in a subject afflicted with a neurodegenerative disease, the method comprising administering to a subject a therapeutic amount of a composition that increases histone acetylation in the subject, wherein the composition comprises a compound of formula (I). In some
embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some
embodiments, the composition crosses the blood brain barrier. In some embodiments, the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism,
Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt- Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative
FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt- Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, or Toxic encephalopathy. In some embodiments, synaptic plasticity comprises learning, memory, or a combination thereof. In some embodiments, synaptic plasticity comprises long term potentiation (LTP). In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
[0020] Another aspect of the invention provides a method for ameliorating symptoms of Parkinson's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some
embodiments, the composition crosses the blood brain barrier. In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof. In some embodiments, the symptoms of Parkinson's Disease comprise tremor, bradykinesia, dyskinesia, rigidity, postural instability, dystonia, akathisia, dementia, impaired gross motor coordination, or a combination of the listed symptoms. In some embodiments, the postural instability comprises impaired imbalance, impaired coordination, or a combination thereof.
[0021] Another aspect of the invention also provides a method for treating cancer in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the composition crosses the blood brain barrier. In some embodiments, the cancer comprises B cell lymphoma, colon cancer, lung cancer, renal cancer, bladder cancer, T cell lymphoma, myeloma, leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic
lymphocytic leukemia, acute lymphocytic leukemia, hematopoietic neoplasias, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, uterine cancer, renal cell carcinoma, hepatoma, adenocarcinoma, breast cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, ovarian cancer, primary or metastatic melanoma, squamous cell carcinoma, basal cell carcinoma, brain cancer, angiosarcoma, hemangiosarcoma, bone sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, testicular cancer, uterine cancer, cervical cancer, gastrointestinal cancer, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia, papillary adenocarcinomas, cystadenocarcinoma, bronchogenic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, lung carcinoma, epithelial carcinoma, cervical cancer, testicular tumor, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, retinoblastoma, leukemia, melanoma, neuroblastoma, small cell lung carcinoma, bladder carcinoma, lymphoma, multiple myeloma, or medullary carcinoma. In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof. [0022] Another aspect of the invention provides a method for treating Huntington's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the
composition crosses the blood brain barrier. In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
[0023] Another aspect of the invention provides for a method of treating a neurodegenerative disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the
composition crosses the blood brain barrier. In some embodiments, the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome,
Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia,
Frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia,
Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren- Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, or Toxic encephalopathy. In other embodiments, synaptic plasticity comprises learning, memory, or a combination thereof. In some embodiments, synaptic plasticity comprises long term potentiation (LTP). In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
[0024] Another aspect of the invention provides for a method of decreasing inclusion bodies in a subject afflicted with a neurodegenerative disorder, the method comprising administering to the subject an effective amount of a compound of formula (I) or a composition comprising a compound of formula (I). In some embodiments, a compound of formula (I) is
administered. In some embodiments, a composition comprising a compound of formula (I) is administered. In some embodiments, the inclusion bodies comprise beta-amyloid peptides, native and phosphorylated Tau proteins, native and phosphorylated alpha-synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof. In other embodiments, the subject exhibits abnormally elevated levels of amyloid beta plaques. In some
embodiments, the beta-amyloid peptides comprises an Αβ40 isomer, an Αβ42 isomer, or a combination of isomers. In some embodiments, the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight. In some embodiments, the composition crosses the blood brain barrier. In some embodiments, the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV- associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia,
Neuroborreliosis, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele- Richardson-Olszewski disease, Tabes dorsalis, or Toxic encephalopathy. In other embodiments, synaptic plasticity comprises learning, memory, or a combination thereof. In some embodiments, synaptic plasticity comprises long term potentiation (LTP). In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is any of compounds 1-26 or any combination thereof. In some embodiments, the compound increases histone acetylation. In some embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof. In some embodiments, histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof. BRIEF DESCRIPTION OF THE FIGURES
[0025] FIG. 1 is a schematic showing that CBP is recruited to act as a bridge between DNA- bound phosphorylated CREB and the basal transcription machinery located at the start site of transcription. In addition, CBP acts as a HAT, making the chromatin more accessible and increasing the transcription of memory associated genes. Unlike CBP, HDACs remove an acetyl group from histones, thus restricting access of the transcriptional machinery to the DNA (figure was modified from Lodish H., B.A., Zipursky LS., Matsudaira P., Baltimore D., Darnell J., Molecular Cell Biology. 4 ed. 2000, New York: W. H. Freeman and Company).
[0026] FIG. 2 is a schematic of histone acetylation and the role of HATs.
[0027] FIG. 3 is a schematic showing the role of a HDAC inhibitor (HDACi; e.g., TSA) in histone acetylation and deacetylation.
[0028] FIG. 4 is a schematic of the compound D/CTPB/CTB (FIG. 4A) and nemorosone (FIG. 4B) scaffolds.
[0029] FIG. 5 is an exemplary synthetic scheme for compounds (I-g). Modifications at C2, where Yis OH, or NH2. Modifications at C2 for compounds (I-g), where Y is O, or NH; R is alkyl, cycloalkyl, alkenyl, heterocycle, aryl, heteroaryl, alkylamino, or cycloalkylamino.
[0030] FIG. 6 is an exemplary synthetic scheme for compounds (I-h). Modifications at C6, where R is alkyl, cycloalkyl, alkenyl, heterocycle, aryl, heteroaryl, alkylamino, or
cycloalkylamino .
[0031] FIG. 7 are exemplary structures showing modifications at linker between I and II rings. For compound (I-i), X is CO, R is H, alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, or substituted aryl and heteroaryl; For compound 6, X is CH2, R is H; For compound (I-j), X is CH2CO, R is H, Y is 0-3; For compound (I-k), X is CO, R is H, Y is 1-3.
[0032] FIG. 8 is an exemplary structure showing modifications at the II ring, where R is a substituted aryl and heteroaryl for compound (1-1). [0033] FIG. 9 is an exemplary structure showing modifications at the I ring. For compound 1, R2 is ethoxyl, R3 is H, R4 is methyl, R5 is H; For compound 2, R2 is ethoxyl, R3 is CI, R4 is H, R5 is CI; For compound 3, R2 is H, R3 is ethoxyl, R4 is H, R5 is H; For compound 4, R2 is H, R3 is H, R4 is ethoxyl, R5 is H.
[0034] FIG. 10 are drawings of molecular structures that are constrained, where Y is O, or NH; and where R is ethyl, or 2-(dimethylamino)ethyl.
[0035] FIG. 11 is a synthetic scheme for compound 5.
[0036] FIG. 12 shows the synthetic scheme for (I-d) compounds 3-alkyloxyphthalimide (FIG. 12A) and 3-aminophthalimide derivatives (FIG. 12B).
[0037] FIG. 13 shows in vitro measurements of HAT enzymatic activity for selected compounds.
DETAILED DESCRIPTION OF THE INVENTION
[0038] In one aspect, the invention is directed to a compound of formula (I).
Figure imgf000024_0001
wherein,
Figure imgf000024_0002
Ra is H, Ci-Ce-alkyl, Ci-C6-haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or N02;
Rb is H, Ci-Ce-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-heteroalkyl, C3-C8- heterocycloalkyl, aryl, heteroaryl, 0-(Ci-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8-heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), S-(Ci-C6- alkyl), 0-(C2-C6-alkyl)-N(Rlu)2, 0-(C3-C8-cycloalkyl)-N(Rlu)2, N(Rlu)-(C2-C6-alkyl)-N(Rlu)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, 0-(C3-C8-cylcoalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Ce-alkyl), 0-(Ci-C6-alkyl), C(=0)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl;
Rd is H, OH, -(Ci-Ce-alkyl), 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(C2-C6- alkenyl), 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C2-C6-alkenyl), -N(R10)-(C3-C8- cycloalkyl), -N(R10)-(C3-C8-heterocycloalkyl), N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl )- N(R10)2, S-(C2-C6-alkyl)-N(R10)2, OCH2C(0)0-alkyl, O-aryl, N-aryl, O-heteroaryl, or N- heteroaryl;
W and Z are independently N or CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nCON(R10)-, -(CH2)nCON(R10)( CH2)n-, - SON(R10)-, -SON(R10)(CH2)n-, -S02N(R10)-, -SO2N(R10)(CH2)n-, -N(R10)C(=O)N(R10)-, - N(R10)CO-, -N(R10)CO(CH2)n-, or -N(R10)CO(CH2)n-, -(CH2)nN(R10)-, -C=N-; or
Ar and X together form
Figure imgf000025_0001
or
Figure imgf000025_0002
Y is N or CR2;
R1 is H, halogen, 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
R2 is H, Ci-Ce-alkyl, Ci-C6-haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or N02; R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S; R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3-C8- heterocycloalkyl), aryl or heteroaryl; and
each n is independently an integer from 1-3, or a pharmaceutically acceptable salt or hydrate
thereof; with the proviso that Ar is not
Figure imgf000026_0001
[0039] In some embodiments, the compound of formula (I)
Figure imgf000026_0002
wherein,
Figure imgf000026_0003
Ra is H, halogen, or haloalkyl;
Rb is H, Ci-Ce-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-heteroalkyl, C3-C8- heterocycloalkyl, aryl, heteroaryl, 0-(Ci-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8-heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), S-(Ci-C6- alkyl), O-(C2-C6-alkyl)-N(R10)2, O-(C3-C8-cycloalkyl)-N(R10)2, N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, 0-(C3-C8-cylcoalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Ce-alkyl), 0-(Ci-C6-alkyl), C(=0)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl;
Rd is H, OH, Ci-Ce-alkyl, 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(C2-C6- alkenyl), 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C2-C6-alkenyl), -N(R10)-(C3-C8- cycloalkyl), -N(R10)-(C3-C8-heterocycloalkyl), N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl )- N(R1U)2, S-(C2-C6-alkyl)-N(Rlu)2, OCH2C(0)0-alkyl, O-aryl, N-aryl, O-heteroaryl, or N- heteroaryl;
W and Z are independently N or CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nCON(R10)-, -(CH2)nCON(R10)(CH2)n-, - SON(R10)-, -SON(R10)(CH2)n-, -S02N(R10)-, -SO2N(R10)(CH2)n-, -N(R10)C(=O)N(R10)-, - N(R10)CO-, -N(R10)CO(CH2)n-, or -N(R10)CO(CH2)n-, -(CH2)nN(R10)-, -C=N-; or
Ar and X together form
Figure imgf000027_0001
or
Figure imgf000027_0002
Y is N or CR2;
R1 is H, halogen, 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
R2 is H, halogen, haloalkyl, -N02 or CN;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S; R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3-C8- heterocycloalkyl), aryl or heteroaryl; and
n is an integer from 1-3, or a pharmaceutically acceptable salt thereof; with the proviso that
Figure imgf000027_0003
[0040] In some embodiments, Ra is H, halogen, or haloalkyl;
Y is CH, C-halogen, or C-CN;
Rb is H, 0-(Ci-C2-alkyl), S-(Ci-C2-alkyl), O-cyclopentyl, OCH2CH2N(CH3)2, or
CH2CH2CH2N(CH3)2; Rc is H; C(=0)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl; Rd is H, Ci-Cs-alkyl, OH, O-alkyl, OCH2CH2N(CH3)2, CH2CH2CH2N(CH3)2,
SCH2CH2N(CH3)2, or OCH2C(=0)0-alkyl;
Z is CH, C-0-(Ci-C2-alkyl), C-OCH2CH2N(CH3)2; and
X is CONH, SONH, S02NH, NHC(=0)NH, or NHCO, or a pharmaceutically acceptable salt or hydrate thereof.
Figure imgf000028_0001
wherein
W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2 or OH; or wherein W is C-OCH2CH2N(CH3)2, Z is CH, Rb is hydrogen, Rc is hydrogen, and Rd is hydrogen; or
wherein W and Z are each CH, Rb is cyclopentyloxy, Rc is hydrogen, and Rd is
OCH2CH2N(CH3)2; or
wherein W and Z are each CH, Rb is -OCH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-C1- phenyl), and Rd is -OCH2CH2N(CH3)2; or
wherein W is CH, Z is C-ethoxy, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen; or
wherein W and Z are each CH, Rb is -CH2CH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-Cl- phenyl), and Rd is -CH2CH2CH2N(CH3)2 or hydrogen; or
wherein W and Z are each CH, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen or -OCH2CH2N(CH3)2; or wherein W and Z are nitrogen, Rb is ethoxy, Rc is hydrogen, and Rd is-OCH2CH2N(CH3)2; or
when ~* X
Figure imgf000029_0001
, Ar is not wherein R is ethoxy, or Ar is
Rb not Rc A Z A Rd wherein W and Z are each CH, Rb is -Sethyl, Rc is hydrogen, and Rd is n- pentyl; or
when -° A
Figure imgf000029_0002
. Ar is not wherein W is nitrogen, Rb is -SCH3, Rc is hydrogen, and Rd is n-pentyl; or
when ~* "X
Figure imgf000029_0003
wherein W and Z are each CH,
Rb is hydrogen, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2; or
when X
Figure imgf000029_0004
wherein W and Z are each CH,
Rb is ethoxy, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2; or
when
Figure imgf000029_0005
wherein W and Z are each CH, Rb is methoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2; or when
Figure imgf000030_0001
wherein W and Z are each CH, Rb is -OCH2C(0)OR wherein R is H or alkyl, Rc is hydrogen, and Rd is -Sethyl; or
when X
Figure imgf000030_0002
not wherein W and Z are each
CH, Rb is ethoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2.
[0042] Thus, in some embodiments, the compound of formula (I) is not selected from the
Figure imgf000030_0003
group consisting of
Figure imgf000030_0004
wherein R is H or alkyl,
Figure imgf000030_0005
Figure imgf000031_0001
[0043] In some embodiments Ar is
Figure imgf000032_0001
;
Ra is H, halogen, or haloalkyl;
Rb is H, 0-(Ci-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8- heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), O-(C2-C6-alkyl)-N(R10)2, O-(C3-C8-cycloalkyl)-N(R10)2, N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6- alkyl)-R3, 0-(Ci-C6-alkyl)-R3, 0-(C3-C8-cycloalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Ce-alkyl), or 0-(Ci-C6-alkyl);
Rd is H, OH, Ci-Ce-alkyl, 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(Ci-C6- alkyl), -0-(C2-C6-alkenyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C3-C8-cycloalkyl), -N(R10)-(C3-C8- heterocycloalkyl), -N(R10)-(C2-C6-alkenyl), N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-Ce-alkyl )- N(R10)2, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl;
W and Z are CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nN(R10)-, -C=N-; or
Ar and X together form
Figure imgf000032_0002
or
Figure imgf000032_0003
Y is CR2;
R1 is H, halogen, 0-(d-C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
halogen or haloalkyl; R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S; R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3-C8- heterocycloalkyl), aryl or heteroaryl; and
n is an integer from 1-3, or a pharmaceutically acceptable salt thereof.
[0044] In some embodiments , Ar is .
[0045] In some embodiments, Ar is
Figure imgf000033_0001
[0046] In some embodiments, Ra is H, Ci-C6-alkyl, Ci-C6-haloalkyl, 0-(Ci-C6-alkyl), 0-(C C6-haloalkyl), halogen, CN, or N02. In some embodiments, Ra is Ci-C6-alkyl, Ci-C6- haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or N02. In some
embodiments, Ra is Ci-C3-alkyl, Ci-C3-haloalkyl, 0-(Ci-C3-haloalkyl), halogen, CN, or N02. In some embodiments, Ra is H, halogen, or Ci-C6-haloalkyl. In some embodiments, Ra is H, halogen, or Ci-C3-haloalkyl. In some embodiments, Ra is halogen or Ci-C6-haloalkyl. In some embodiments, Ra is halogen or Ci-C3-haloalkyl. In some embodiments, Ra is Ci-C6- haloalkyl. In some embodiments, Ra is Ci-C3-haloalkyl. In some embodiments, Ra is CF3.
[0047] In some embodiments, Rb is H, 0-(C2-C6-alkyl), S-(C2-C6-alkyl), 0-(C3-C8- cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8-heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)- (C3-C8-cycloalkyl), O-(C2-C6-alkyl)-N(R10)2, O-(C3-C8-cycloalkyl)-N(R10)2, N(R10)-(C2-C6- alkyl)-N(R10)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(C C6-alkyl)-R3, 0-(C3-C8- cycloalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl. In some embodiments, Rb is H, 0-(C2-C6-alkyl), S-(C2-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8- heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), O-(C2-C6-alkyl)-N(R10)2, O-aryl, or O-heteroaryl. In some embodiments, Rb is H, 0-(C2-C6-alkyl), S-(C2-C6-alkyl), O- (C3-C8-cycloalkyl), N(R10)-(Ci-C6-alkyl), or N(R10)-(C3-C8-cycloalkyl). In some embodiments, Rb is H, 0-(C2-C4-alkyl), or N(R10)-(Ci-C6-alkyl). In some embodiments, Rb is H or 0-(C2-C6-alkyl). In some embodiments, Rb is H or 0-(C2-C4-alkyl). In some embodiments, Rb is 0-(C2-C4-alkyl) or S-(C2-C4-alkyl). In some embodiments, Rb is 0-(C2- C4-alkyl). In some embodiments, Rb is O-ethyl, O-propyl, O-butyl, O-cyclopropyl, or O- cyclobutyl. In some embodiments, Rb is O-ethyl, O-propyl, or O-butyl. In some
embodiments, Rb is O-ethyl.
[0048] In some embodiments, Rc is H, -(Ci-C6-alkyl), or 0-(C2-C6-alkyl). In some embodiments, Rc is H or -(Ci-C6-alkyl). In some embodiments, Rc is H, or 0-(C2-C6-alkyl). In some embodiments, Rc is H.
[0049] In some embodiments, Rd is H, OH, Ci-C6-alkyl, 0-(C3-C8-cycloalkyl), 0-(C3-C8- heterocycloalkyl), 0-(Ci-C6-alkyl), -0-(C2-C6-alkenyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6- alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C3- C8-cycloalkyl), -N(R10)-(C3-C8-heterocycloalkyl), -N(R10)-(C2-C6-alkenyl), N(R10)-(C2-C6- alkyl)-N(R10)2, -(Ci-C6-alkyl )-N(R10)2, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl. In some embodiments, Rd is 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(Ci-C6- alkyl), -0-(C2-C6-alkenyl), O-(C2-C6-alkyl)-N(R10)2, -(C C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C3-C8-cycloalkyl), -N(R10)-(C3-C8 heterocycloalkyl), -N(R10)-(C2-C6-alkenyl), N(R10)-(C2-C6-alkyl)-N(R10)2, -(C C6-alkyl )- N(R10)2, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl. In some embodiments, Rd is 0-(Ci C6-alkyl), -0-(C2-C6-alkenyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)- R3, N(R10)-(C1-C6-alkyl)-R3, N(R10)-(C2-C6-alkyl)-N(R10)2, -(C C6-alkyl )-N(R10)2, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl. In some embodiments, Rd is O-(C2-C6-alkyl)-N(R10)2 -(Ci-C6-alkyl)-R3, 0-(C C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, N(R10)-(C2-C6-alkyl)- N(R10)2, or -(Ci-C6-alkyl )-N(R10)2. In some embodiments, Rd is O-(C2-C4-alkyl)-N(R10)2, (Ci-C4-alkyl)-R3, 0-(Ci-C4-alkyl)-R3, N(R10)-(Ci-C4-alkyl)-R3, N(R10)-(C2-C4-alkyl)- N(R10)2, or -(Ci-C4-alkyl )-N(R10)2. In some embodiments, Rd is O-(C2-C4-alkyl)-N(R10)2 or 0-(Ci-C4-alkyl)-R3.
[0050] In some embodiments, W and Z are independently N or CR1. In some embodiments, W is N. In some embodiments, Z is N. In some embodiments, W is CR1. In some embodiments, Z is CR1. In some embodiments, W and Z are both CR1. In some
embodiments, W and Z are both N.
[0051] In some embodiments, X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nN(R10)-, or -C=N-. In some embodiments, X is -CO-, -CON(R10)-, -CON(R10)(CH2)-, or -C=N-. In some embodiments, X is -CON(R10)- or -C=N-. In some embodiments, X is -CON(R10).
[0052] In some embodiments, Ar and X together form
Figure imgf000035_0001
Figure imgf000035_0002
In some embodiments, Ar and X together form
[0054] In some embodiments, Ar and X together form
[0055] In some embodiments, Ar and X together form
Figure imgf000035_0003
[0056] In some embodiments, Ar and X together form
[0057] In some embodiments, the compound of formul
Figure imgf000036_0001
a (I) is
Figure imgf000036_0002
[0058] In some embodiments, the compound of formula (I) is
Figure imgf000036_0003
or
Figure imgf000036_0004
In some embodiments, the compound of formula (I) is
[0060] In some embodiments, the compound of formula (I) is, X
Figure imgf000036_0005
Ar^
[0061] In some embodiments, the compound of formula (I) is X
[0062] In some embodiments, Y is N or CR2. In some embodiments, Y is CR2. In some embodiments, Y is N. [0063] In some embodiments, R1 is H, halogen, 0-(Ci-C6-alkyl), or O-(C2-C6-alkyl)N(R10)2. In some embodiments, R1 is H or halogen. In some embodiments, R1 is H. In some embodiments, R1 is halogen. In some embodiments, R1 is CI or F.
[0064] In some embodiments, R2 is H, Ci-C6-alkyl, Ci-C6-haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci- C6-haloalkyl), halogen, CN, or N02. In some embodiments, R2 is H, Ci-C6-alkyl, Ci-C6- haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or N02. In some
embodiments, R2 is Ci-C3-alkyl, Ci-C3-haloalkyl, 0-(Ci-C3-haloalkyl), halogen, CN, or N02. In some embodiments, R2 is H, halogen, Ci-C6-haloalkyl, N02 or CN. In some embodiments, R2 is H, halogen, or Ci-C6-haloalkyl. In some embodiments, R2 is H, halogen, or C1-C3- haloalkyl. In some embodiments, R2 is halogen or Ci-C6-haloalkyl. In some embodiments, R2 is halogen or Ci-C3-haloalkyl. In some embodiments, R2 is Ci-C6-haloalkyl. In some embodiments, R2 is halogen. In some embodiments, R2 is Ci-C3-haloalkyl. In some embodiments, R2 is CI, F, or CF3.
[0065] In some embodiments, R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S. In some embodiments, R3 is C3-C8-cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S. In some embodiments, R3 is C3-C8-cycloalkylamino, morpolinyl, thiomorpholinyl, or N-alkylpiperazinyl. In some embodiments, R3 is piperidinyl, or N-alkylpiperazinyl.
[0066] In some embodiments, R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), - (C3-C8-cycloalkyl), aryl or heteroaryl. In some embodiments, R10 is independently H, -(Ci- C4-alkyl), or -(Ci-C4-haloalkyl). In some embodiments, R10 is independently H or -(Ci-C4- alkyl). In some embodiments, R10 is independently H or -(Ci-C2-alkyl). In some
embodiments, R10 is independently H or methyl. In some embodiments, R10 is H.
[0067] In some embodiments, the compound of formula (I) is a compound of formula (I-a),
Figure imgf000038_0001
s wherein,
Ra is H, halogen, or haloalkyl;
Rb is 0-(Ci-C6)-alkyl or S-(Ci-C6)-alkyl;
Rd is (Ci-C6)-alkyl or 0-(Ci-C6)-alkyl-N(CH3)2;
Y is haloalkyl, C-CN, C-N02, or N;
W is CH or N; and
Z is CH or N, or a pharmaceutically acceptable salt or hydrate thereof.
[0068] In some embodiments, the compound of formula (I) is a compound of formula (I-b),
Figure imgf000038_0002
(I-b) , wherein
Ra is haloalkyl;
R2 is CN; and
Rb is 0-(Ci-C6)-alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0069] In some embodiments, the compound of formula (I) is a compound of formula (I-c),
Figure imgf000038_0003
, wherein Rb is H, or ethoxyl;
W and Z are independently CH, C-Cl, or C-OEt; and
Rc is H, ethoxyl, or methyl; or a pharmaceutically acceptable salt or hydrate thereof.
[0070] In some embodiments of formula (I-c), Rb is ethoxyl, W and Z are each CH, and Rc is methyl. In some embodiments of formula (I-c), Rb is ethoxyl, W and Z are each C-Cl, and Rc is H. In other embodiments of formula (I-c), Rb is H, W is ethoxyl, Rc is H, and Z is CH. In a further embodiment of formula (I-c), Rb is H, W and Z are each CH, and Rc is ethoxyl.
[0071] In some embodiments, the compound of formula (I) is
Figure imgf000039_0001
, or a pharmaceutically acceptable salt or hydrate thereof.
[0072] In some embodiments, the compound of formula (I) is compound (I-d),
Figure imgf000039_0002
(I-d) , wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or -NH-CH2CH2N(CH3)2, or a pharmaceutically acceptable salt or hydrate thereof.
[0073] In some embodiments, the compound of formula (I) is compound (I-e),
Figure imgf000039_0003
(!-e) , wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or
-NH-CH2CH2N(CH3)2, or a pharmaceutically acceptable salt or hydrate thereof.
[0074] In some embodiments, the compound of formula (I) is compound (I-f),
Figure imgf000040_0001
Of ) , wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or -NH-CH2CH2N(CH3)2, or a pharmaceutically acceptable salt or hydrate thereof.
[0075] In some embodiments, the compound of formula (I) is compound (I-g):
Figure imgf000040_0002
!"§) , whereinRd is -0-(d-C6)-alkyl, -NH-(Ci-C6)-alkyl, -O-
(C2-C6)-alkenyl, -NH-(C2-C6)-alkenyl, -0-(C3-C8)-cycloalkyl, -NH-(C3-C8)-cycloalkyl, - 0-(C3-C8)-heterocycloalkyl, -NH-(C3-C8)-heterocycloalkyl, -O-aryl, -N-aryl, -O-heteroaryl, -N-heteroaryl, -O-(Ci-C6)-alkyl-N(R10)2, -NH-(Ci-C6)-alkyl-N(R10)2, -0-(Ci-C6-alkyl)-R3, or -NH-(Ci-C6-alkyl)-R3.
[0076] In some embodiments, the compound of formula (I) is compound (I-h):
Figure imgf000040_0003
wherein Rb is -0-(Ci-C6)-alkyl, -0-(C2-C6)-alkenyl, -0-(C3
Cg)-cycloalkyl, -0-(C3-C8)-heterocycloalkyl, -O-aryl, -O-heteroaryl, -0-(Ci-Ce)-alkyl- N(R10)2, or -0-(Ci-C6-alkyl)-R3.
[0077] In some embodiments, the compound of formula (I) is compound (I-i):
Figure imgf000040_0004
, wherein R1U is H, -(d-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8 cycloalkyl), -(C3-C8-heterocycloalkyl), aryl or heteroaryl. In some embodiments, R is H, - (Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-Cg-cycloalkyl), or
Figure imgf000041_0001
In some embodiments, R10 is H, -(Ci-C4-alkyl), or -(Ci-C4-haloalkyl). In some embodiments, R10 is H, or -(Ci-C4-alkyl). In some embodiments, R10 is -(Ci-C4-alkyl).
[0078] In some embodiments, the compound of formula (I) is
[0079] In some embodiments, the compound of formula (I) is
Figure imgf000041_0002
[0080] In some embodiments, the compound of formula (I) is -j) wherein X is CH2CONH(CH2)n, and n is 0-3.
[0081] In some embodiments, the compound of formula (I) is
Figure imgf000041_0003
fl"k) , wherein X is CONH(CH2)n, and n is 0-3.
Figure imgf000042_0001
[0082] In some embodiments, the compound of formula (I) is /N \ .
[0083] In some embodiments, the compound of formula (I) is a pharmaceutically acceptable salt. In some embodiments, the compound of formula (I) is a hydrate.
[0084] The term "HAT modulator" as used herein encompasses, for example, compound of formula (I) and subgenera and/or species thereof. For example, in some embodiments, the HAT modulator compound is a compound of formula (I). In some embodiments, the HAT modulator compound is a compound of formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j), (I-k), (I-l), or any combination thereof. In some embodiments, the compound of formula (I) is a compound of formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j), (I-k), (I-l), or any combination thereof. In some embodiments, the compound is any of compounds 1-26, or any combination thereof. In some embodiments, the compound of formula (I) is any of compounds 1-26, or any combination thereof. In some embodiments, the HAT modulator is a HAT activator. In some embodiments, the HAT modulator is a HAT inhibitor. The term "HAT modulator" may also apply as used elsewhere herein.
[0085] In some embodiments, the compound of formula (I) is a compound of formula (I-a). In some embodiments, the compound of formula (I) is a compound of formula (I-b). In some embodiments, the compound of formula (I) is a compound of formula (I-c). In some embodiments, the compound of formula (I) is a compound of formula (I-d). In some embodiments, the compound of formula (I) is a compound of formula (I-e). In some embodiments, the compound of formula (I) is a compound of formula (I-f). In some embodiments, the compound of formula (I) is a compound of formula (I-g). In some embodiments, the compound of formula (I) is a compound of formula (I-h). In some embodiments, the compound of formula (I) is a compound of formula (I-i). In some embodiments, the compound of formula (I) is a compound of formula (I-j). In some embodiments, the compound of formula (I) is a compound of formula (I-k). In some embodiments, the compound of formula (I) is a compound of formula (1-1). Each of the embodiments of formula (I) may be combined with one or more other embodiments of formula (I) to generate further embodiments of formula (I).
[0086] Early amnesic changes in Alzheimer's disease (AD) are thought to be linked to synaptic dysfunction, β-amyloid (Αβ), a peptide that is present in high amounts in the disease, has been found to inhibit memory (Proc Natl Acad Sci USA, 2006. 103(23): p. 8852-7; Nat Neurosci, 2005. 8(1): p. 79-84; each herein incorporated by reference in its entirety) and its electrophysiological model, long-term potentiation (LTP) (Neuroreport, 1997, 8(15), 3213-7; Eur J Pharmacol, 1999, 382(3),167-75; Proc Natl Acad Sci USA, 2002, 99(20), 13217-21; Nature, 2002, 416(6880), 535-9; J Neurosci Res, 2000, 60(1), 65-72; Proc Natl Acad Sci US A, 1998, 95(11), 6448-53; each herein incorporated by reference in its entirety). Memory is known to be modulated by epigenetics through regulation of gene expression. Epigenetics is defined as the mechanism that changes gene expression by 'marking' DNA or its associated proteins, through processes such as DNA methylation and histone (H) modification, without changing the DNA sequence itself (Biochem J, 2001. 356(Pt 1): p. 1-10; herein incorporated by reference in its entirety). Modification of histones by, for example, the addition or removal of acetyl or methyl functional groups causes the chromatin structure to open or close, so that the information contained within the DNA is made more or less accessible to transcription factors. Deregulation of one of the epigenetic mechanisms may lead to memory disruption. For example, reduction of histone acetylation causes the chromatin structure to close, so that the information contained within the DNA can be less accessible to transcription factors and memory formation (Biochem J, 2001. 356(Pt 1): p. 1-10; herein incorporated by reference in its entirety).
[0087] Epigenetic modifications including acetylation of histones may contribute to gene expression changes important to learning and memory (Science 2010: 328(5979), 701-702; herein incorporated by reference in its entirety). Addition of acetyl groups to histones by histone acyltransferases (HAT) enhances gene expression, while their removal by histone deacetylases (HDAC) reduces gene expression. Reduction in histone acetylation has recently been linked to age-induced memory impairment and various neurodegenerative diseases (Science 2010: 328(5979), 701-702; herein incorporated by reference in its entirety). HDAC inhibitors have been shown to enhance memory in mice (Nature 459, 55-60 (7 May 2009); herein incorporated by reference in its entirety). Although clinical trials of several HDAC inhibitors are currently underway to try to prevent deacetylation, the alternative strategy of increasing histone acetylation by activating HAT has not been significantly explored.
Histone acetylation is discussed in, for example, U.S. Patent Publication Nos. 2010/0166781; 2010/0144885; 2009/0076155; Neuroscience 2011, 194, 272-281; and J. Phys. Chem B 2007, 111(17), 4527-4534 (each of which herein incorporated by reference in its entirety).
[0088] Epigenetics is emerging as a new and powerful area for drug development in the field of memory. Currently used AD therapies have limited efficacy. Major efforts are underway to inhibit tangle formation, to combat inflammation and oxidative damage, and to decrease Αβ load in the brain (Br J Pharmacol, 2002. 137(5): p. 676-82; JNeurosci, 2005. 25(10): p. 2455-62; Nature, 1999. 400(6740): p. 173-7; each hereby incorporated by reference in its entirety). However, the role of tau, APP, Αβ, and the secretases in normal physiological function (Eur J Pharmacol, 1995. 284(3): p. Rl-3; Biochem Biophys Res Commun, 1994. 205(3): p. 1829-35; J Neurochem, 1999. 73(2): p. 532-7; each hereby incorporated by reference in its entirety), can present a problem in providing effective and safe approaches to AD therapy. Many data strongly support an involvement of epigenetic mechanisms in memory dysfunction in neurodegenerative diseases including AD. HAT activators represent a new class of compounds that may effectively counteract the disease progression. Recently, a novel HAT activator has been demonstrated to improve contextual learning in healthy mice (WO 2011/072243; herein incorporated by reference in its entirety). In some embodiments, the invention comprises compounds that show comparable positive effects, but have improved drug-like characteristics.
[0089] The main strategy that is currently used to up-regulate histone acetylation involves inhibition of histone deacetylases (HDACs), enzymes that remove an acetyl group from histones. However, the pleiotropic effect of nonspecific HDAC inhibition can hamper the therapeutic potential of HDAC inhibitors (J Virol, 2001. 75(4): p. 1909-17; J Virol, 2003. 77(21): p. 11425-35; Biochemistry. 2008, Vanderbilt: Nashville, p. 167; PLoS One, 2009. 4(8): p. e6612; each of which herein incorporated by reference in its entirety). It has been demonstrated that hippocampal levels of two HATs, CBP and PCAF, are reduced following Αβ elevation. As discussed herein, the data is focused, in part, toward another target that also up-regulates histone acetylation, the HATs. Selective HAT activators that target specifically CBP and PCAF downstream of Αβ will be designed. For example, new HAT activators will be designed and synthesized which can treat AD; compounds with high affinity and good selectivity for selective HAT activators will be identified that target specifically CBP and PCAF; HAT activators will be assessed as to whether they have a good pharmacokinetic (PK) profile and are safe; select HAT activators will be examined for their ability to rescue synaptic dysfunction in APP/PS1 mice; and HAT activators will be further screened to determine beneficial effects against cognitive abnormalities in APP/PS1 mice.
[0090] The post-translational acetylation status of chromatin is governed by the competing activities of two classes of enzymes, HATs and HDACs. HDAC inhibitors enhance LTP and contextual fear memory, a form of associative memory in which animals must associate a neutral stimulus with an aversive one {J Biol Chem, 2004. 279(39): p. 40545-59; hereby incorporated by reference in its entirety). Also, memory and LTP deficits of CBP+/ mice were reversed by HDAC inhibition {Neuron, 2004. 42(6): p. 947-59; hereby incorporated by reference in its entirety). The potential of inhibiting HDACs to counteract neurodegenerative disorders has been widely explored (Curr Drug Targets CNS Neurol Disord, 2005. 4(1): p. 41-50; hereby incorporated by reference in its entirety). For instance, in a set of experiments, Tsai et al. have reported that HDAC inhibitors induced sprouting of dendrites, increased number of synapses, and reinstated learning and access to long-term memories in the CK-p25 Tg mouse model of neurodegeneration (Nature, 2007. 447(7141): p. 178-82; EMBO J, 2007. 26(13): p. 3169-79; each hereby incorporated by reference in its entirety). Moreover, in recent studies it has been shown that the HDAC inhibitor TSA ameliorates LTP and contextual fear conditioning (FC) in the double Tg APP(K670M:N671L)/PS1(M146L, line 6.2) (APP/PS1) mouse model of amyloid deposition (J Alzheimer s Dis, 2009. 18(1): p. 131-9; hereby incorporated by reference in its entirety). Bolden et al, (Nature Reviews Drug Discovery, 2006, 5:769-84; hereby incorporated by reference in its entirety) describe the histone deacetylases family. HATs, however, have been investigated to a lesser extent.
[0091] HATs can be divided in two main groups, the nuclear HATs and cytoplasmic HATs (Biochim Biophys Acta, 2009. 1789(1): p. 58-68; hereby incorporated by reference in its entirety. Nuclear A-type HATs can be grouped into at least 4 different families based on sequence conservation within the HAT domain: Gcn5 and p300/CBP associated factor (PCAF), MYST (MOZ, Ybf2/ Sas3, Sas2 and Tip60), p300 and CBP (named for the two human paralogs p300 and CBP) and Rttl09. While the Gcn5/PCAF and MYST families have homologs from yeast to man, p300/CBP is metazoan-specific, and Rttl09 is fungal- specific. Cytoplasmic B-type HATs, such as HAT1, are involved in histone deposition {Biochim Biophys Acta, 2009. 1789(1): p. 58-68; hereby incorporated by reference in its entirety). Marmorstein and Roth (Curr Opin in Genet and Develop., 2001, 11 : 155-161; hereby incorporated by reference in its entirety) list the HAT families and their
transcriptional-related functions .
[0092] Although other nuclear HAT families have been described, such as the steroid receptor coactivators, TAF250, ATF-2, and CLOCK, their HAT activities have not been investigated as extensively as the major HAT classes {Biochim Biophys Acta, 2009. 1789(1): p. 58-68; hereby incorporated by reference in its entirety). These 4 families show high sequence similarity within families but poor to no sequence similarity between families. Furthermore, the size of the HAT domain of the different families is different {Biochim Biophys Acta, 2009. 1789(1): p. 58-68; hereby incorporated by reference in its entirety). Interestingly, HATs are highly conserved in mammals {Biochim Biophys Acta, 2009.
1789(1): p. 58-68; hereby incorporated by reference in its entirety). Of all these HATs, three were shown to be involved in memory: CBP, p300 {Nature, 2007. 447(7141): p. 178-82; EMBO J, 2007. 26(13): p. 3169-79; each hereby incorporated by reference in its entirety), and PCAF (J Alzheimers Dis, 2009. 18(1): p. 131-9; hereby incorporated by reference in its entirety). Interestingly, both CBP and PCAF levels are reduced by Αβ elevation.
[0093] HAT activators can be a viable approach to enhance histone acetylation. Two scaffolds for HAT activators have been identified. The first one includes CTPB and its derivative CTB {JPhys Chem B, 2007. 111(17): p. 4527-34; J Biol Chem, 2003. 278(21): p. 19134-40; each hereby incorporated by reference in its entirety). The second one includes only one compound, nemorosone {Chembiochem. 11(6): p. 818-27; hereby incorporated by reference in its entirety). CTPB/CTB were found to be insoluble and membrane -impermeable {JPhys Chem B, 2007. 111(17): p. 4527-34; J Biol Chem, 2003. 278(21): p. 19134-40; each hereby incorporated by reference in its entirety). Moreover, CTPB has unfavorable characteristics to be used in CNS diseases (such as, for example, MW equal to 553.29, clogP equal to 12.70) and the clogP of CTB is 5.13. Nemorosone has a MW of 502 and a clogP of 8.42. Compounds that target CBP and PCAF can be useful in treatment of CNS disorders such as, for example, AD, as their endogenous expression is reduced following Αβ elevation.
[0094] HATs share a highly conserved motif containing an acetyl-CoA binding site. HATs can be involved in the pathology of cancer, asthma, neurodegenerative diseases and viral infection. HAT activators have been reported, but many compounds are neither soluble nor membrane permeant, which makes them poor drug candidates.
[0095] In some embodiments, the invention provides for compounds with histone acetyltransferase activity. In some embodiments, the compounds are HAT activators. In some embodiments, the compounds are HAT inhibitors. In some embodiments, the compounds have good HAT activation potency, high selectivity, reasonable
pharmacokinetics and/or good permeability across the blood-brain-barrier (BBB). In some embodiments, these compounds can be used as therapy with decreased side effects for AD patients. In some embodiments, the compounds improve cognition or memory in AD and Alzheimer' s-like pathologies, as well as minimize the side effects for subjects afflicted with other neurodegenerative diseases. In some embodiments, the compounds of the invention can also be developed as anti-cancer therapies. In some embodiments, acylation of histone proteins increases gene expression in a subject resulting in enhanced memory and cognition.
[0096] In some embodiments, the invention provides for the utilization of HAT agonists as memory enhancers in normal subjects (for example, a subject not afflicted with a
neurodegenerative disease). In some embodiments, the invention provides for the utilization of HAT agonists as memory enhancers in aging subjects (for example, a subject that is greater than about 55 years old). In some embodiments, the invention provides for the utilization of HAT agonists as memory enhancers for other conditions associated with cognitive decrease/impairment. Non-limiting examples of conditions associated with cognitive decrease/impairment include a variety of syndromes associated with mental retardation and syndromes associated with learning disabilities, Parkinson's disease, Pick's disease, a Lewy body disease, amyotrophic lateral sclerosis, Huntington's disease,
Creutzfeld- Jakob disease, Down syndrome, multiple system atrophy, neuronal degeneration with brain iron accumulation type I (Hallervorden-Spatz disease), pure autonomic failure, REM sleep behavior disorder, mild cognitive impairment (MCI), cerebral amyloid angiopathy (CAA), mild cognitive deficits, aging, vascular dementias mixed with
Alzheimer's disease, a neurodegenerative disease characterized by abnormal amyloid deposition, and any combination thereof.
[0097] Eukaryotic DNA is highly organized and packaged into the nucleus. The organization and packaging are achieved through the addition of proteins, including core histones H2A, H2B, H3 and H4, which form a complex structure, the chromatin, together with DNA (See, for example, WO 2011/072243 and references cited therein). The modification of core histones is of fundamental importance to conformational changes of the chromatin. The level of acetylation is related to transcription activity, and then the acetylation induces an open chromatin confirmation that allows the transcription machinery access to promoters. Histone deacetylase (HDAC) and histone acetyltransferase (HAT) are enzymes that influence transcription by selectively deacetylating or acetylating the ε-amino groups of lysine located near the amino termini of core histone proteins. Chromatin acetylation correlates with transcriptional activity (euchromatin), whereas deacetylation correlates with gene silencing. Interestingly, it was shown that increased acetylation of H3 in area CA1 of the hippocampus (an area in the brain that plays an important role in long-tem memory) occurs following associative memory. Additionally, inhibiting HDAC, may manipulate changes in the chromatin and enhance the formation of long-tem memory. [0098] Histone acetylation and deacetylation are increasingly recognized for their
contribution to the tight regulation of gene activation and silencing, respectively.
Deregulation of these mechanisms may lead to the disruption of memory-associated gene expression, resulting in a number of syndromes associated with mental retardation.
[0099] The DNA is firstly wrapped around an octamer complex of histones (H) to form nucleosomal units, giving the appearance of beads on a string {Nature, 2001. 409(6822): p. 860-921; herein incorporated by reference in its entirety). In turn, these nucleosomal units, fold into a higher-order chromatin fiber {Cell, 1999. 98(3): p. 285-94; herein incorporated by reference in its entirety). Each histone-octamer complex contains two copies of histones H3 and H4 bordered by two copies of histones 2A and 2B {Cell, 1999. 98(3): p. 285-94; herein incorporated by reference in its entirety). HI and its avian variant H5 are linker histones that bind the nucleosome and both the entry and exit sites of the DNA, thus locking the DNA into place and allowing the formation of higher order structure. Every histone has a globular domain, which mediates histone-histone interactions, and an N-terminal 'tail' extension. The histone cores and in particular their tails, are targets for a considerable number of covalent modifications, such as acetylation, ubiquitination, sumoylation, phosphorylation,
citrullination, ADP-ribosylation, and methylation {Angew Chem Int Ed Engl, 2005. 44(21): p. 3186-216; herein incorporated by reference in its entirety). Histone modifications associated with active gene transcription, such as H3 Lys4 methylation and H3 Lys56 acetylation, were found to lead to gene expression. On the other hand, histone modifications associated with the inactivation of gene transcription, such as H3 Lys27 methylation and H2A Lysl 19 ubiquitination were found to cause gene silencing. Histones 2B, 3 and 4 have been shown to be involved in memory processes {Nature, 2007. 447(7141): p. 178-82; Neuron, 2004. 42(6): p. 947-59; each herein incorporated by reference in its entirety). [00100] Histone modifications and their combinations can be involved in gene regulation by modifying the chromatin accessibility and by acting as docking sites for transcription factors and modifying enzymes (Bioessays, 2005. 27(2): p. 164-75; Nature, 2000. 403(6765): p. 41-5; each herein incorporated by reference in its entirety). One of the most studied histone modifications is the acetylation of the evolutionary-conserved lysine residues on the histone N-termini by histone acetyltransferase (HAT). In contrast, histone deacetylation, catalyzed by histone deacetylase (HDAC), was found to package the DNA into a more condensed form, limiting the access of transcription factors and thus acting as a gene silencer (Trends Biochem Sci, 2000. 25(3): p. 121-6; herein incorporated by reference in its entirety). The HATs involved in the regulation of gene expression include at least three groups of enzymes (J Biochem, 2005. 138(6): p. 647-62; herein incorporated by reference in its entirety). The general control non-derepressible 5 (Gcn5) is the founding member of the Gcn5 N-acetyltransferases (GNATs). The GNAT family members include Gcn5, PCAF, Elp3, HATlm Hpa2 and Nutl . The MYST family is named after the founding members of the family: Morf, Ybf2, Sas2 and Tip60 (J Biochem, 2005. 138(6): p. 647-62; herein incorporated by reference in its entirety). In addition, other proteins including CBP/p300, Tafl and a number of nuclear receptor co-activators have been shown to possess intrinsic HAT activity. However, these proteins do not contain a consensus domain and therefore represent an Orphan class' of HAT enzymes (J Biochem, 2005. 138(6): p. 647-62; herein incorporated by reference in its entirety).
[00101] HDACs form repressor complexes with transcription activators and with other
HDACs (Biochem J, 2003. 370(Pt 3): p. 737-49; herein incorporated by reference in its entirety). Mammalian HDACs can be divided into the classical and the silent information regulator 2 (Sir2)-related protein (sirtruin) families (Oncogene, 2007. 26(37): p. 5310-8; herein incorporated by reference in its entirety). In humans, members of the classical family have another subdivision, which include class I, II and IV, that share sequence similarity and require Zn+ for deacetylase activity. Class I HDACs (HDACl-3, HDAC8) are related to the yeast gene repressor Rpd3p, and are subunits of at least two distinct co-repressor complexes, the Sin3 complex and the NuRD complex. Class II HDACs (HDAC4-7, 9 and 10) are similar to the yeast Hdalp HDAC, they act as gene repressors and have been implicated in various roles in cell differentiation and development. Class IV comprises HDAC11, which has some features of both class I and II HDACs. The sirtruin family includes class III HDACs (SIRT1- 7), which are similar to yeast Sir2. Class III HDACs are biochemically and structurally distinct from the classical family and require NAD+ as a cofactor. HDACs appear to be involved in gene silencing and heterochromatin formation at centromeres and telomeres (J Mol Biol, 2004. 338(1): p. 17-31; herein incorporated by reference in its entirety).
[00102] Alterations in epigenetic modifications including acetylation and methylation of DNA and histones can contribute to gene expression changes in cancer and neurological diseases. Addition of acetyl group on histones by Histone Acetyltransferases (HATs) enhances gene expression, while its removal by Histone Deacetylases (HDAC) reduces gene expression. Reduction in histone acetylation has been found in a variety of ailments such as tumors, mood disorders, and neurodegenerative diseases. Examples of HATs include, but are not limited to GCN5, GCN5L, PCAF, HAT1, ELP3, HPA2, ESA1, SAS2, SAS3, TIP60, HBOl, MOZ, MORF, MOF, SRC1, SRC3, TIF2, GRIP1, ATF-2 [see Lee and Workman (2007) Nat Rev Mol Cell Biol, 8(4):284-95, Marmorstein (2001) J Molec Biol. 311 : 433-444; and Kimura et al., (2005) J Biochem. 138(6): 647-662, which are each hereby incorporated by reference in their entireties]. In some embodiments, the HAT modulator compound of the invention is directed to GCN5, GCN5L, HAT1, PCAF, or a combination thereof. In some embodiments, the HAT modulator compound of the invention is directed to proteins that possess intrinsic HAT activity, such as nuclear receptor co-activators (for example, CBP/p300 and Tafl). In some embodiments, the acetylation of H2, H3, and/or H4 histones is increased. In some embodiments, the HAT modulator compound is a compound of formula (I). In some embodiments, the HAT modulator compound is any of compounds 1-26 or any combination thereof.
[00103] Increasing histone acetylation has been shown to improve outcome in a wide variety of diseases as diverse as asthma, infectious disease and psychiatric diseases.
Although clinical trials of several HDAC inhibitors are currently underway, the alternative strategy where by histone acetylation is increased by HAT modulator has not been
extensively explored. For example, compounds in U.S. Patent Publication No.
US2009/076155 and PCT Publication No. WO2004/053140 (which are each hereby incorporated by reference in their entireties) have poor solubility and membrane permeability.
[00104] No HAT activator is currently in clinical trials, however several HDAC inhibitors are currently in clinical trials. Some of these HDAC inhibitors (HDACi) have shown therapeutic efficacy in preclinical trials. Without being bound by theory, HAT modulators may be useful therapeutic candidates with a role similar to HDACi. However, many HAT activators have little solubility and membrane permeability, making them unsuitable as drugs.
[00105] Several HDACi are in trials for cancer, some of which are, for example, 4SC-
202 (Nycomed, Germany), which is in a Preclinical stage; AR-42 (Arno therapeutics, Parsippany, NJ) which is in a Preclinical stage; Belinostat (TopoTarget, Rockaway, NJ) which is in Phase II clinical trials; and Entinostat (Bayer Schering) which is in Phase II clinical trials. For example, in Table 3 of Lane and Chabner (2009, J Clin Oncol.,
27(32):5459-68; incorporated by reference in its entirety), selected clinical trials of HDAC inhibitors are discussed, which include Vorinostat, Depsipeptide, and MGCD0103. In Table 2 of Lane and Chabner (2009, J Clin Oncol., 27(32):5459-68; incorporated by reference in its entirety), selected HDAC inhibitors in clinical use or development are discussed, which include hydroxamic acid compounds (e.g., Vorinostat, Trichostatin A, LAQ824,
Panobinostat, Belinostat, and ITF2357), cyclic tetrapeptide compounds (e.g., Depsipeptide), benzamide compounds (e.g., Entinostat and MGCD0103), and short-chain aliphatic acid compounds (e.g., valproic acid, phenyl butyrate, and pivanex).
[00106] Some HDACi are or were being developed for neurological diseases, such as an HDACi from Merck (Whitehouse Station, NJ) that is being used for the treatment of neurodegenerative diseases; and HDACi from TopoTarget (Rockaway, NJ) that was being used for the treatment of Huntington's disease, now discontinued; isovaleramide NPS-1776 (NPS Pharmaceutical, Bedminster, New Jersey) that was being used for bipolar disorder, epilepsy, and migraines, now discontinued; and a histone acetyltransferase inhibitor for cancer from TopoTarget A/S (Kobenhavn, Denmark), which was discontinued in the preclinical stage.
[00107] In some embodiments, the synthesis of a new class of HAT modulators with improved solubility and membrane permeability are described. For example, the HAT modulators of formula (I) and/or compounds 1-26 may be used as adjuvant therapy in several cancers, psychiatric and neurodegenerative diseases and may improve efficacy and safety of treatment for these disorders. In some embodiments, the compounds of formula (I) and/or compounds 1-26 have improved solubility and membrane and Blood-brain-Barrier (BBB) permeability. See Abel and Zukin (2008) Current Opinion in Pharmacology 8:57-64; and Lee and Workman (2007) Nat Rev Mol Cell Biol 8:284-295 (each hereby incorporated by reference in their entireties).
[00108] In some embodiments, a HAT modulator compound is used to treat a cancer in a subject in need thereof. Non-limiting examples of cancers include B cell lymphoma, colon cancer, lung cancer, renal cancer, bladder cancer, T cell lymphoma, myeloma, leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, hematopoietic neoplasias, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, uterine cancer, renal cell carcinoma, hepatoma, adenocarcinoma, breast cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, ovarian cancer, primary or metastatic melanoma, squamous cell carcinoma, basal cell carcinoma, brain cancer, angiosarcoma, hemangiosarcoma, bone sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,
endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, testicular cancer, uterine cancer, cervical cancer, gastrointestinal cancer, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia, papillary adenocarcinomas,
cystadenocarcinoma, bronchogenic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, lung carcinoma, epithelial carcinoma, cervical cancer, testicular tumor, glioma, astrocytoma, meduUoblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, retinoblastoma, leukemia, melanoma, neuroblastoma, small cell lung carcinoma, bladder carcinoma, lymphoma, multiple myeloma, and medullary carcinoma.
[00109] In some embodiments, a HAT modulator compound is used to treat a neurodegenerative disease in a subject in need thereof. Non-limiting examples of
neurodegenerative diseases include Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren- Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseasesm Progressive Supranuclear Palsy, Refsum's disease, Rett's syndrome, Tau-positive FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren- Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, and Toxic encephalopathy.
[00110] A schematic representation of the processes involved in gene transcription and memory is shown, for example, WO 2011/072243 (herein incorporated by reference in its entirety). In the brain, CREB phosphorylation is required for CREB ability to bind to CBP and to stimulate memory associated gene expression. CBP functions as a co-activator that facilitates interactions with the basal transcription machinery and through its HAT activity catalyzes acetylation of the histones, causing a loss in chromosomal repression and increase in the transcription of memory associated genes. Mutations in HAT domain CBP were found to cause LTM impairment. For instance, Korzus et a\. demonstrated that inducible dominant- negative CBP mice, with no CBP HAT activity, exhibited normal short-tern memory while LTM was impaired {Neuron, 2004. 42(6): p. 961-72; herein incorporated by reference in its entirety). Moreover, the impaired LTM was rescued by suppression of the transgene expression and by HDAC inhibitor administration {Neuron, 2004. 42(6): p. 961-72; herein incorporated by reference in its entirety).
[00111] The relevance of histone deacetylation in memory processes is underscored by a study from Levenson et al. {J Biol Chem, 2004. 279(39): p. 40545-59; herein incorporated by reference in its entirety). In this work acetylation of H3 in area CA1 of the hippocampus (an area in the brain that plays important roles in LTM) was found to be increased following training for contextual fear conditioning, a form of associative memory in which mice associate a new context with an aversive stimulus. However, HDAC inhibition enhanced LTM (J Biol Chem, 2004. 279(39): p. 40545-59; herein incorporated by reference in its entiretyHDAC inhibition can be beneficial in certain neurodegenerative disorders, such as Huntington's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, ischemia and Rubinstein-Taybi syndrome (Nature, 2007. 447(7141): p. 178-82; Neuron, 2004. 42(6): p. 947-59; Curr Drug Targets CNS Neurol Disord, 2005. 4(1): p. 41-50; Proc Natl Acad Sci US A, 2003. 100(4): p. 2041-6; each herein incorporated by reference in its entirety). The effect of HDAC inhibitors can depend upon specific HDACs, as neuron-specific overexpression of HDAC2, but not that of HDAC 1, reduced dendritic spine density, synapse number, synaptic plasticity and memory formation (Nature, 2009. 459(7243): p. 55-60; herein incorporated by reference in its entirety). Conversely, HDAC2 deficiency increased synapse number and facilitated memory, similar to chronic treatment with HDAC inhibitors in mice (Nature, 2009. 459(7243): p. 55-60; herein incorporated by reference in its entirety). HDAC inhibition can provide a therapeutic avenue for memory impairment in neurodegenerative diseases characterized by cognitive disorders such as AD.
[00112] Recent studies have linked CREB/CBP dysfunction to AD.
APP(K670N:M671L) transgenic animals showed a decrease in CREB phosphorylation at the downstream level of the α-7-nicotinic-receptor (a7-nAChR)/ERK/MAPK cascade (J Neurosci, 2001. 21(12): p. 4125-33; J Biol Chem, 2002. 277(25): p. 22768-80; each herein incorporated by reference in its entirety). Perfusion of hippocampal slices with a preparation containing oligomeric Αβ42 revealed a reduction of the tetanus-induced increase in CREB phosphorylation, providing a clue to the mechanisms underlying the Αβ-mediated changes in LTP {J Neurosci, 2005. 25(29): p. 6887-97; herein incorporated by reference in its entirety). Consistent with these results, Αβ blocked the glutamate-induced increase in CREB
phosphorylation in rat hippocampal cultures (Proc Natl Acad Sci USA, 2002. 99(20): p. 13217-21; herein incorporated by reference in its entirety). Gong et al. also found that rolipram, a selective PDE IV inhibitor which increases cAMP levels and therefore CREB phosphorylation, ameliorates deficits in both LTP and contextual learning in the APP/PS1 double-transgenic mouse (J Clin Invest, 2004. 114(11): p. 1624-34; herein incorporated by reference in its entirety). Without being bound by theory, this protective effect is due to CREB activation that can lead to CBP recruitment and thus histone acetylation. Another investigation demonstrated that PSl and 2 conditional double knockout (PS cDKO) mice showed impaired memory and LTP that were amplified with age. In addition PS cDKO mice showed a reduction in CBP levels and in CRE-dependent gene expression in the cerebral cortex, which contributed to subsequent neuronal degeneration (Neuron, 2004. 42(1): p. 23- 36; herein incorporated by reference in its entirety). In addition, a recent study has demonstrated that wild-type (WT) PSl stimulates the transcriptional ability of CBP and p300, whereas the AD associated mutant of PSl (M146L) does not have this effect (Neuroreport, 2006. 17(9): p. 917-21; Neurosci Lett, 2007. 413(2): p. 137-40; each herein incorporated by reference in its entirety). In these experiments, a response to WT PSl was observed with a construct containing the 721-1679 region of CBP, which contains the CBP acetyltransferase domain (Neuroreport, 2006. 17(9): p. 917-21; herein incorporated by reference in its entirety). Moreover, it was shown that CBP loss and histone deacetylation takes place during neuronal death, which was induced by an APP-directed antibody in primary cortical neurons (Embo J, 2003. 22(24): p. 6537-49; herein incorporated by reference in its entirety).
[00113] An emerging view of the processes involved in memory impairment indicates that the subtlety and variability of the earliest amnesic symptoms, occurring in the absence of any other clinical signs of brain injury, could be due to discrete changes in the function of a single synapse, produced at least in part, by Αβ (Proc Natl Acad Sci USA, 2002. 99(20): p. 13217-21; Neuroreport, 1997. 8(15): p. 3213-7; Eur J Pharmacol, 1999. 382(3): p. 167-75; Nature, 2002. 416(6880): p. 535-9; each herein incorporated by reference in its entirety).
[00114] Several evidences have indicate that LTM and synaptic plasticity rely on gene expression after an early induction phase characterized by the activation of a number of pathways (Philos Trans R Soc Lond B Biol Sci, 2003. 358(1432): p. 757-63; herein incorporated by reference in its entirety). More recently, a fine regulation of memory-related genes and long-term synaptic plasticity has been discovered to involve epigenetic factors (Nat Rev Neurosci, 2005. 6(2): p. 108-18; herein incorporated by reference in its entirety). Indeed, epigenetic modifications, such as DNA methylation and histone post-translational
modifications profoundly affect the ability of polymerases to interact with the open reading frame of DNA without changing the DNA sequence itself. Deregulation of epigenetic mechanisms can lead to the disruption of memory-associated gene expression and synaptic plasticity (Nat Rev Neurosci, 2005. 6(2): p. 108-18; herein incorporated by reference in its entirety), and contribute to the pathogenesis of diseases characterized by cognitive disorders, such as AD.
[00115] The process of memory storage has been described as a dialogue between genes and synapses (Biosci Rep, 2001. 21(5): p. 565-611; herein incorporated by reference in its entirety). The formation of long-term memory (LTM) is dependent upon gene
transcription (Nature, 1990. 345(6277): p. 718-21; herein incorporated by reference in its entirety), synthesis of new proteins {Science, 1986. 234(4781): p. 1249-54; herein
incorporated by reference in its entirety) and structural changes of the synapse {Science, 1983. 220(4592): p. 91-3; herein incorporated by reference in its entirety). In addition, the proper regulation of gene expression in LTM is modulated by epigenetics {Nat Rev Neurosci, 2005. 6(2): p. 108-18; herein incorporated by reference in its entirety). The N-terminal tails of histone proteins are known to undergo post-translational modifications, such as histone acetylation, ubiquitination, sumoylation, phosphorylation, citrullination, ADP-ribosylation, and methylation that can dictate the transitions between transcriptionally active or transcriptionally silent chromatin states {Curr Biol, 2004. 14(14): p. R546-5; herein incorporated by reference in its entirety). Deregulation of one of these mechanisms can lead to disruption of memory associated gene expression and cognitive disorders. Studies of the mechanisms underlying synaptic and memory dysfunction in AD have indicated central roles for the transcription factor CREB (CRE binding protein) and the coactivator CREB binding protein (CBP).
[00116] Alzheimer's disease (AD) is characterized by neuronal loss, extracellular senile plaques and intracellular neurofibrillary tangles, leading to memory loss. AD purportedly begins as a synaptic disorder produced at least in part, by Αβ {Science 298, 789- 791 (2002); herein incorporated by reference in its entirety). Αβ-induced reduction in long- term-potentiation (LTP), a physiological correlate of synaptic plasticity that is thought to underlie learning and memory, and phosphorylation of the memory transcription factor CREB, are ameliorated by nitric oxide (NO) donors and cGMP-analogs {J Neurosci 25, 6887-6897 (2005); herein incorporated by reference in its entirety). Vice-versa, genetic ablation of NO-synthase 2 (NOS2) results in worsening of the AD phenotype in mice expressing mutated amyloid precursor protein (APP) {Proceedings of the National Academy of Sciences 103, 12867-12872 (2006); herein incorporated by reference in its entirety). These findings show that up-regulation of the NO pathway may be protective in AD.
[00117] Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder, in which the earliest stages are thought to be linked to synaptic dysfunction leading to memory disorders. In this regard, β-amyloid (Αβ) has been found to inhibit memory {Proc Natl Acad Sci USA, 2006. 103:8852-7; Nat Neurosci, 2005. 8:79 84; each herein
incorporated by reference in its entirety) and its cellular model, long-term potentiation (LTP) (Neuroreport, 1997. 8:3213-7; Eur J Pharmacol, 1999. 382: 167-75; Proc Natl Acad Sci US A, 2002. 99:13217-21; Nature, 2002. 416:535-9; J Neurosci Res, 2000. 60:65-72; Proc Natl Acad Sci USA, 1998. 95:6448-53; each herein incorporated by reference in its entirety). Αβ is the proteolytic product of a larger precursor protein, the amyloid precursor protein (APP), which in its mutant form has been found to be implicated in familial AD (FAD) (Nature, 1987. 325:733-6; herein incorporated by reference in its entirety). Subsequently, two AD associated genes, presenilin 1 (PS1) and presenilin 2 (PS2) (Nature, 1995. 375:754-60;
Science, 1995. 269:970-3; each herein incorporated by reference in its entirety) were found to be involved in FAD as well (Prog Neurobiol, 2000. 60:363-84; herein incorporated by reference in its entirety). Presenilins are part of the γ- secretase complex responsible for cleaving APP and producing the Αβ42 peptide (Neurosci Lett, 1999. 260: 121-4; herein incorporated by reference in its entirety).
[00118] AD is characterized neuropathologically by neuronal loss, extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFTs). SPs are chiefly comprised of Αβ aggregates. The major component of NFTs is the microtubule binding protein tau.
Clinically, AD is characterized by cognitive dysfunction and begins as a synaptic disorder that involves progressively larger areas of the brain over time (Histol Histopathol, 1995. 10(2): p. 509-19; herein incorporated by reference in its entirety). An emerging view of the processes involved in synaptic impairment shows that the subtlety and variability of the earliest amnesic symptoms, occurring in the absence of any other clinical signs of brain injury, can be due to discrete changes in the function of a single synapse, produced at least in part, by Αβ (Neuroreport, 1997. 8(15): p. 3213-7; Eur J Pharmacol, 1999. 382(3): p. 167-75; Proc Natl Acad Sci USA, 2002. 99(20): p. 13217-21; Nature, 2002. 416(6880): p. 535-9; herein incorporated by reference in its entirety).
[00119] A target for developing a causal therapy for Alzheimer's disease is represented by synapses. Synaptic alterations are highly correlated with the severity of clinical dementia (Histol Histopathol, 1995. 10(2): p. 509-19; Science, 2002. 298(5594): p. 789-91; each herein incorporated by reference in its entirety), whereas other important variables such as senile plaques and neurofibrillary tangles are involved to a lesser extent (Histol Histopathol, 1995. 10(2): p. 509-19; herein incorporated by reference in its entirety). The importance of synaptic alterations in AD has been confirmed by studies of transgenic (Tg) mouse models of AD (Neurochem Res, 2003. 28(7): p. 1009-15; herein incorporated by reference in its entirety), as well as of long-term potentiation (LTP), a widely studied cellular model of learning and memory (L&M) (Nature, 2002. 416(6880): p. 535-9; herein incorporated by reference in its entirety), which is impaired following application of amyloid-β (Αβ) both in slices and in vivo (Neurochem Res, 2003. 28(7): p. 1009-15; Neuroreport, 1997 '. 8(15): p. 3213-7; J Neurophysiol, 2001. 85(2): p. 708-13; Eur J Pharmacol, 1999. 382(3): p. 167-75; J Neurosci, 2001. 21(4): p. 1327-33; JNeurosci, 2001. 21(15): p. 5703-14; Proc Natl Acad Sci USA, 2002. 99(20): p. 13217-21; Nature, 2002. 416(6880): p. 535-9; JNeurosci, 2005. 25(29): p. 6887-97; each herein incorporated by reference in its entirety). Αβ has been found to markedly inhibit LTP. Electrophysiological studies using Tg, human Αβ producing mice have often revealed significant deficits in basal synaptic transmission and/or LTP in the hippocampus (Ann Neurol, 2004. 55(6): p. 801-14; Nat Neurosci, 1999. 2(3): p. 271-6; J Neurosci, 2001. 21(13): p. 4691-8; Proc Natl Acad Sci USA, 1999. 96(6): p. 3228-33;
Neurobiol Dis, 2002. 11(3): p. 394-409; Brain Res, 1999. 840(1-2): p. 23-35; J Biol Chem, 1999. 274(10): p. 6483-92; Nature, 1997. 387(6632): p. 500-5; each herein incorporated by reference in its entirety).
[00120] Recent studies have linked the transcriptional machinery to Alzheimer's disease (AD), a pathology characterized by profound memory disorders. Both the
transcription factor CREB (CRE binding protein) and the coactivator CREB binding protein (CBP), two molecules that are known to be associated with chromatin and memory processes {Neuron, 2004. 42(6): p. 961-72; Cell, 1994. 79(1): p. 59-68; Cell, 1994. 79(1): p. 49-58; each herein incorporated by reference in its entirety), play central roles in the mechanisms underlying synaptic and memory dysfunction in AD. Drugs enhancing CREB
phosphorylation were shown to ameliorate memory and long-term potentiation (LTP), a type of synaptic plasticity that is thought to underlie learning and memory, both in mouse models of AD and following exposure to sublethal doses of Αβ42, a proteolytic product of the amyloid precursor protein (APP) (Proc Natl Acad Sci USA, 2002. 99(20): p. 13217-21; J Neurosci, 2005. 25(29): p. 6887-97; Puzzo, D., A. et al, Sildenafil rescues synaptic and cognitive impairment in a mouse model of Alzheimer's disease, in Soc Neurosci. Abstr. 2006. Atlanta; J. Clin. Invest., 2004. 114: p. 1624-1634; each herein incorporated by reference in its entirety). Following exposure to sublethal doses of Αβ42 and in mouse models of AD, drugs enhancing CREB phosphorylation were shown to ameliorate LTP and memory (Proc Natl Acad Sci USA, 2002. 99:13217-21; J Neurosci, 2005. 25:6887-97; Puzzo et al, in Soc Neurosci. Abstr. 2006. Atlanta; J. Clin. Invest., 2004. 114: 1624-1634; each herein
incorporated by reference in its entirety). Dysregulation of CBP histone acetyltransferase (HAT) activity disrupts memory associated gene expression (Neuron, 2004. 42:961-72; herein incorporated by reference in its entirety). In addition, cerebral CBP levels are reduced in mice lacking functional presenilin 1 (PS1) and presenilin 2 (PS2) {Neuron, 2004. 42(1): p. 23-36; each herein incorporated by reference in its entirety), two genes that have been implicated in AD (Nature, 1995. 375(6534): p. 754-60; Science, 1995. 269(5226): p. 970-3; each herein incorporated by reference in its entirety). Moreover, wild-type (WT) PS1 stimulates CBP transcriptional ability, whereas PS1(M146L) mutation does not have this effect (Neuroreport, 2006. 17(9): p. 917-21; herein incorporated by reference in its entirety).
[00121] NO is a central molecule in cellular biochemical processes. This gas has been established as an important messenger molecule in various steps of brain physiology, from development to synaptic plasticity and learning and memory. In AD research, NO has been found to have a protective effect on Αβ-induced damage of the nervous system (Med
Hypotheses, 1998. 51(6): p. 465-76; JNeurosci, 2000. 20(4): p. 1386-92; Neuroscience, 2000. 99(4): p. 737-50; each herein incorporated by reference in its entirety). Studies performed on PC 12 cells, sympathetic neurons and hippocampal neurons, have shown that treatment with the NO generator S-nitroso penicillamine exerts a neuroprotective effect due to the inhibition of the pro-apoptotic factor caspase-2 by nitrosylation (J Neurosci, 2000. 20(4): p. 1386-92; herein incorporated by reference in its entirety), whereas inhibition of NO synthesis by N-nitro-L-arginine methyl ester does not protect against Αβ-induced
neurotoxicity. Αβ has been found to impair NO generation by decreasing NMDA receptor signal transduction (Med Hypotheses, 1998. 51(6): p. 465-76; herein incorporated by reference in its entirety), by subtracting NADPH availability to NO-synthase (NOS) (Faseb J, 2002. 16(14): p. 1970-2; herein incorporated by reference in its entirety), or by inhibiting the phosphorylation of the serine-threonine kinase Akt (Neurobiol Aging, 2003. 24(3): p. 437-51; herein incorporated by reference in its entirety). Moreover, i-NOS deletion enhances AD pathology in the APP mice (Proc Natl Acad Sci USA, 2006. 103(34): p. 12867-72; herein incorporated by reference in its entirety). Thus, drugs enhancing the NO-cascade can have a beneficial effect against AD (Curr Alzheimer Res, 2005. 2(2): p. 171-82; herein incorporated by reference in its entirety).
[00122] Despite the neuroprotective function of NO, it has also been viewed as a major agent of neuropathology and cell death when it is produced in high quantities. High amounts of NO lead to generation of significant quantity of peroxinitrites that are responsible for oxidative and nitrosative stress in Αβ-induced cell death {Neurosci Lett, 2002. 322(2): p. 121- 5; Faseb J, 2001. 15(8): p. 1407 -9; Exp Gerontol, 1997. 32(4-5): p. 431-40; J Neurosci, 2002. 22(9): p. 3484-92; Brain Res, 2001. 920(1-2): p. 32-40; J Neurosci, 2004. 24(27): p. 6049-56; J Immunol, 2003. 171(5): p. 2216-24; each herein incorporated by reference in its entirety). In fact, release of low amounts of NO by the constitutive forms of NOS that include both the neuronal and the endothelial isoforms, n-NOS and e-NOS, promotes synaptic plasticity and learning, whereas uncontrolled production of high amounts of the gas by the inducible form of NOS (i-NOS) can promote oxidative and nitrosative stress via production of peroxinitrite (Neurosci Lett, 2002. 322(2): p. 121-5; Faseb J, 2001. 15(8): p. 1407-9; Exp Gerontol, 1997. 32(4-5): p. 431-40; J Neurosci, 2002. 22(9): p. 3484-92; Brain Res, 2001. 920(1-2): p. 32-40; J Neurosci, 2004. 24(27): p. 6049-56; J Immunol, 2003. 171(5): p. 2216-24; each herein incorporated by reference in its entirety). Both Αβ-induced downregulation of the NO cascade which blocks plasticity and memory and generation of peroxinitrites leading to cell death, can play roles in AD. The current status of drug research exploiting these discoveries is focused both on finding ways to upregulate the NO cascade and therefore elicit
neuroprotection, as well as on finding ways to block peroxinitrite toxic effects in order to limit neuropathology (Curr Med Chem, 2003. 10(20): p. 2147-74; herein incorporated by reference in its entirety).
[00123] In some embodiments, the compounds of the invention are HAT modulators.
The term "modulate", as it appears herein, refers to a change in the activity or expression of a protein molecule. For example, modulation can cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of a secretase protein molecule. In some embodiments, the compounds activate HAT. In some embodiments, the compounds inhibit HAT.
[00124] A HAT modulator compound can be a compound that increases the activity and/or expression of a HAT molecule (e.g., GCN5, GCN5L, PCAF, or HATl) in vivo and/or in vitro. HAT modulator compounds can be compounds that exert their effect on the activity of a HAT protein via the expression, via post-translational modifications, or by other means. In some embodiments, a HAT modulator compound increases HAT protein or mRNA expression, or acetyltransferase activity by at least about 10%, at least about 20%, at least about 30%), at least about 40%>, at least about 50%>, at least about 60%>, at least about 70%>, at least about 75%, at least about 80%>, at least about 85%, at least about 90%>, at least about 95%, at least about 97%, at least about 99%, or 100%.
[00125] Test compounds or agents that bind to a HAT molecule (such as GCN5,
GCN5L, PCAF, or HATl), and/or have a stimulatory effect on the activity or the expression of a HAT molecule, can be identified by various assays. The assay can be a binding assay comprising direct or indirect measurement of the binding of a test compound or a known HAT ligand to the active site of a HAT protein. The assay can also be an activity assay comprising direct or indirect measurement of the activity of a HAT molecule. The assay can also be an expression assay comprising direct or indirect measurement of the expression of a HAT mRNA or protein. The various screening assays can be combined with an in vivo assay comprising measuring the effect of the test compound on cognitive and synaptic function in an animal model for neurodegenerative disorders, such as, but not limited to, AD or
Huntington's Disease. [00126] The inhibitors of the expression of a HAT molecule can be identified via contacting a HAT -positive cell or tissue with a test compound and determining the expression of a HAT protein or HAT mRNA in the cell. The protein or mRNA expression level of a HAT molecule in the presence of the test compound can be compared to the protein or mRNA expression level of a HAT protein in the absence of the test compound. The test compound can then be identified as an inhibitor of expression of a HAT protein (such as GCN5, GCN5L, PCAF, or HATl) based on this comparison. In other words, the test compound can also be a HAT inhibitor compound (such as an antagonist).
[00127] Acivators of the expression of a HAT molecule can also be identified via contacting a HAT -positive cell or tissue with a test compound and determining the expression of a HAT protein or HAT mRNA in the cell. The protein or mRNA expression level of a HAT molecule in the presence of the test compound can be compared to the protein or mRNA expression level of a HAT protein in the absence of the test compound. The test compound can then be identified as an activator of expression of a HAT protein (such as GCN5, GCN5L, PCAF, or HATl) based on this comparison. For example, when expression of HAT protein or mRNA is statistically or significantly more in the presence of the test compound than in its absence, the compound is identified as an activator of the expression of a HAT protein or mRNA. In other words, the test compound can also be a HAT Activator compound (such as an agonist). The expression level of a HAT protein or mRNA in cells can be determined by methods described herein.
[00128] Determining the ability of a test compound to bind to a HAT molecule or a variant thereof can be accomplished using real-time Bimolecular Interaction Analysis (BIA) [McConnell, (1992); Sjolander, (1991)]. BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIA-core™). Changes in optical phenomenon surface plasmon resonance (SPR) can be used as an indication of realtime reactions between biological molecules.
[00129] In some embodiments, the invention provides for compounds that bind to a
HAT activator protein, such as GCN5, GCN5L, PCAF, or HATl . These compounds can be identified by the screening methods and assays described herein, and enhance the activity or expression of HAT activator proteins.
[00130] In some embodiments, the compound of formula (I) is 8, 9, 10, 11, 12, 13, and/or 14.
Figure imgf000068_0001
[00131] In some embodiments, the compound of formula (I) is 16 and/or 17.
Figure imgf000068_0002
[00132] In some embodiments, the compound of formula (I) is 18, 19, 20, and/or 21.
Figure imgf000069_0001
[00133] In some embodiments, the compound of formula (I) is 22, 23, and/or 24.
Figure imgf000069_0002
(22) (23) (24)
[00134] In some embodiments, the compound of formula (I) is 25 and/or 26.
Figure imgf000069_0003
(25) (26)
[00135] In some embodiments, Ra is H, halogen, or haloalkyl;
Y is CH, C-halogen, or C-CN;
Rb is H, 0-(Ci-C2-alkyl), S-(d-C2-alkyl), O-cyclopentyl, OCH2CH2N(CH3)2, or
CH2CH2CH2N(CH )2;
Rc is H; C(=0)NH-phenyl, wherein phenyl is substituted with one or more halo or haloalkyl; Rd is H, Ci-C5-alkyl, OH, O-alkyl, OCH2CH2N(CH3)2, CH2CH2CH2N(CH )2,
SCH2CH2N(CH3)2, or OCH2C(=0)0-alkyl;
Z is CH, C-0-(Ci-C2-alkyl), C-OCH2CH2N(CH3)2; and
X is CONH, SONH, S02NH, NHC(=0)NH, or NHCO, or a pharmaceutically acceptable salt or hydrate thereof. [00136] In some embodiments, the compound of formula (I) is compound (I-g):
Figure imgf000070_0001
0-8) , wherein Rd is -0-(Ci-C6)-alkyl, -NH-(Ci-C6)-alkyl, -O-
(C2-C6)-alkenyl, -NH-(C2-C6)-alkenyl, -0-(C3-C8)-cycloalkyl, -NH-(C3-C8)-cycloalkyl, - 0-(C3-C8)-heterocycloalkyl, -NH-(C3-C8)-heterocycloalkyl, -O-aryl, -N-aryl, -O-heteroaryl, -N-heteroaryl, -O-(Ci-C6)-alkyl-N(R10)2, -NH-(Ci-C6)-alkyl-N(R10)2, -0-(Ci-C6-alkyl)-R3, or -NH-(Ci-C6-alkyl)-R3. Compounds (I-g) can be synthesized according to the scheme depicted in FIG. 5.
[00137] In some embodiments, the compound of formula (I) is compound (I-h):
Figure imgf000070_0002
wherein Rb is -0-(d-C6)-alkyl, -0-(C2-C6)-alkenyl, -0-(C3
C8)-cycloalkyl, -0-(C3-C8)-heterocycloalkyl, -O-aryl, -O-heteroaryl, -0-(Ci-C6)-alkyl- N(R10)2, or -0-(Ci-C6-alkyl)-R3. Compounds (I-h) can be synthesized according to the scheme depicted in FIG. 6.
[00138] In some embodiments, the compound of formula (I) is compound (I-i):
Figure imgf000070_0003
, wherein R1U is H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8 cycloalkyl), -(C3-C8-heterocycloalkyl), aryl or heteroaryl, wherein aryl or heteroaryl. [00139] In some embodiments, the compound of formula (I) is
Figure imgf000071_0001
[00140] In some embodiments, the compound of formula (I) is
Figure imgf000071_0002
[00141] In some embodiments, the compound of formula (I) is
Figure imgf000071_0003
wherein X is CH2CONH(CH2)n, and n is 0-3.
[00142] In some embodiments, the compound of formula (I) is
Figure imgf000071_0004
, wherein X is CONH(CH2)n, and n is 0-3.
some embodiments, the compound of formula (I)
Figure imgf000071_0005
[00144] In some embodiments, the compound of formula (I) is
Figure imgf000072_0001
, wherein, Ra is H, halogen, or haloalkyl; Rb is 0-(Ci-C6)-alkyl or S-
(Ci-C6)-alkyl; Rd is (Ci-C6)-alkyl or 0-(Ci-C6)-alkyl-N(CH3)2; Y is haloalkyl, C-CN, C-N02, or N; W is CH or N; and Z is CH or N, or a pharmaceutically acceptable salt or hydrate thereof.
[00145] In some embodiments, the compound of formula (I) is
Figure imgf000072_0002
(∑-b) , wherein Ra is haloalkyl; R2 is CN; and Rb is 0-(Ci-C6)-alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[00146] In some embodiments, the compound of formula (I) is
Figure imgf000072_0003
is H, or ethoxyl; W and Z are independently CH, C-
Cl, or C-OEt; and Rc is H, ethoxyl, or methyl; or a pharmaceutically acceptable salt or hydrate thereof.
[00147] In some embodiments of formula (I-c), Rb is ethoxyl, W and Z are each CH, and Rc is methyl. In some embodiments of formula (I-c), Rb is ethoxyl, W and Z are each C- Cl, and Rc is H. In other embodiments of formula (I-c), Rb is H, W is ethoxyl, Rc is H, and Z is CH. In a further embodiment of formula (I-c), Rb is H, W and Z are each CH, and Rc is ethoxyl.
Figure imgf000073_0001
[00148] In some embodiments, the compound of formula (I) is CH 3 , or a pharmaceutically acceptable salt or hydrate thereof. Compound 5 can be synthesized according to the scheme depicted in FIG. 11.
[00149] In some embodiments, the compound of formula (I) is
Figure imgf000073_0002
, wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or -NH- CH2CH2N(CH3)2, or a pharmaceutically acceptable salt or hydrate thereof. Compounds (I-d) can be synthesized according to the scheme depicted in FIG. 12.
[00150] In some embodiments, the compound of formula (I) is
Figure imgf000073_0003
, wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or -NH- CH2CH2N(CH3)2, or a pharmaceutically acceptable salt or hydrate thereof. Compounds (I-e) can be synthesized from commercially available 8-hydroxy-3,4-dihydro-lH-isochromen-l- one, which may be converted to the N-substituted 8-hydroxy-isochincolone via treatment with the corresponding amine in pyridine at reflux; followed by alkylation of the hydroxyl group. [00151] In some embodiments, the compound of formula (I) is
Figure imgf000074_0001
, wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or -NH
CH2CH2N(CH3)2, or a pharmaceutically acceptable salt or hydrate thereof. Compounds (I-f) can be synthesized analogous to a published procedure {Org. Proc. Res. & Dev. 2009, 13, 1407-1412; hereby incorporated by reference in its entirety).
[00152] In some embodiments, the compound of formula (I) is
Figure imgf000074_0002
, wherein Rd is 2-(piperidin-l-yl) ethyloxy (8); 2- morpholinoethyloxy (9); 2-(piperaz-l-yl)-ethyloxy (10); 2-(4-methylpiperazin-l-yl)-ethyloxy (11); 2-(N,N-diethylamino)ethyloxy (12); 3-(N,N-dimethylamino)propyloxy (13), 3-(N,N- diethylamino)propyloxy (14); 3-methylbutyloxy (15). The compounds 8-15 can be synthesized, for example, via Scheme 1.
[00153] Scheme l(a)
Figure imgf000074_0003
(A) (B)
Figure imgf000074_0004
(25) (8-15) 8, R= 2-(piperidin- l-yl) ethyl; 9, R= 2-morpholinoethyl; 10, R= 2-(piperaz- 1 -yl) ethyl; 11, R= 2-(4- methylpiperazin-l-yl) ethyl; 12, R= 2-(N,N-diethylamino)ethyl; 13, R= 3-(N,N- dimethylamino)propyl, 14, R= 3-(N,N-diethylamino)propyl; 15, R= 3-methylbutyl.
(a)Reagents and conditions: (i) NaOH/EtOH, reflux, 6h; (ii) [4-chloro-3-(trifluoromethyl) phenyl] methanamine, EDC, DCM, rt, overnight; (iii) ROH, PPh3, DIAD, THF, rt, 24h or RX, K2C03, DMF, 80°C, 24h (X= Halogen).
[00154] In some embodiments, the compound of formula (I) is
Figure imgf000075_0001
, which can be synthesized, for example, via Scheme 2.
[00155] Scheme 2 )
Figure imgf000075_0002
(A) (B)
Figure imgf000075_0003
Reagents and conditions: (i) NaOH/EtOH, reflux, 6h; (ii) [4-chloro-3-(trifluoromethyl) phenyl] methanamine, EDC, DCM, rt, overnight; (iii) 2-(N,N-dimethylamino)ethanol, PPh3, DIAD, THF, rt, 24h. [00156] In some embodiments, the compound of formula (I) is
Figure imgf000076_0001
, which can be synthesized, for example, via Scheme 3.
[00157] Scheme 3
Figure imgf000076_0002
3C' N ¾CH3 (D) 3C' , , XCH3 (1 7)
(c)Reagents and conditions: (i) NaBH4, BF3-OEt2, THF, 60°C, 24h.
[00158] In some embodiments, the compound of formula (I) is
Figure imgf000076_0003
, wherein R1 is ethoxyl and Rc is H (18); or R1 is H and Rc is ethoxyl (19). The compounds 18 and 19 can be synthesized, for example, via Scheme 4.
[00159] Scheme 4(d)
Figure imgf000076_0004
E, G and 18, R5= ethoxyl, RA= H; F, H and 19, R5= H, 1^= ethoxyl.
(d)Reagents and conditions: (i) 4-chloro-3-(trifluoromethyl) aniline, EDC, DCM, rt, 24 h; (ii) 2-chloro- N, N-dimethylethanamine, K2C03, DMF, 80 °C, 24 h.
[00160] In some embodiments, the compound of formula (I) is
Figure imgf000077_0001
Figure imgf000077_0002
21 The compounds 20 and 21 can be synthesized, for example,
Scheme 5(e)
Figure imgf000077_0003
(J) (K) (20, 21)
20, R= 2-(N,N-dimethylamino)ethyl; 21, R= ethyl.
^Reagents and Conditions: (i) SOCl2, 4-chloro-3-(trifluoromethyl) aniline, DCM, reflux, 16 h; (ii) ROH, PPh3, DIAD, THF, rt, 24 h or RX, K2C03, DMF, 80 °C, 24 h (X= halogen).
[00162] In some embodiments, the compound of formula (I) is
Figure imgf000077_0004
. The compound 22 can be synthesized, for example, via Scheme 6. [00163] Scheme 6 (ft
Figure imgf000078_0001
(25) (26) (22)
(i)Reagents and Conditions: (i) LAH, THF, reflux, 0.5 h; (ii) Formalin, EtOH, reflux, 2.5 h.
[00164] In some embodiments, the compound of formula (I) is
Figure imgf000078_0002
, wherein R is ethoxy (23), or 2-(N, N-dimethyl)-ethoxy (24). The compounds 23 and 24 can be synthesized, for example, via Scheme 7.
[00165] Scheme 7( )
Figure imgf000078_0003
23, R = ethyl; 24, R = 2-(N, N-dimethylamino)-ethyl.
(s)Reagents and Conditions: (i) 4-chloro-3-(trifluoromethyl) aniline , AcOH, reflux, 2 h; (ii) RX, K2C03, DMF, 80 °C, 8 h (For 23, X= halogen and R is ethyl; for 24, RX is 2-chloro-N, N- dimethy lethanamine) .
[00166] Pharmaceutically acceptable salts are known in the art, and can be selected from those listed in Berge, et al. ["Pharmaceutical Salts," J. Pharm. Sci., 66(1): 1-19 (Jan. 1977); herein incorporated by reference in its entirety]. In some embodiments, a pharmaceutically acceptable salt of a compound of formula (I) is an acid addition salt, for example a hydrohalide (such as hydrochloride or hydrobromide), sulfate, or phosphate salt. In some embodiments, a pharmaceutically acceptable salt of a compound of formula (I) is a base addition salt, for example a sodium, potassium, calcium, or ammonium salt. In some embodiments, the base addition salt is a tetrafluoroboro salt.
[00167] In some embodiments, the invention provides methods for reducing inclusion bodies (e.g., amyloid beta (Αβ) protein deposits, native and phosphorylated Tau proteins, native and phosphorylated alpha-synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof) in a subject afflicted with a neurodegenerative disease (e.g., a AD, Huntington's Disease, or Parkinson's Disease) by administering any one of the HAT modulator compounds having formula (I). In some embodiments, the invention provides methods for treating a neurodegenerative disease in a subject by administering any one of the HAT modulator compounds having formula (I). In some embodiments, the invention further provides methods for treating cancer in a subject by administering any one of the HAT modulator compounds having formula (I). In some embodiments, the compound administered to a subject is any one of the compounds of formula (I). In some embodiments, the compound administered to a subject is any one of compounds any of compounds 1-26 or any combination thereof.
[00168] In some embodiments, the methods comprise administering to the subject an effective amount of a composition comprising a HAT modulator compound. In some embodiments, the subject exhibits abnormally elevated amyloid beta plaques, or elevated Tau protein levels, or accumulations of alpha-synuclein, or accumulations of lipofuscin, or accumulation of cleaved TARDBP (TDB-43) levels, or a combination thereof. In some embodiments, the Αβ protein deposit comprises an Αβ40 isomer, an Αβ42 isomer, or a combination thereof. In a further embodiment, the subject is afflicted with Alzheimer's disease, Lewy body dementia, inclusion body myositis, Huntington's Disease, Parkinson's Disease, or cerebral amyloid angiopathy. In some embodiments, the subject is afflicted with cancer. [00169] The dosage administered can be a therapeutically effective amount of the composition sufficient to result in amelioration of symptoms of a neurodegenerative disease such as, but not limited to reducing inclusion bodies (e.g., amyloid beta (Αβ) protein deposits, native and phosphorylated Tau proteins, native and phosphorylated alpha-synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof), or reducing memory loss in a subject. For example, observing at least, about a 25% reduction, at least about a 30% reduction, at least about a 40% reduction, at least about a 50% reduction, at least about a 60% reduction, at least about a 70%> reduction, at least about a 80%> reduction, at least about a 85% reduction, at least about a 90%> reduction, at least about a 95% reduction, at least about a 97% reduction, at least about a 98% reduction, or a 100% reduction in inclusion bodies or memory loss in a subject is indicative of amelioration of symptoms of a neurodegenerative disease (for example, including, but not limited to, AD, Huntington's Disease, Parkinson's Disease). This efficacy in reducing inclusion occurrence, can be, for example, a meaure of ameliorating symptoms of a neurodegenerative disease.
[00170] In some embodiments, the therapeutically effective amount is at least about
0.1 mg/kg body weight, at least about 0.25 mg/kg body weight, at least about 0.5 mg/kg body weight, at least about 0.75 mg/kg body weight, at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, at least about 100 mg/kg body weight, at least about 200 mg/kg body weight, at least about 250 mg/kg body weight, at least about 300 mg/kg body weight, at least about 3500 mg/kg body weight, at least about 400 mg/kg body weight, at least about 450 mg/kg body weight, at least about 500 mg/kg body weight, at least about 550 mg/kg body weight, at least about 600 mg/kg body weight, at least about 650 mg/kg body weight, at least about 700 mg/kg body weight, at least about 750 mg/kg body weight, at least about 800 mg/kg body weight, at least about 900 mg/kg body weight, or at least about 1000 mg/kg body weight.
[00171] A HAT modulator compound can be administered to the subject one time
(e.g., as a single injection or deposition). Alternatively, a HAT modulator compound of the invention can be administered once or twice daily to a subject in need thereof for a period of from about 2 to about 28 days, or from about 7 to about 10 days, or from about 7 to about 15 days. It can also be administered once or twice daily to a subject for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 times per year, or a combination thereof.
[00172] The dosage administered can vary depending upon known factors such as the pharmacodynamic characteristics of the active ingredient and its mode and route of administration; time of administration of active ingredient; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired; and rate of excretion.
[00173] Toxicity and therapeutic efficacy of therapeutic compositions of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LO50/ED50. Therapeutic agents that exhibit large therapeutic indices are useful. Therapeutic compositions that exhibit some toxic side effects can also be used. [00174] A therapeutically effective dose of a HAT modulator compound can depend upon a number of factors known to those of ordinary skill in the art. The dose(s) of a HAT modulator compound, for example a compound of formula (I), can vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the HAT modulator compound to have upon a HAT protein or a protein exhibiting intrinsic HAT activity. These amounts can be readily determined by a skilled artisan.
[00175] HAT modulator compounds of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions can comprise a HAT modulator compound (e.g., a compound of formula (I), or any of compounds 1-26 or any combination thereof) and a pharmaceutically acceptable carrier. The compositions can be administered alone or in combination with at least one other agent, such as a stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.
[00176] According to the invention, a pharmaceutically acceptable carrier can comprise any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Any conventional media or agent that is compatible with the active compound can be used. Supplementary active compounds can also be incorporated into the compositions. [00177] Any of the therapeutic applications described herein can be applied to any subject in need of such therapy, including, for example, a mammal such as a mouse, rat, dog, cat, cow, horse, rabbit, monkey, pig, sheep, goat, or human. In some embodiments, the subject is mouse, rat, monkey, dog or human. In some embodiments, the subject is a mouse, monkey or human. In some embodiments, the subject is a human.
[00178] A pharmaceutical composition of the invention can be formulated to be compatible with its intended route of administration. Examplary routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following
components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
[00179] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EM™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The injectable composition should be sterile and should be fluid to the extent that easy syringability exists. It should also be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a
pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyetheylene glycol, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many embodiments, it can be useful to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
[00180] Sterile injectable solutions can be prepared by incorporating the HAT modulator compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated herein. In the case of sterile powders for the preparation of sterile injectable solutions, examples of useful preparation methods are vacuum drying and freeze- drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[00181] Oral compositions generally include an inert diluent or an edible carrier.
They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
[00182] Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
[00183] Systemic administration can also be by transmucosal or transdermal means.
For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
[00184] It will recognized that one or more features of any embodiments or aspects disclosed herein can be combined and/or rearranged within the scope of the invention to produce further embodiments that are also within the scope of the invention.
[00185] As will be apparent to one of ordinary skill in the art from a reading of this disclosure, the embodiments of the present disclosure can be embodied in forms other than those specifically disclosed above. The particular embodiments described herein are, therefore, to be considered as illustrative and not restrictive. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described herein. The scope of the invention is as set forth in the appended claims and equivalents thereof, rather than being limited to the examples contained in the foregoing description.
EXAMPLES
[00186] Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.
[00187] A compound, D, that increases histone acetylation was recently discovered
(WO 2011/072243; hereby incorporated by reference in its entirety). Compound D (MW 431, clogP 5.15, clogBB 0.17) is soluble, membrane permeable and BBB permeant, and is safe in acute toxicity tests. Compound D is a N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2- (dimethyl-amino) ethoxy]-6-ethoxybenzamide. Its benzamide ring (I ring) has two substituents at C2 and C6, 2-dimethylamino ethoxy and ethoxy groups, respectively. The nitrogen atom of its amide group bears a substituted phenyl ring (II ring).
[00188] A strategy was employed to assess impact of structure on metabolic stability of D and explore the binding site through SAR analysis, and analysis of DCTPB/CTB and nemorosone. An analysis of D/CTPB/CTB and nemorosone scaffolds shows that the two scaffolds consist of two ring-systems connected by a linker (FIG. 4). In particular, two mono-cyclic rings (I and II ring) linked by a 2-nodes linker form the scaffold of
D/CTPB/CTB while in nemorosone 's scaffold a bi-cyclic ring is connected with a monocyclic ring by a 1-node linker. Derivatives at the level of I ring were explored. In addition, modification of length of the linker in D explored whether the distance between ring I and II is important for HAT activity. With respect to metabolic stability, the N atoms D can be dealkylated by microsomes {J Pharmacol Toxicol Methods, 1994. 31(4): p. 177-86; hereby incorporated by reference in its entirety). Amide groups can undergo hydrolysis by carboxylesterase enzymes {Med Res Rev, 2001. 21(5): p. 412-49; hereby incorporated by reference in its entirety).
[00189] Example 1 - DESIGNING AND SYNTHESIZING HAT MODULATORS
[00190] Modifications at C2: The ether/amino (I-g) can be obtained using the same synthesis scheme as in FIG. 5 (starting from 2-ethoxy-6-hydroxybenzoate or 2-amino-6- ethoxybenzoate esters). Mitsunobu reaction with an alcohol, in the presence of PPh3 and DIAD, can provide a library of compounds. Should alcohols not be commercially available, corresponding halides will be engaged to carry out simple nucleophilic substitutions. The N,N-dimethylaminoethyl group at the C2 position of D was replaced with other groups. Substituents at the nitrogen such as piperidine (8), morpholine (9), piperazine (10), N- methylpiperazine (11), have been chosen to evaluate whether or not the enzymatic pocket can accommodate such groups (Scheme 1). Compounds 12-14 were synthesized to elucidate impact of increased in the chain length of the alkyl substituents at the N atom. Compound 15 was prepared to elucidate whether or not the nitrogen is important for HAT activity (Scheme
1).
[00191] Modifications at C6 (Fig. 6). D is described, for example, in WO 2011/072243 hereby incorporated by reference in its entirety). The amide is obtained by reaction of carboxylic acid with 4-chloro-3-(trifluoromethyl)aniline. Chemoselective monoalkylation of one phenol group should occur with halide in the presence of base in acetone {Tetrahedron Letters, 2010. 51 : p. 495-498; hereby incorporated by reference in its entirety). Subsequent reaction with 2-chloro-N,N-dimethylethanamine, according to Mitsunobu conditions, gives derivative (I-h). [00192] Modifications at linker between I and II rings: N- substitution of amide group
(I-i), reduction of amide into amine group (6) and shortening/lengthening of linker between the two aromatic rings [7, (I-j), and (I-k)] will be explored (FIG. 7). (I-i) and (I-k) can be obtained following the same synthetic scheme used for D (WO 2011/072243 hereby incorporated by reference in its entirety) but using different amines; N,N-disubsituted amines provide (I-i) while N-monosubstituted amines give (I-k). Amine 6 was prepared after reduction of the amide group of D (J. Org. Chem., 1977. 42: p. 2082-2087; hereby incorporated by reference in its entirety). After Mitsunobu reaction with 2- (dimethylamino)ethanol and the subsequent reaction with 4-bromo-2-chloro-l- (trifluoromethyl)benzene in the presence of nBuLi, 7 was obtained (J. Org. Chem., 2006. 71 : p. 4992-4995; hereby incorporated by reference in its entirety). (I-j) can be synthesized in 3 steps starting from 4-hydroxy-benzofuranone, which provides its O-alkylated derivative by a nucleophilic substitution reaction with CH3CH2I. The lactone opening-ring of O-alkylated derivative and the amide bond formation can be carried out directly by using amine in the presence of reducing agent in pyridine (WO 2009/115707, PTC/FR2009/000233; each hereby incorporated by reference in its entirety). Such a reaction can be also performed without reducing agents (Eur. J. Org. Chem., 2008: p. 655-672; hereby incorporated by reference in its entirety). Then, Mitsunobu reaction can give amide (I-j). Compound 16 contains a methylene group in the linker, and was synthesized using 4-chloro-3- (trifluoromethyl)benzylamine in the second step of the synthetic scheme for D as shown above (Scheme 2). The reduction of D by using a reducing agent gave the imine 17 (Scheme
3).
[00193] Modifications at II ring (FIG. 8): This modification strategy involves the replacement of II ring with other substituted aromatic or heterocyclic rings (1-1). Similar to D preparation, these compounds can be synthesized by using requisite amine in the second step of reaction.
[00194] Modifications at I ring (FIG. 9): Similar to the procedure shown on FIG. 6, 1 was prepared starting from 2,6-dihydroxy-4-methyl benzoic acid while 2 was synthesized using the D synthetic procedure, except that it required initial chlorination of the I ring.
Compounds 3 and 4 bearing an ethoxyl group at W and Z, respectively were also synthesized. The synthesis of these two compounds follows D scheme of synthesis and starts from the corresponding commercially available esters ethyl 5-ethoxy-2-hydroxybenzoate and ethyl 4- ethoxy-2-hydroxybenzoate. Some of the structures in which the ethoxyl group has been moved from the 6-position to the 5- and 4-positions of ring I have also been prepared (18 and 19, respectively) (Scheme 4). Compounds 20 and 21 only have two substituents at ring I: with respect to D, 20 lacks an ethoxyl group while 21 bears an ethoxyl group instead of an N,N-dimethylaminoethoxyl group (Scheme 5).
[00195] Constraining the molecular structure: Several structures [5, (I-d), (I-e), and
(I-f)] that contain the amide group into a bicyclic ring have been designed (FIG. 10). This constriction blocks the free rotation bond between I ring and amide group and provides bicyclic scaffolds. Phthalimide derivative 5 bears di-substitution at the benzendicarboximide ring , while (I-d) has only one substitution. Synthesis of each can be carried out in a few steps (FIG. 11 and FIG. 12).
[00196] Isoquinolinone (I-e) can be prepared in two steps from commercially available
8-hydroxy-3,4-dihydro-lH-isochromen-l-one, which is converted in N-substituted 8- hydroxy-isochinolone by treatment with the corresponding amine in pyridine under refluxing conditions. Alkylation of hydroxyl group can provide the desired ligand {Synthetic
Communications, 2010. 40: p. 666-676; hereby incorporated by reference in its entirety). Finally, phthalimidine (I-f) can be synthesized analagous to a published procedure {Organic Process Research & Development, 2009. 13: p. 1407-1412; hereby incorporated by reference in its entirety). Structures 23 and 24 that contain a maleimide moiety have been prepared (Scheme
7). Moreover, 22 bears a tertiary amine in place of the amide function (Scheme 6). This constriction blocks the free rotation bond between the I ring and the amide group and provides bicyclic scaffolds.
[00197] Example 1-1: (Scheme 1)
[00198] 2-ethoxy-6-hydroxybenzoic acid, B
[00199] A solution of A (3.0 g) in ethanol (5 mL) was treated with a solution of NaOH
IN (15 mL). The solution was stirred to reflux for 6 h. After cooling the solution down, HC1 cone, was added until acidic pH. The white precipitate was collected by filtration and dried under pressure to give 2.55 g of a white solid.
[00200] N-[4-chloro-3-(trifluoromethyl) phenyl] -2-ethoxy-6-hydroxybenzamide, (25)
[00201] N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide (EDC, 2.19 mL) was added to a solution of B (1.5 g) in methylene chloride (5 mL) at 0 °C, and then 4-chloro-3- (trifluoromethyl) aniline (1.61 g) was added. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was dissolved in AcOEt (100 mL) and the organic layer was washed with a solution of HC1 6N (3x50 mL) and a solution of NaOH 20% (3x50 mL). The organic layer was dried over Na2S04, filtered and evaporated. Compound 25 (2.2 g) was obtained by crystallization from MeOH.
[00202] Example 1-2: (Scheme 2)
[00203] N-[4-chloro-3-(trifluoromethyl) benzyl]-2-ethoxy-6-hydroxybenzamide, C
[00204] EDC (0.473 mL) was added to a solution of B (300.0 mg) and [4-chloro-3-
(trifluoromethyl) phenyl] methanamine (0.243 mL) in 2mL of methylene chloride at 0 °C. The reaction was stirred overnight at room temperature. The solvent was evaporated and the desired product (371.0 mg) was isolated by crystallization from MeOH. [00205] Example 1-3: (Scheme 1)
[00206] N-[4-chloro-3-(trifluoromethyl) phenyl]-2-ethoxy-6-[2-(piperidin- 1 -yl) ethoxy] benzamide, 8
[00207] Diisopropyl azodicarboxylate (DIAD, 0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-(piperidin-l-yl) ethanol (0.096 mL) and triphenylphosphine (PPI13, 188.8 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H20 (3x30 mL). The organic layer was dried over Na2S04, filtered and evaporated. Purification by flash chromatography (10% MeOH in AcOEt) gave a colorless oil (145.0 mg). 1H NMR (CDC13, 300 MHz) δ 8.16 (s, IH), 7.92-7.87 (m, 2H), 7.46 (d, IH, J= 8.4 Hz), 7.28 (t, IH, J= 8.4 Hz), 7.57 (m, 2H), 4.16 (t, 2H, J= 5.4 Hz), 4.08 (q, 2H, J= 6.9 Hz), 2.72 (t, 2H, J= 5.4 Hz), 2.42 (m, 4H), 1.52-1.45 (m, 4H), 1.38 (t, 5H, J= 6.9 Hz).
[00208] Example 1-4: (Scheme 1)
[00209] N-[4-chloro-3-(trifluoromethyl) phenyl]-2-ethoxy-6-(2-morpholinoethoxy) benzamide, 9
[00210] A suspension of 25 (200.0 mg), 4-(2-chloroethyl)-morpholine (124.1 mg) and
K2C03 (230.5 mg) in DMF (4 mL) was stirred at 80 °C for 24 h. The reaction mixture was diluted with AcOEt (20 mL) and washed with H20 (3x20 mL). The organic layer was dried over Na2S04, filtered and evaporated. The crude product was purified by flash
chromatography (10% MeOH in AcOEt) to provide 110 mg of desired product as a colorless oil. 1H NMPv (CDCl3, 300 MHz) δ 7.90 (s, IH), 7.87 (s, IH), 7.46 (t, IH, J= 8.4 Hz), 7.30 (d, IH, J= 8.4 Hz), 6.88 (t, IH, J= 8.7 Hz), 6.59 (t, 2H, J= 9.0 Hz), 4.17 (t, 2H, J= 5.4 Hz), 4.08 (q, 2H, J= 6.9 Hz), 3.62 (t, 4H, J= 4.5 Hz), 2.77 (t, 2H, J= 5.4 Hz), 2.52 (t, 4H, J= 4.5 Hz), 1.40 (t, 3H, J= 6.9 Hz).
[00211] Example 1-5: (Scheme 4) [00212] N-(4-chloro-3-(trifluoromethyl)phenyl)-5-ethoxy-2-hydroxybenzamide, G
[00213] EDC (0.73 mL) was slowly added to a solution of E (500.0 mg) and 4-chloro-
3-(trifluoromethyl)aniline (508 mg) in DCM (5 mL) at 0 °C. The reaction was stirred at room temperature for 24 h. The solvent was evaporated and the residue was dissolved in AcOEt (100 mL) and washed with HC1 4N (3x80 mL). The organic layer was dried over Na2S04, filtered and evaporated to give a crude oil, which was purified by flash
chromatography (hexane:AcOEt 1 :2) to provide 380.0 mg of desired product as an off-white solid.
[00214] N-(4-chloro-3-(trifluoromethyl)phenyl)-2-(2-(dimethylamino)ethoxy)-5- ethoxybenzamide, 18
[00215] A mixture of G (350.0 mg) and K2C03 (402.19 mg)in DMF (5 mL) was stirred for 30 minutes at 80 °C and then 2-chloro-N,N-dimethylethanamine hydrochloride (140.15 mg) was added. The reaction mixture was stirred at 80 °C for 24h. After this time, the reaction was partitioned between AcOEt (30 mL) and H20 (30 mL) and the organic layer was washed with H20 (3x30 mL), dried over Na2S04, filtered and evaporated. The crude product was purified by flash chromatography (10% MeOH in AcOEt) to provide 79.0 mg of 18 as a colorless solid. 1H NMR (CDC13, 300 MHz) δ 10.7 (s, 1H), 8.09 (dd, 1H, Jx= 1.8, J2= 9.0 Hz), 8.01 (s, 1H), 7.79 (d, 1H, J=3.0 Hz), 7.45 (d, 1H, J= 8.7 Hz), 7.06-7.02 (m, 1H), 6.96 (d, 1H, J= 9.0 Hz), 4.22 (t, 2H, J= 5.1 Hz), 4.07 (q, 2H, J= 7.0 Hz), 2.77 (t, 2H, J= 4.8 Hz), 2.29 (s, 6H), 1.42 (t, 3H, J= 7.0 Hz).
[00216] Example 1-6: (Scheme 4)
[00217] N-(4-chloro-3 -(trifluoromethyl)phenyl)-4-ethoxy-2-hydroxybenzamide, H
[00218] EDC (0.73 mL) was slowly added to a solution of F (500.0 mg) and 4-chloro-
3-(trifluoromethyl)aniline (508 mg) in DCM (5 mL) at 0 °C. The reaction was stirred at room temperature for 24 h. The solvent was evaporated and the residue was dissolved in AcOEt (100 mL) and washed with HC1 4N (3x80 mL). The organic layer was dried over Na2S04, filtered and evaporated. The oily residue was purified by flash chromatography (hexane:AcOEt 1 :2) to provide 490.0 mg of desired product as a sticky yellow solid.
[00219] N-(4-chloro-3-(trifluoromethyl)phenyl)-2-(2-(dimethylamino)ethoxy)-4- ethoxybenzamide, 19
[00220] A mixture of H (370 mg) and K2C03 (426.46 mg)in DMF (5 mL) was stirred for 30 minutes at 80 °C and then 2-chloro-N,N-dimethylethanamine hydrochloride (148.16 mg) was added. The reaction mixture was stirred at 80 °C for 24 h. After this time, the reaction was partitioned between AcOEt (30 mL) and H20 (30 mL) and the organic layer was washed with H20 (3x30 mL), dried over Na2S04, filtered and evaporated. The crude product was purified by flash chromatography (10% MeOH in AcOEt) to provide 33.0 mg of 19 as a waxy white solid.1H NMR (CDC13, 300 MHz) δ 10.4 (s, 1H), 8.21 (d, 1H, J= 9.3 Hz), 8.10 (dd, 1H, Ji= 2.1, J2= 8.7 Hz), 7.96 (d, 1H, J= 2.4 Hz), 7.43 (d, 1H, J= 8.7 Hz), 6.64 (dd, 1H, Ji= 2.4, J2= 9.0 Hz), 6.51 (d, 1H, J= 2.1 Hz), 4.21 (t, 2H, J= 5.7 Hz), 4.10 (q, 2H, J= 6.9 Hz), 2.79 (t, 2H, J= 5.1 Hz), 2.30 (s, 6H), 1.44 (t, 3H, J= 6.9 Hz).
[00221] Example 1-7: (Scheme 2)
[00222] N-(4-chloro-3-(trifluoromethyl)benzyl)-2-ethoxy-6-hydroxybenzamide, C
[00223] EDC (0.437 mL) was slowly added to a solution of B (300.0 mg) and (4- chloro-3-(trifluoromethyl)phenyl)methanamine (0.243 mL) in DCM (5 mL) at 0 °C. The reaction was stirred at room temperature overnight. The solvent was evaporated and the residue was dissolved in AcOEt (100 mL) and washed with HC1 4N (3x80 mL). The organic layer was dried over Na2S04, filtered and evaporated. The desired product (371.0 mg) was obtained by crystallization from MeOH.
[00224] N-[4-chloro-3-(trifluoromethyl)benzyl]-2-(2-(dimethylamino)ethoxy)-6- ethoxybenzamide, 16 [00225] A mixture of C (200.0 mg) and K2C03 (223.9 mg)in DMF (5 mL) was stirred for 30 minutes at 80 °C and then 2-chloro-N,N-dimethylethanamine hydrochloride (77.1 mg) was added. The reaction mixture was stirred at 80 °C for 24 h. After this time, the reaction was partitioned between AcOEt (30 mL) and H20 (30 mL) and the organic layer was washed with H20 (3x30 mL), dried over Na2S04, filtered and evaporated. The crude product was purified by flash chromatography (MeOH in AcOEt 1 : 1) to provide 130.0 mg of desired product as an off-white solid.1H NMR (CDC13, 300 MHz) δ 7.72 (d, IH, J= 2.1 Hz), 7.60- 7.56 (m, IH), 7.46 (d, IH, J= 8.1 Hz), 7.23 (d, 2H, J= 8.7 Hz), 6.57 (d, 2H, J= 8.4 Hz), 4.65 (d, 2H, J= 6.6 Hz), 4.15 (t, 2H, J= 6.0 Hz), 4.08 (q, 2H, J= 6.9 Hz), 2.58 (t, 2H, J= 6.0 Hz), 2.18 (s, 6H), 1.38 (t, 3H, J= 6.9 Hz).
[00226] Example 1-8: (Scheme 1)
[00227] N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxy-6-[2-(piperazin-l- yl)ethoxy]benzamide, 10
[00228] DIAD (0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-
(piperazin-l-yl) ethanol (0.088 mL) and PPh3 (188.8 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H20 (3x30 mL). The organic layer was dried over Na2S04, filtered and evaporated. Purification by flash chromatography (AcOE MeOH 1 : 1) gave a colorless oil (38.0 mg).1H NMR (CDC13, 300 MHz) δ 7.90-7.85 (m, 3H), 7.46 (d, IH, J= 6.6 Hz), 7.30 (d, IH, J= 8.1 Hz), 6.60-6.55 (m, 2H), 4.15 (t, 2H, J= 5.4 Hz), 4.08 (q, 2H, J= 6.9 Hz), 2.79-2.72 (m, 5H), 2.48-2.45 (m, 5H), 1.37 (t, 3H, J= 6.9 Hz).
[00229] Example 1-9: (Scheme 1)
[00230] N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxy-6-[2-(4-methylpiperazin- 1 - yl)ethoxy]benzamide, 11 [00231] DIAD (0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-(4- methylpiperazin-l-yl)ethanol (0.103 mL) and PPh3 (188.8 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H20 (3x30 mL). The organic layer was dried over Na2SC"4, filtered and evaporated. Purification by flash chromatography (AcOE MeOH 7:3) gave a white solid (38.0 mg).1H NMR (CDC13, 300 MHz) δ 7.95-7.92 (m, 2H), 7.82 (s, 1H), 7.46 (d, 1H, J= 9.0 Hz), 7.28-7.25 (m, 1H), 6.60-6.55 (m, 2H), 4.15 (t, 2H, J= 5.4 Hz), 4.08 (q, 2H, J= 6.9 Hz), 2.76 (t, 2H, J= 5.4 Hz), 2.53 (s, 4H), 2.33 (s, 4H), 2.21 (s, 3H), 1.37 (t, 3H, J= 6.9 Hz).
[00232] Example 1-10: (Scheme 1)
[00233] N-(4-chloro-3-(trifluoromethyl)phenyl)-2-(2-(diethylamino)ethoxy)-6- ethoxybenzamide, 12
[00234] DIAD (0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-
(diethylamino)ethanol (0.096 mL) and PPh3 (188.8 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H20 (3x30 mL). The organic layer was dried over Na2SC"4, filtered and evaporated. Purification by flash chromatography (10% MeOH in DCM) gave 95.0 mg of light yellow oil.1H NMR (CDC13, 300 MHz) δ 8.14 (s, 1H), 7.92-7.87 (m, 2H), 7.45 (d, 1H, J= 8.7 Hz), 7.30-7.24 (m, 1H), 6.57 (dd, 2H, Jx= 2.4, J2= 8.4 Hz), 4.13- 4.04 (m, 4H), 2.82 (t, 2H, J= 5.4 Hz), 2.58 (q, 4H, J= 7.2 Hz), 1.37 (t, 3H, J= 6.9 Hz), 0.95 (t, 6H, J= 6.9 Hz).
[00235] Example 1-11: (Scheme 1)
[00236] N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(dimethylamino)propoxy]-6- ethoxybenzamide, 13 [00237] DIAD (0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-
(diethylamino)ethanol (0.084 mL) and PPh3 (188.8 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H20 (3x30 mL). The organic layer was dried over Na2SC"4, filtered and evaporated. Purification by flash chromatography (10% MeOH in DCM) gave 83.0 mg of a waxy white solid. 1H NMR(CDC13, 300 MHz) δ 7.90 (s, 2H), 7.84 (s, 1H), 7.46 (d, 1H, J= 9.0 Hz), 7.30-7.24 (m, 1H), 6.57 (dd, 2H, J = 3.0, J2= 8.4 Hz), 4.11- 4.04 (m, 2H), 2.42 (t, 2H, J= 7.2 Hz), 2.16 (s, 6H), 1.97-1.88 (m, 2H), 1.37 (t, 3H, J= 6.9 Hz).
[00238] Example 1-12: (Scheme 1)
[00239] N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(diethylamino)propoxy]-6- ethoxybenzamide, 14
[00240] DIAD (0.14 mL) was added dropwise to a solution of 25 (200.0 mg), 2-
(diethylamino)ethanol (0.106 mL) and PPh3 (188.8 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H20 (3x30 mL). The organic layer was dried over Na2SC"4, filtered and evaporated. Purification by flash chromatography (10% MeOH in DCM) gave 146.0 mg of a colorless oil.1H NMR(CDC13, 300 MHz) δ 7.94-7.82 (m, 3H), 7.46 (d, 1H, J= 8.7 Hz), 7.31-7.25 (m, 1H), 6.57 (d, 2H, J= 8.4 Hz), 4.07 (t, 4H, J= 6.6 Hz), 2.61 (t, 2H, J= 7.2 Hz), 2.53 (q, 2H, J= 6.9 Hz), 1.97-1.89 (m, 2H), 1.37 (t, 3H, J= 6.9 Hz), 0.98 (t, 6H, J= 7.2 Hz).
[00241] Example 1-13: (Scheme 3)
[00242] 4-chloro-N-[2-(2-(dimethylamino)ethoxy)-6-ethoxybenzylidene]-3- (trifluoromethyl)aniline, 17 [00243] A solution of 80.0 mg of N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-
(dimethylamino)ethoxy]-6-ethoxybenzamide (D) in THF (2 mL) was treated with NaBH4 (64.69 mg) at 0 °C. After 10 minutes a solution of BF3OEt2 (0.286 mL) was added dropwise. The resulting solution was stirred for 0.5 h at 0 °C and then 24 h at 60 °C. The reaction mixture was concentrated under pressure and dissolved in AcOEt (20 mL) and washed with a saturated solution of NaHC03 (2x20 mL) and brine (20 mL).The organic layer was dried over Na2S04, filtered and evaporated. Purification by flash chromatography (Hexane; AcOEt 2: 1) provided 23.0 mg of desired product as a white solid. 1H NMR (CDC13, 300 MHz) δ 7.89 (s, 1H), 7.82 (d, 1H, J= 8.7 Hz), 7.64 (s, 1H), 7.47 (d, 1H, J= 8.7 Hz), 7.32 (t, 1H, J= 8.4 Hz), 6.61 (dd, 2H, Ji= 3.3, J2= 8.4 Hz), 4.44 (t, 2H, J= 5.4 Hz), 4.09 (q, 2H, J= 6.9 Hz), 3.14 (t, 2H, J= 5.4 Hz), 2.63 (s, 6H), 1.37 (t, 3H, J= 6.9 Hz).
[00244] Example 1-14: (Scheme 6)
[00245] 2-[((4-chloro-3-(trifluoromethyl)phenyl)amino)methyl]-3-ethoxyphenol, 26
[00246] LAH was added portionwise at 0 °C to a solution of C (200.0 mg) in 2 mL of
THF. The reaction was heated to refiux for 0.5 h and then quenched with AcOEt (1 mL) followed by Rochelle's salt. After 1 h of stirring at room temperature, the aqueous layer was removed and the organic layer was washed with H20 (3x30 mL), dried over Na2S04, filtered and evaporated to give an off-white solid (130.0 mg). 1H NMR (CDC13, 300 MHz) δ 7.25 (d, 1H, J= 11.6 Hz), 7.12-7.06 (m, 2H), 6.85 (dd, lH, Ji= 3.6, J2= 11.6 Hz), 6.49-6.44 (m, 2H), 4.46 (s, 2H), 4.06 (q, 2H, J= 7.0 Hz), 1.43 (t, 3H, J= 7.0 Hz).
[00247] Example 1-15: (Scheme 5)
[00248] N-(4-chloro-3-(trifluoromethyl)phenyl)-2-hydroxybenzamide, K
[00249] A solution of J (1.0 g) and SOCl2 in DCM (10 mL) was heated to reflux for 12 h. After this time 4-chloro-3-(trifluoromethyl)aniline (1.4 g) was added and the mixture was stirred at refiux for 4 h. The solvent was evaporated and the residue was dissolved in AcOEt (50 mL) and washed with HC1 2N (2x50 mL) and NaHC03 (2x50 mL). The organic layer was dried over Na2S04, filtered and evaporated. The crude compound was treated with MeOH and the resulting white precipitate (300.0 mg) was collected by filtration.
[00250] N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2- (dimethylamino)ethoxy]benzamide, 20
[00251] DIAD (0.136 mL) was added dropwise to a solution of K (200.0 mg), 2-
(diethylamino)ethanol (0.070 mL) and PPh3 (180.0 mg) in THF (2 mL) at 0 °C. The solution was stirred at room temperature for 24 h. The solvent was evaporated and the residue was diluted in AcOEt (30 mL) and washed with H20 (3x30 mL). The organic layer was dried over Na2S04, filtered and evaporated. Purification by flash chromatography (AcOEt) gave 80.0 mg of a white solid.1H NMR (CDC13, 300 MHz) δ 10.61 (s, IH), 8.27 (dd, IH, J = 1.8, J2= 7.8 Hz), 8.11 (dd, IH, Ji= 2.7, J2= 8.7 Hz), 7.98 (d, IH, J= 2.7 Hz), 7.49-7.43 (m, 2H), 7.14 (t, IH, J= 6.0 Hz), 7.02 (d, IH, J= 8.1 Hz), 4.27(t, 2H, J= 5.4 Hz), 2.80 (t, 2H, J= 5.4 Hz), 2.31 (s, 6H).
[00252] Example 1-16: (Scheme 5)
[00253] N-(4-chloro-3-(trifluoromethyl)phenyl)-2-propoxybenzamide, 21
[00254] A suspension of K (100.0 mg), 85.69 mg of K2C03 and iodoethane (0.025 mL) was heated to 80 °C for 24 h. The reaction was partitioned between AcOEt (30 mL) and H20 (30 mL) and the organic layer was washed with H20 (3x30 mL), dried over Na2S04, filtered and evaporated to give the desired product (70.0 mg) as an off-white solid.
[00255] Example 1-17: (Scheme 1)
[00256] N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxy-6-(isopentyloxy)benzamide, 15
[00257] A mixture of 25 (200.0 mg) and K2C03 (153.7 mg)in DMF (5 mL) was stirred for 30 minutes at 80 °C and then l-bromo-3-methylbutane (77.1 mg) was added dropwise. The reaction mixture was stirred at 80 °C for 24 h. After this time, the reaction was partitioned between DCM (20 mL) and H20 (20 mL) and the organic layer was washed with H20 (3x30 mL), dried over Na2S04, filtered and evaporated. The crude product was purified by flash chromatography (hexane:AcOEt 9: 1) to provide 103.0 mg of desired product as an off-white solid.1H NMR (CDC13, 300 MHz) δ 7.88 (d, IH, J= 8.4 Hz), 7.81 (s, IH), 7.55 (s, IH), 7.46 (d, IH, J= 8.4 Hz), 7.27 (t, IH, J= 8.4 Hz), 6.57 (d, 2H, J= 8.4 Hz), 4.11-4.00 (m, 4H), 1.79-1.68 (m, IH), 1.63 (q, 2H, J= 6.3 Hz), 1.37 (t, 3H, J= 6.9 Hz), 0.89 (d, 6H, J= 6.3 Hz).
[00258] Example 1-18: (Scheme 6)
[00259] 3-[4-chloro-3-(trifluoromethyl)phenyl]-5-ethoxy-3,4-dihydro-2H- benzo[e][l,3]oxazine, 22
[00260] A solution of 85.0 mg of 2-[((4-chloro-3-
(trifluoromethyl)phenyl)amino)methyl]-3-ethoxyphenol (26) and 0.060 mL of formalin in EtOH (2 mL) was heated to reflux for 2.5 h. The reaction was diluted with H20 (20 mL) and extracted with DCM (3x 20 mL). The organic layer was dried over Na2S04, filtered and evaporated. Purification by flash chromatography provided 33.0 mg of desired compound as a white solid.1H NMR(CDC13, 300 MHz) δ 7.40 (d, IH, J= 3.0 Hz), 7.34 (d, IH, J= 9.0 Hz), 7.18 (dd, IH, Ji= 3.0, J2= 9.0 Hz), 7.07 (t, IH, J= 8.4 Hz), 6.44 (t, 2H, J= 8.4 Hz), 5.29 (s, 2H), 4.54 (s, 2H), 4.03 (q, 2H, J= 6.9 Hz), 1.42 (t, 3H, J= 6.9 Hz).
[00261] Example 1-19: (Scheme 7)
[00262] 2-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxyisoindoline- 1 ,3-dione, M
[00263] A solution of L (100.0 mg) and 4-chloro-3-(trifluoromethyl) aniline (142.9 mg) in AcOH (3 mL) was heated to reflux for 2 h. After cooling the reaction down, cold H20 was added. The white precipitate (189.0 mg) was collected by filtration.
[00264] 2-[4-chloro-3-(trifluoromethyl)phenyl]-4-ethoxyisoindoline- 1 ,3-dione, 23 [00265] A mixture of M (300.0 mg), iodoethane ( 0.140 mL) and K2C03 (485.4 mg) was stirred at 80 °C for 8 h. The reaction was allowed to cool down and H20 (10.0 mL) was added and the white precipitate (181.0 mg) was filtered.1H NMR(CDC13, 300 MHz) δ 7.86 (s, IH), 7.74 (t, IH, J= 7.2 Hz), 7.62 (d, 2H, J= 2.1 Hz), 7.53 (d, IH, J= 7.2 Hz), 7.27 (d, IH, J= 8.4 Hz), 4.30 (q, 2H, J= 6.9 Hz), 1.55 (t, 3H, J= 6.9 Hz).
[00266] Example 1-20: (Scheme 7)
[00267] 2-[4-chloro-3-(trifluoromethyl)phenyl]-4-[2- (dimethylamino)ethoxy]isoindoline- 1 ,3-dione, 24
[00268] A mixture of M (300.0 mg), K2C03 (485.4 mg) and 2-chloro-N,N- dimethylethanamine hydrochloride (252.9 mg) was stirred at 80 °C for 8 h. The reaction was allowed to cool down and was partitioned between H20 (10.0 mL) and AcOEt (40 mL). The organic layer was washed with H20 (3x30 mL), dried over Na2S04, filtered and evaporated. Purification by flash chromatography (AcOE MeOH 2: 1) gave the desired compound as a pale yellow oil. 1H NMR(CDC13, 300 MHz) δ 7.84 (s, IH), 7.74 (t, IH, J= 7.2 Hz), 7.62 (d, 2H, J= 2.1 Hz), 7.54 (d, IH, J= 7.5 Hz), 7.27 (d, IH, J= 8.1 Hz), 4.32 (t, 2H, J= 5.4 Hz), 2.87 (t, 2H, J= 5.41 Hz), 2.40 (s, 6H).
[00269] Example 2: Assays for HAT Affinity and Selectivity for CBP, PCAF, and P300
[00270] Compounds can be tested for HAT modulator activity using the HAT Assay kit from Active Motif (USA, CA). For this assay, the catalytic domain of human CBP, PCAF, p300 and GCN5 (Enzo Life Sci., USA) can be used. The catalytic domains for the remaining HATs can be produced using New England Biolabs K. lactis Protein Expression Kit. In addition to being potent activators of CBP and/or PCAF (EC50<100 nM), the candidate compounds can also be selective. When assayed against all other HATs, they can show a 50-fold greater potency towards CBP and/or PCAF. The most potent/selective compounds that show efficacy in tests of synaptic and memory dysfunction outlined in Examples 4 and 5 can be assayed for selectivity against HDACs. While performing these tests, solubility can also be evaluated (neutral aqueous buffer > 10 μg/ml).
[00271] Confirmation of in vitro data can be performed using a neuronal preparation.
In particular, compounds can be assayed in primary cultures and adult mice. Whether the compounds can increase specific histone acetylation in 10 day old cultured hippocampal neurons (prepared as described in Neuron, 2004. 42(1): p. 129-41; hereby incorporated by reference in its entirety) can also be determined. Media can be aspirated and replaced with 0.5 mL of PBS containing the HAT activator. After 30 min at 37°C, cells can be removed and lysed for WB analysis. Selected compounds can also be tested in adult mice, following an assessment of acute toxicity to determine the dose of compound to be administered to the animal (see "toxicity tests" below). Testing in adult mice is useful as cell cultures do not mimic the whole body with complex cell-cell interactions and in vivo drug PK, BBB penetration, etc (see also Example 3 below). Animals can be treated with the HAT compound, hippocampi can be collected 30 min after the i.p. injection, and lysed for WB analysis. Experiments can be performed in triplicate.
[00272] On selected compounds, interactions with channels, receptors, transporters can be examined using the NIMH PDSP program (see http://pdsp.cwru.edu for a list of CNS targets; hereby incorporated by reference in its entirety), in addition to ADMET/Tox studies discussed in Example 3.
[00273] Example 3: Determination of Pharmacokinetic (PK) and Safety Profiles
[00274] Rudimentary PK properties and toxicity of the new HAT modulators can be determined. Pharmacokinetic assays can include the measurement of a) bioavailability and b) brain uptake. Mice can be i.p. injected with the compounds (for some compounds, PK tests can also be performed using p.o. and i.v. routes of administration). 5-6 mice/sex can be used for each time -point. For the assessment of bioavailability (concentration of compound in the blood as a function of time after administration), blood samples can be obtained from test animals following a single acute administration (collected at time intervals up to
approximately 24 h). Blood can be harvested by retro-orbital puncture, collected in heparanized tubes, and plasma obtained by centrifugation. Samples can be analyzed by LC- MS to measure the amounts of the candidate compound and metabolites. An indication of brain uptake and BBB penetration can be obtained by tissue extraction of the candidate compound from brain. Brain homogenates can be centrifuged 11,000 rpm for 10 min. An aliquot of the sample can be added to acetonitrile, then injected onto LC-MS/MS for analysis. Similar patterns of brain and plasma concentrations can be indicative of brain uptake as a reflection of concentration in the blood. A peak brain/blood concentration ratio >1 can indicate that brain uptake comparable with that of known CNS drugs in clinical use. For example, the brain/blood ratio for minaprine, a 6-phenylaminopyridazine CNS drug, is >2 {Xenobiotica, 1985. 15(12): p. 1111-9; herein incorporated by refrence in its entirety).
[00275] Acute toxicity can also be evaluated. All clinical signs, time of onset, duration, reversibility of toxicity and mortalities can be recorded. Animals can be observed periodically during the first 24 hrs with continuous monitoring given to the first 4 hrs, then at least once a day for 14 days or until they die to check food and liquid intake, weight, as well as locomotion and exploratory behavior. Maximum tolerated dose (MTD) and chronic toxicity can also be evaluated. MTD can be computed as the maximum administered dose that does not produce any toxicity effect in terms of malaise or death (body weight will be monitored over time). Chronic toxicity can be assessed at the MTD. All clinical signs, time of onset, duration, reversibility of toxicity and mortalities can also be recorded. The occurrence of chronic toxicity signs can be assessed for at least 1 month after the end of the treatment. [00276] It has been estimated that over half of all drugs fail to reach the market because of ADMET problems (Nat Biotechnol, 2001. 19(8): p. 722-6; herein incorporated by refrence in its entirety). Therefore, before embarking on a course of costly animal toxicological work and following efficacy assessment (see Examples 4 and 5), recent advances in in vitro ADMET testing can be used to screen selected compounds with a quick, inexpensive battery of assays. Two areas that have resulted in the withdrawal of many drugs from the market can be evaluated: drug-drug interactions (liver metabolism), hERG channel blockage (cardiac dysfunction). To test for drug-drug interactions related to hepatotoxicity, the Cytochrome P450 inhibition assay can be performed (performed by SRI international). Additionally, hERG channel blockage assay can be performed using the NIMH PDSP program.
[00277] Example 4: Selecting HAT Modulators that rescue LTP in APP/PSl mice
[00278] Synaptic dysfunction is a major hallmark of AD (Histol Histopathol, 1995.
10(2): p. 509-19; herein incorporated by refrence in its entirety). An aspect of the drug screening protocol can include a measurement of the effect of compounds onto synaptic function. The APP/PSl mouse presents an impairment of LTP by the age of 3 months (Ann Neurol, 2004. 55(6): p. 801-14; herein incorporated by refrence in its entirety), and therefore permits a relatively fast assessment of synaptic function without waiting a long time for mice aging. LTP can be examined because it is a type of synaptic plasticity thought to underlie learning and memory. D rescues the Αβ-induced reduction of LTP, and other compounds can also be screened to identify those that can re-establish normal LTP. The compounds can be applied for 30 min. Controls can be performed on slices from APP/PSl mice treated with vehicle, and WT mice treated with compound or vehicle. If the compounds re-establish normal LTP in APP/PSl slices, one can conclude that the compounds rescue impairment of synaptic plasticity in APP/PSl mice. Cognitive impairment can also be investigated (see Example 5).
[00279] Animals: Tg mice can be obtained by crossing APP(K670M:N671L) with
PS1(M146L) (line 6.2) animals. The genotype can be identified by PCR on tail samples
(Nature, 1996. 383(6602): p. 710-3; Science, 1996. 274(5284): p. 99-102; J Mol Neurosci,
2002. 19(1-2): p. 135-41; each hereby incorporated by refrence in its entirety).
[00280] Electrophysiology can be performed on males (see description in Cell, 2006.
126(4): p. 775-88; hereby incorporated by refrence in its entirety).
[00281] Statistical Analyses: see Example 5.
[00282] Example 5: Screening for Amelioration of Cognitive Abnormalities in APP/PSl Mice
[00283] Treatment with a new HAT modulator indicated by Example 4 will study rescue of cognitive deficits in 3 and 6 month old APP/PSl mice. As behavioral tasks, the RAWM and contextual FC will be used, two types of tests that assess different types of memory (reference ad associative) that are affected in AD patients. The treatment can be performed with the same timing (i.e. 30min before training for fear conditioning or before the 1st and 2nd group of tests for the RAWM). Conditions to be tested can include: APP/PSl and WT treated with HAT activators, APP/PSl and WT treated with vehicle. After behavioral testing, mice can be sacrificed and their blood and brains used for Αβ level, Tau protein, TARDBP and TDB levels, and alpha-synuclein measurements. As a control for effectiveness of HAT modulator, hippocampal acetyl-H4 levels can be measured after administration of the compounds 30 min prior to training for fear conditioning and removal of the hippocampi lhr after the electric shock (APP/PSl mice have been shown to have a reduction of acetylated H4 after the electric shock (J Alzheimers Dis, 2009. 18(1): p. 131-9; hereby incoporated by reference in its entirety). Further screening can include assays focusing on two areas that have resulted in the withdrawal of many drugs from the market: drug-drug interactions, hERG channel blockage (see Example 3).
[00284] Animals: see Example 4.
[00285] Behavioral Studies: Experiments can be performed in blind only on male animals to reduce variability. A) Spatial memory. This type of reference memory will be studied with the 2-day RAWM test, as described (Nat Protoc, 2006. 1(4): p. 1671-9; hereby incorporated by reference in its entirety). The task is a hybrid of the Morris Water Maze (MWM) and the radial arm land maze. For these experiments, visible platform testing can be conducted to exclude that visual, motor and motivation deficits affect the mouse
performance, as described (Ann Neurol, 2004. 55(6): p. 801-14; hereby incorporated by reference in its entirety). B) Fear Conditioning to examine both contextual and cued learning will be assessed as described (J. Clin. Invest., 2004. 114: p. 1624-1634; hereby incorporated by reference in its entirety). For these experiments, threshold assessment test can be performed to check sensory perception of electric foot in different groups of mice (J. Clin. Invest., 2004. 114: p. 1624-1634; hereby incorporated by reference in its entirety). In addition, the open-field test can be conducted to evaluate exploratory as described
(Neuroscience, 2007. 147(1): p. 28-36; JNeurosci, 2008. 28(53): p. 14537-45; each hereby incorporated by reference in its entirety).
[00286] Histone acetylation assay: Western blot can be performed from snap-frozen in liquid nitrogen hippocampi. Tissue can be homogenized in RIPA buffer, then sonicated before centrifugation at 10,000 rpm for 5 min. Whole cell extracts can be electrophoresed on 10-20% gradient PAGE gel (Invitrogen) and then immunob lotted. Antibodies can be used at a 1 : 1,000 concentration for immunoblotting. All anti-histone antibodies can be purchased from Millipore. Immunoblot data can be quantified by measuring the band intensity using imaging software (NIH Image J). [00287] Determination of Αβ levels can be performed on homogenates of frozen hemi- brains and plasma as previously described (Ann Neurol, 2004. 55(6): p. 801-14; hereby incorporated by reference in its entirety).
[00288] Determination of alpha-synuclein levels can be performed on homogenates of frozen hemi-brains using an a-Synuclein ELISA Kit (Catalog # NS400; Millipore, Billerica, MA) according to manufacturer's instructions.
[00289] Determination of TARDBP/TDP-43 levels can be performed on homogenates of frozen hemi-brains using a Human TAR DNA binding protein 43, TARDBP/TDP-43 ELISA Kit (Catalog # E1951h; Wuhan EIAab Science Co, Wuhan, China) according to manufacturer's instructions.
[00290] Determination of total Tau and phosphorylated Tau (Thr 231) levels can be performed on homogenates of frozen hemi-brains and plasma using assay and kits according to manufacturer's instructions available from MesoScale Discovery (Gaithersburg, MD) (see http://www.mesoscale.com catalogsystemweb/webroot/products/assays/alzheimers.aspx; hereby incorporated by reference in its entirety).
[00291] Statistics: Experiments involving mice can be performed in blind. Results can be expressed as Standard Error Mean (SEM). Level of significance can be set for p<0.05. Results can be analyzed with AN OVA with post-hoc correction with drug or genotype as main effect.
[00292] Example 6: Screening for Amelioration of Cognitive Abnormalities in Mouse Models for Huntington's Disease
[00293] Treatment with a HAT compound indicated by Example 13 to assess whether the compound can rescue the cognitive deficits in a mouse model of Huntington's Disease (e.g., FVB-Tg(YAC128)53Hay/J and FVB/NJ-Tg(YAC72)251 IHay/J mice, available from the Jackson Laboratory, Bar Harbor ME) can be examined. As behavioral tasks, the RAWM and contextual FC can be employed, two types of tests assessing different types of memory (reference ad associative). The treatment can be performed with the same timing (i.e. 30 min before training for fear conditioning or before the 1st and 2nd group of tests for the RAWM). Conditions to be tested can include: Huntington's Disease mice and WT treated with HAT modulator, Huntington's Disease mice and WT treated with vehicle. After behavioral testing mice can be sacrificed and their blood and brains used for Huntingtin protein level measurement. As a control for effectiveness of HAT modulation, hippocampal acetyl-H4 levels can be measured after administration of the compounds 30 min prior to training for fear conditioning and removal of the hippocampi 1 hr after the electric shock. Assays focusing on two areas that have resulted in the withdrawal of many drugs from the market can also be employed: drug-drug interactions, hERG channel blockage (see Example 3).
[00294] Animals: Mouse models of Huntington's Disease (e.g., FVB-
Tg(YAC128)53Hay/J [Stock no. 004938] and FVB/NJ-Tg(YAC72)251 lHay/J mice [Stock no. 003640]) can be obtained from the Jackson Laboratory (Bar Harbor ME). See also, Hodgson et al, (May 1999) Neuron, Vol. 23, 181-192; hereby incorporated by reference in its entirety.
[00295] Behavioral Studies: Experiments can be performed in blind only on male animals to reduce variability. A) Spatial memory. This type of reference memory can be studied with the 2-day RAWM test, as described (Nat Protoc, 2006. 1(4): p. 1671-9; hereby incorporated by reference in its entirety). The task is a hybrid of the Morris Water Maze (MWM) and the radial arm land maze. For these experiments, visible platform testing can be conducted to exclude that visual, motor and motivation deficits affect the mouse
performance, as described (Ann Neurol, 2004. 55(6): p. 801-14; hereby incorporated by reference in its entirety). B) Fear Conditionins to examine both contextual and cued learning can be assessed as described (J. Clin. Invest., 2004. 114: p. 1624-1634; hereby incorporated by reference in its entirety). For these experiments, threshold assessment test can performed to check sensory perception of electric foot in different groups of mice (J. Clin. Invest., 2004. 114: p. 1624-1634; hereby incorporated by reference in its entirety). In addition, the open- field test can be conducted to evaluate exploratory as described (Neuroscience, 2007. 147(1): p. 28-36; JNeurosci, 2008. 28(53): p. 14537-45; each hereby incorporated by reference in its entirety).
[00296] Histone acetylation assay: Western blot can be performed from snap-frozen in liquid nitrogen hippocampi. Tissue can be homogenized in RIPA buffer, then sonicated before centrifugation at 10,000 rpm for 5 min. Whole cell extracts can be electrophoresed on 10-20% gradient PAGE gel (Invitrogen) and then immunob lotted. Antibodies can be used at a 1 : 1 ,000 concentration for immunoblotting. All anti-histone antibodies can be purchased from Millipore. Immunoblot data can be quantified by measuring the band intensity using imaging software (NIH Image J).
[00297] Determination of huntingtin levels can be performed on homogenates of frozen hemi-brains and plasma using a Huntingtin (Htt) ELISA Kit (Catalog # ABIN423526; Antibodies-online, Atlanta, GA) according to manufacturer's instructions.
[00298] Statistics: Experiments on mice can be performed in blind. Results can be expressed as Standard Error Mean (SEM). Level of significance can be set for p<0.05.
Results can be analyzed with AN OVA with post-hoc correction with drug or genotype as main effect.
[00299] Example 7: Screening for Amelioration of Cognitive Abnormalities in Mouse Modles for Parkinson's Disease
[00300] Parkinson's Disease (PD) is a degenerative disease with a neuronal death up to 75-95% of the dopamine neurons in the substantia nigra nucleus. Treatment with a HAT modulator compound indicated by Example 4 to assess rescue of abnormal motor movements in a mouse model of PD (e.g., see Parkinson's Disease mice models available from the Jackson Laboratory, Bar Harbor ME at http://jaxmice.jax.org/list/ ral594.html; see also Emborg, Journal of Neuroscience Methods 139 (2004) 121-143; Lane, Psychopharmacology (2008) 199:303-312; and Meredith et al, Acta Neuropathol (2008) 115:385-398; each hereby incorporated by reference in its entirety) can be assessed. Behavioral tasks, for example, dyskinesia, bradykinesia, tremor, and/or grip force for the evaluation of the compound's efficacy, can be examined at various stages of PD. Conditions to be tested can include: PD mice and WT treated with HAT modulator, PD mice and WT treated with vehicle. After behavioral evaluation, mice can be sacrificed and their brains used for aggregated alpha-synuclein protein measurement. As a control for effectiveness of HAT modulation, hippocampal acetyl-H4 levels can be measured.
[00301] Animals: Mouse models of Parkinson's Disease can be obtained from the
Jackson Laboratory (Bar Harbor ME). See also, Meredith et al, Acta Neuropathol (2008) 115:385-398; hereby incorporated by reference in its entirety).
[00302] Behavioral Studies: Experiments can be performed in blind only on male animals to reduce variability, according to methods described by Fleming et al., ((2004) The Journal of Neuroscience, 24(42):9434 -9440) and Hwang et al, ((2005) The Journal of Neuroscience, 25(8):2132-2137; each hereby incorporated by reference in its entirety).
[00303] Histone acetylation assay: Western blot can be performed from snap-frozen in liquid nitrogen hippocampi. Tissue can be homogenized in RIPA buffer, then sonicated before centrifugation at 10,000 rpm for 5 min. Whole cell extracts can be electrophoresed on 10-20% gradient PAGE gel (Invitrogen) and then immunob lotted. Antibodies can be used at a 1 : 1 ,000 concentration for immunoblotting. All anti-histone antibodies can be purchased from Millipore. Immunoblot data can be quantified by measuring the band intensity using imaging software (NIH Image J). [00304] Determination of alpha-synuclein levels can be performed on homogenates of frozen hemi-brains using an a-Synuclein ELISA Kit (Catalog # NS400; Millipore, Billerica, MA) according to manufacturer's instructions or via standard neuropatho logical methods (brain tissue histology).
[00305] Statistics: Experiments in mice can be performed in blind. Results can be expressed as Standard Error Mean (SEM). Level of significance can be set for p<0.05.
Results can be analyzed with AN OVA with post-hoc correction with drug or genotype as main effect.
[00306] Example 8: Biological Screening of Compounds
[00307] Commercial human HATs (CBP, p300, GCN5, PCAF (Enzo Life Sciences), and Tip60 (SignalChem)) were assayed in an acetyltransferase activity assay (Enzo Life Sciences, Cat. No. ADI-907-026). Each well contained, in addition to a HAT, histone 3 as the acetyl acceptor, acetyl-CoA as the acetyl donor in the reaction mixture and compounds (1% DMSO) at the appropriate concentrations. The reaction was carried out at room temperature. Enzyme activity was measured by monitoring the breakage of the substrate acetyl-CoA by HAT using a proprietary detection mixture. The fluorescent signal was measured using a Tecan microplate reader (excitation: 380 nm, emission: 520 nm). The assay methodology was adopted as it provided a 10-fold higher signal/background ratio and was more sensitive than other assays. Using this method, the EC50 values of D for CBP (4.5 nM) and Tip60 (>200 μΜ) were established. Initial screening revealed that compounds such as 8, 9, 12-14, and 19 behave as activators with respect to CBP and P300. Compounds 16, 17, 18, 25 and 26 activated only CBP, whereas 11 inhibited P300 and had no effect on CBP. Compound 10 had no effect with either P300 or CBP (Figure 13).
[00308] Representative compounds exhibited EC50 values for activation of P300 of about 3 nM or less. EC50 values for some compounds are provided in Table 1. Table 1 : EC50 Values for Selected Compounds
Figure imgf000111_0001
EQUIVALENTS
[00309] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

Claims

What is claimed is:
1. A compound of formula (I):
Figure imgf000112_0001
wherein,
Figure imgf000112_0002
Ra is H, Ci-Ce-alkyl, Ci-C6-haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or N02;
Rb is H, Ci-Ce-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-heteroalkyl, C3-C8- heterocycloalkyl, aryl, heteroaryl, O-(Ci-Ce-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2- Ce-alkenyl), 0-(C3-C8-heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8- cycloalkyl), S-(Ci-C6-alkyl), O-(C2-C6-alkyl)-N(R10)2, 0-(C3-C8-cycloalkyl)- N(R10)2, N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, 0-(C3-C8-cylcoalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Cg-alkyl), 0-(Ci-C6-alkyl), C(=0)NH-phenyl, wherein phenyl is
substituted with one or more halo or haloalkyl;
Rd is H, OH, Ci-Cg-alkyl, 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(C2- Ce-alkenyl), 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci- C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C2-C6- alkenyl), -N(R10)-(C3-C8-cycloalkyl), -N(R10)-(C3-C8-heterocycloalkyl), N(R10)- (C2-C6-alkyl)-N(R10)2, -(Ci-Cg-alkyl )-N(R10)2, S-(C2-C6-alkyl)-N(R10)2, OCH2C(0)0-alkyl, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl;
W and Z are independently N or CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nCON(R10)-, -
(CH2)nCON(R10)(CH2)n-, -SON(R10)-, -SON(R10)(CH2)n-, -S02N(R10)-, - SO2N(R10)(CH2)n-, -N(R10)C(=O)N(R10)-, -N(R10)CO-, -N(R10)CO(CH2)n-, or - N(R10)CO(CH2)n-, -(CH2)nN(R10)-, -C=N-; or
Ar and X together form
Figure imgf000113_0001
Y is N or CR2;
R1 is H, halogen, 0-(C C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
R2 is H, Ci-Ce-alkyl, Ci-C6-haloalkyl, 0-(Ci-C6-alkyl), 0-(Ci-C6-haloalkyl), halogen, CN, or N02;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and
S;
R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3-
C8-heterocycloalkyl), aryl or heteroaryl; and
n is an integer from 1-3, or a pharmaceutically acceptable salt thereof;
with the proviso that Ar is not
Figure imgf000113_0002
or ; or
when
Figure imgf000113_0003
wherein
W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2 or
OH; or
WW iiss CC--OCH2CH2N(CH3)2, Z is CH, Rb is hydrogen, Rc is hydrogen, and Rd is hydrogen; or
WW aanndd ZZ aarree ί each CH, Rb is cyclopentyloxy, Rc is hydrogen, and Rd is
OCH2CH2N(CH3)2; or
W and Z are each CH, Rb is -OCH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-Cl- phenyl), and Rd is -OCH2CH2N(CH3)2; or
W is CH, Z is C-ethoxy, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen; or
W and Z are each CH, Rb is -CH2CH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-Cl- phenyl), and Rd is -CH2CH2CH2N(CH3)2 or hydrogen; or
W and Z are each CH, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen or -OCH2CH2N(CH3)2; or W and Z are nitrogen, Rb is ethoxy, Rc is hydrogen, and Rd is-OCH2CH2N(CH3)2; or
wherein Rb is ethoxy, or Ar
Figure imgf000114_0001
W and Z are each CH, Rb is -Sethyl, Rc is hydrogen, and Rd is n-pentyl; or
when
Figure imgf000114_0002
wherein
W is CH, Z is nitrogen, Rb is -SCH3, Rc is hydrogen, and Rd is n-pentyl; or
Figure imgf000114_0003
not Rc A Z X R ri a wherein
W and Z are each CH, Rb is hydrogen, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2; or
when X
Figure imgf000114_0004
wherein
W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2; or
when
Figure imgf000114_0005
wherein
W and Z are each CH, Rb is methoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2; or
when X
Figure imgf000114_0006
wherein W and Z are each CH, Rb is -OCH2C(0)OR wherein R is H or alkyl, Rc is hydrogen, and Rd is -Sethyl; or
Figure imgf000115_0001
W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2
2. The compound of claim 1, wherein the compound is
Figure imgf000115_0002
wherein,
Figure imgf000115_0003
Ra is H, halogen, or haloalkyl;
Rb is H, Ci-Ce-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C2-C6-heteroalkyl, C3-C8- heterocycloalkyl, aryl, heteroaryl, 0-(Ci-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2- C6-alkenyl), 0-(C3-C8-heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8- cycloalkyl), S-(Ci-C6-alkyl), O-(C2-C6-alkyl)-N(R10)2, 0-(C3-C8-cycloalkyl)- N(R10)2, N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, 0-(C3-C8-cylcoalkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Ce-alkyl), 0-(Ci-C6-alkyl), C(=0)NH-phenyl, wherein phenyl is
substituted with one or more halo or haloalkyl;
Rd is H, OH, Ci-Ce-alkyl, 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(C2- Ce-alkenyl), 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci- C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C2-C6- alkenyl), -N(R10)-(C3-C8-cycloalkyl), -N(R10)-(C3-C8-heterocycloalkyl), N(R10)- (C2-C6-alkyl)-N(R10)2, -(Ci-Ce-alkyl )-N(R10)2, S-(C2-C6-alkyl)-N(R10)2, OCH2C(0)0-alkyl, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl; W and Z are independently N or CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nCON(R10)-, -
(CH2)nCON(R10)(CH2)n-, -SON(R10)-, -SON(R10)(CH2)n-, -S02N(R10)-, - SO2N(R10)(CH2)n-, -N(R10)C(=O)N(R10)-, -N(R10)CO-, -N(R10)CO(CH2)n-, or - N(R10)CO(CH2)n-, -(CH2)nN(R10)-, -C=N-; or
Ar and X to ether form
Figure imgf000116_0001
Y is N or CR2;
R1 is H, halogen, 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
R2 is H, halogen, haloalkyl, -N02 or CN;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S;
R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3-
C8-heterocycloalkyl), aryl or heteroaryl; and
n is an integer from 1-3, or a pharmaceutically acceptable salt thereof;
Figure imgf000116_0002
W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2 or OH; or
W is C-OCH2CH2N(CH3)2, Z is CH, Rb is hydrogen, Rc is hydrogen, and Rd is hydrogen; or
W and Z are each CH, Rb is cyclopentyloxy, Rc is hydrogen, and Rd is - OCH2CH2N(CH3)2; or
W and Z are each CH, Rb is -OCH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-C1- phenyl), and Rd is -OCH2CH2N(CH3)2; or W is CH, Z is C-ethoxy, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen; or
W and Z are each CH, Rb is -CH2CH2CH2N(CH3)2, Rc is -C(0)NH-(3-CF3, 4-Cl- phenyl), and Rd is -CH2CH2CH2N(CH3)2 or hydrogen; or
W and Z are each CH, Rb is ethoxy, Rc is -C(0)NH-(3-CF3, 4-Cl-phenyl), and Rd is hydrogen or -OCH2CH2N(CH3)2; or
W and Z are nitrogen, Rb is ethoxy, Rc is hydrogen, and Rd is-OCH2CH2N(CH3)2; or
when
Figure imgf000117_0001
r isc , A A nr isc t ninott wherein Rb is ethoxy, or Ar
Rb is not Rc Λ Z X R d a wherein
W and Z are each CH, Rb is -Sethyl, Rc is hydrogen, and Rd is n-pentyl; or
when
Figure imgf000117_0002
wherein
W is CH, Z is nitrogen, Rb is -SCH3, Rc is hydrogen, and Rd is n-pentyl; or
when
Figure imgf000117_0003
Ar is not Rc Z Ra wherein
W and Z are each CH, Rb is hydrogen, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2; or
when
Figure imgf000117_0004
Ar is not Rc Z Ra wherein
W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is -OCH2CH2N(CH3)2; or
when
Figure imgf000117_0005
wherein W and Z are each CH, Rb is methoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2; or
Figure imgf000118_0001
W and Z are each CH, Rb is -OCH2C(0)OR wherein R is H or alkyl, Rc is hydrogen, and Rd is -Sethyl; or
Figure imgf000118_0002
W and Z are each CH, Rb is ethoxy, Rc is hydrogen, and Rd is -SCH2CH2N(CH3)2. 3. The compound of claims 1 or 2, wherein
Figure imgf000118_0003
Ra is H, halogen, or haloalkyl;
Rb is H, 0-(Ci-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8
heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), 0-(C2-C6- alkyl)-N(R10)2, O-(C3-C8-cycloalkyl)-N(R10)2, N(R10)-(C2-C6-alkyl)-N(R10)2, -(Ci- C6-alkyl)-N(R10)2, -(C C6-alkyl)-R3, 0-(C C6-alkyl)-R3, 0-(C3-C8-cycloalkyl)- R3, N(R10)-(Ci-C6-alkyl)-R3, O-aryl, or O-heteroaryl;
Rc is H, -(Ci-Ce-alkyl), or 0-(Ci-C6-alkyl);
Rd is H, OH, Ci-Ce-alkyl, 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(Ci- Ce-alkyl), -0-(C2-C6-alkenyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci- C6-alkyl)-R3, N(R10)-(Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C3-C8- cycloalkyl), -N(R10)-(C3-C8-heterocycloalkyl), -N(R10)-(C2-C6-alkenyl), N(R10)- (C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl )-N(R10)2, O-aryl, N-aryl, O-heteroaryl, or N- heteroaryl;
W and Z are CR1;
X is -CO-, -CON(R10)-, -CON(R10)(CH2)n-, -(CH2)nN(R10)-, -C=N-; or
Ar and X together form
Figure imgf000119_0001
Y is CR2;
R1 is H, halogen, 0-(Ci-C6-alkyl), O-(C2-C6-alkyl)N(R10)2;
R2 is halogen or haloalkyl;
R3 is cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S;
R10 is independently H, -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8-cycloalkyl), -(C3- Cg-heterocycloalkyl), aryl or heteroaryl; and
n is an integer from 1-3.
4. The compound of any of claims 1-3, wherein
Figure imgf000119_0002
Ra is halogen, or haloalkyl;
Rb is H, 0-(C2-C6-alkyl), 0-(C3-C8-cycloalkyl), 0-(C2-C6-alkenyl), 0-(C3-C8- heterocycloalkyl), N(R10)-(Ci-C6-alkyl), N(R10)-(C3-C8-cycloalkyl), 0-(C2-C6- alkyl)-N(R10)2, O-aryl, or O-heteroaryl;
Rc is H, or 0-(Ci-C6-alkyl);
Rd is 0-(C3-C8-cycloalkyl), 0-(C3-C8-heterocycloalkyl), 0-(Ci-C6-alkyl), -0-(C2-C6- alkenyl), O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)- (Ci-C6-alkyl)-R3, -N(R10)-(Ci-C6-alkyl), -N(R10)-(C3-C8-cycloalkyl), -N(R10)-(C3- C8-heterocycloalkyl), -N(R10)-(C2-C6-alkenyl), N(R10)-(C2-C6-alkyl)-N(R10)2, - (Ci-Ce-alkyl )-N(R10)2, O-aryl, N-aryl, O-heteroaryl, or N-heteroaryl;
W and Z are independently CR1;
X is -CO-, or -CON(R10)-; or
Ar and X together form
Figure imgf000120_0001
Y is CR2;
R1 is H, halogen, 0-(Ci-C6-alkyl), or O-(C2-C6-alkyl)N(R10)2;
R2 is halogen or haloalkyl;
R3 is C3-C8-cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S; and
R10 is independently H, -(Ci-C4-alkyl), or -(C3-C8-cycloalkyl).
The compound of any of claims 1-4, wherein
Figure imgf000120_0002
Ra is halogen, or haloalkyl;
Rb is 0-(C2-C6-alkyl), 0-(C3-C8-cycloalkyl), N(R10)-(Ci-C6-alkyl), or N(R10)-(C3-C8- cycloalkyl);
Rc is H;
Rd is O-(C2-C6-alkyl)-N(R10)2, -(Ci-C6-alkyl)-R3, 0-(Ci-C6-alkyl)-R3, N(R10)-(Ci-C6- alkyl)-R3, -N(R10)-(Ci-C6-alkyl), N(R10)-(C2-C6-alkyl)-N(R10)2, or -(Ci-C6-alkyl )-
N(R1U)2;
W and Z are each CH;
X is -CON(R10)-; or
Ar and X together form
Figure imgf000120_0003
Y is CR2;
R2 is halogen or haloalkyl; R3 is C3-C8-cycloalkylamino, optionally containing a heteroatom selected from N(R10), O and S; and
R10 is independently H, -(Ci-C4-alkyl), or -(C3-C8-cycloalkyl).
The compound of any of claims 1-5, wherein
Figure imgf000121_0001
Ra is halogen, or haloalkyl;
Rb is 0-(C2-C4-alkyl), 0-(C3-C5-cycloalkyl), N(R10)-(Ci-C4-alkyl), or N(R10)-(C3-C5- cycloalkyl);
Rc is H;
Rd is O-(C2-C4-alkyl)-N(R10)2, -(Ci-C4-alkyl)-R3, 0-(Ci-C4-alkyl)-R3, or -(Ci-C4-alkyl
)-N(R10)2;
W and Z are each CH;
X is -CON(R10)-;
Y is CR2;
R2 is halogen or haloalkyl;
R3 is C3-C8-cycloalkylamino, morpolinyl, thiomorpholinyl, or N-alkylpiperazinyl; and R10 is independently H, -(Ci-C2-alkyl).
The compound of any of claims 1-6, wherein
Figure imgf000121_0002
Ra is halogen, or haloalkyl;
Rb is 0-(C2-C4-alkyl), or 0-(C3-C5-cycloalkyl);
Rc is H; Rd is O-(C2-C4-alkyl)-N(R10)2, -(Ci-C4-alkyl)-R3, 0-(Ci-C4-alkyl)-R3, or -(Ci-C4-alkyl
)-N(R10)2;
W and Z are each CH;
X is -CON(H)-;
Y is CR2;
R2 is halogen or haloalkyl;
R3 is C3-C6-cycloalkylamino, morpolinyl, or thiomorpholinyl; and
R10 is independently H, -(C C2-alkyl).
8. The compound of any of claims 1-7, wherein
Figure imgf000122_0001
Ra is halogen, or haloalkyl;
Rb is 0-(C2-C4-alkyl);
Rc is H;
Rd is O-(C2-C4-alkyl)-N(R10)2 or -(Ci-C4-alkyl )-N(R10)2
W and Z are each CH;
X is -CON(H)-;
Y is CR2;
R2 is halogen or haloalkyl; and
R10 is independently H, -(Ci-C2-alkyl).
The compound of claims 1 or 2, wherein:
Figure imgf000122_0002
Ra is H, halogen, or haloalkyl;
X is -CON(R10)-; and
Y is C-CN. The compound of any of claims 1-8, wherein the compound
Figure imgf000123_0001
, wherein
Rb is H, or ethoxyl;
W and Z are independently CH, C-Cl, or C-OEt; and
Rc is H, ethoxyl, or methyl.
11. The compound of any of claims 1-8, wherein the compound is
Figure imgf000123_0002
12. The compound of any of claims 1-8, wherein the compound is
Figure imgf000123_0003
, wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or
-NH-CH2CH2N(CH3)2.
13. The compound of any of claims 1-8, wherein the compound is
Figure imgf000123_0004
wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or
-NH-CH2CH2N(CH3)2. The com ound of any of claims 1-8, wherein the compound is
Figure imgf000124_0001
, wherein Rb is -O-ethyl, -0-CH2CH2N(CH3)2, -NH-ethyl, or -NH-CH2CH2N(CH3)2.
The com ound of any of claims 1-8, wherein the compound is
Figure imgf000124_0002
, wherein Rd is -0-(Ci-C6)-alkyl, -NH-(Ci-C6)-alkyl,
(C2-C6)-alkenyl, -NH-(C2-C6)-alkenyl, -0-(C3-C8)-cycloalkyl, -NH-(C3-C8)- cycloalkyl, -0-(C3-C8)-heterocycloalkyl, -NH-(C3-C8)-heterocycloalkyl, -O-aryl, - N-aryl, -O-heteroaryl, -N-heteroaryl, -O-(Ci-C6)-alkyl-N(R10)2, -NH-(Ci-C6)-alkyl- N(R10)2, -0-(Ci-C6-alkyl)-R3, or -NH-(Ci-C6-alkyl)-R3.
The com ound of any of claims 1-8, wherein the compound is
Figure imgf000124_0003
, wherein Rb is -0-(d-C6)-alkyl, -0-(C3-C6)-alkyl, -0-(C2-
C6)-alkenyl, -0-(C3-Cg)-cycloalkyl, -0-(C3-C8)-heterocycloalkyl, -O-aryl, -O- heteroaryl, -O-(Ci-C6)-alkyl-N(R10)2, or -0-(Ci-C6-alkyl)-R3.
The com ound of any of claims 1-8, wherein the compound is
Figure imgf000124_0004
, wherein R1U is -(Ci-C4-alkyl), -(Ci-C4-haloalkyl), -(C3-C8- cycloalkyl), -(C3-C8-heterocycloalkyl), aryl or heteroaryl, wherein aryl or heteroaryl.
18. The com ound of any of claims 1-8, wherein the compound
Figure imgf000125_0001
The compound of any of claims 1-8, wherein the compound
Figure imgf000125_0002
20. The compound of any of claims 1-8, wherein the compound
Figure imgf000125_0003
, wherein X is CH2CONH(CH2)„, and n is
Figure imgf000125_0004
The compound of any of claims 1-8, wherein the compound
wherein X is CONH(CH2)n, and n is 0-3.
Figure imgf000125_0005
22. The compound of any of claims 1-8, wherein the compound is
23. A method for reducing amyloid beta (Αβ) protein deposits in a subject, the method comprising: a) administering to the subject an effective amount of a composition comprising a compound of any of claims 1-22 or a composition comprising a compound of any of claims 1-22, thereby decreasing Αβ protein deposits in the subject.
24. The method of claim 23, wherein the subject exhibits abnormally elevated levels of amyloid beta plaques.
25. The method of claims 23 or 24 wherein the subject is afflicted with Alzheimer's
disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy.
26. The method of any of claims 23-25, wherein the Αβ protein deposit comprises an Αβ4ο isomer, an Αβ42 isomer, or a combination thereof.
27. A method for treating Alzheimer's Disease in a subject, the method comprising
administering to a subject a therapeutic amount of a compound of any of claims 1-22 or a pharmaceutical composition comprising a compound of any of claims 1-22.
28. A method for increasing memory retention in a subject afflicted with a
neurodegenerative disease, the method comprising administering to a subject a therapeutic amount of a compound of any of claims 1-22 or a pharmaceutical composition comprising a compound of any of claims 1-22.
29. A method for increasing synaptic plasticity in a subject afflicted with a
neurodegenerative disease, the method comprising administering to a subject a therapeutic amount of a compound of any of claims 1-22 or a composition comprising a compound of any of claims 1-22 that increases histone acetylation in the subject.
30. A method for treating a neurodegenerative disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of any of claims 1-22 or a pharmaceutical composition comprising a compound of any of claims 1-22, thereby treating the neurodegenerative disease in the subject.
31. A method for decreasing inclusion bodies in a subject afflicted with a
neurodegenerative disease, the method comprising administering to the subject an effective amount of a compound of any of claims 1-22 or a composition comprising a compound of any of claims 1-22, thereby decreasing inclusion bodies in the subject.
32. A method for treating cancer in a subject, the method comprising administering to a subject a therapeutic amount of a compound of any of claims 1-22 or a
pharmaceutical composition comprising a compound of any of claims 1-22.
33. A method for ameliorating symptoms of Parkinson's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of any of claims 1-22 or a pharmaceutical composition comprising a compound of any of claims 1-22.
34. A method for treating Huntington's Disease in a subject, the method comprising administering to a subject a therapeutic amount of a compound of any of claims 1-22 or a pharmaceutical composition comprising a compound of any of claims 1-22.
35. The method of any of claims 23-34, wherein the effective amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight.
36. The method of any of claims 28-31 , wherein the neurodegenerative disease comprises Adrenoleukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia,
Neuroborreliosis, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Progressive Supranuclear Palsy, Rett's syndrome, Tau-positive
FrontoTemporal dementia, Tau-negative FrontoTemporal dementia, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease, Batten disease, Spinocerebellar ataxia, Spinal muscular atrophy, Steele-Richardson- Olszewski disease, Tabes dorsalis, or Toxic encephalopathy.
37. The method of claim 29, wherein synaptic plasticity comprises learning, memory, or a combination thereof.
38. The method of claim 29, wherein synaptic plasticity comprises long term potentiation (LTP).
39. The method of claim 32, wherein the cancer comprises B cell lymphoma, colon
cancer, lung cancer, renal cancer, bladder cancer, T cell lymphoma, myeloma, leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, hematopoietic neoplasias, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, uterine cancer, renal cell carcinoma, hepatoma, adenocarcinoma, breast cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, ovarian cancer, primary or metastatic melanoma, squamous cell carcinoma, basal cell carcinoma, brain cancer,
angiosarcoma, hemangiosarcoma, bone sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, testicular cancer, uterine cancer, cervical cancer, gastrointestinal cancer,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia, papillary adenocarcinomas, cystadenocarcinoma, bronchogenic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, lung carcinoma, epithelial carcinoma, cervical cancer, testicular tumor, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, retinoblastoma, leukemia, melanoma, neuroblastoma, small cell lung carcinoma, bladder carcinoma, lymphoma, multiple myeloma, or medullary carcinoma.
40. The method of any of claims 23-39, wherein the compound is a compound of formula (I) or any of compounds 1-27 or any combination thereof.
41. The method of any of claims 23-40, wherein the compound increases histone
acetylation.
42. The method of claim 41, wherein histone acetylation comprises acetylation of
histones H2B, H3, H4, or a combination thereof.
43. The method of claim 41, wherein histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.
44. The method of claim 31 , wherein the inclusion bodies comprise beta-amyloid
peptides, native and phosphorylated Tau proteins, native and phosphorylated alpha- synuclein, lipofuscin, cleaved TARDBP (TDB-43), or a combination thereof.
45. The method of claim 33, wherein the symptoms of Parkinson's Disease comprise tremor, bradykinesia, dyskinesia, rigidity, postural instability, dystonia, akathisia, dementia, impaired gross motor coordination, or a combination thereof.
46. The method of claim 45, wherein the postural instability comprises impaired
imbalance, impaired coordination, or a combination thereof.
PCT/US2011/066851 2010-12-22 2011-12-22 Histone acetyltransferase modulators and usese thereof WO2012088420A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2013546423A JP6616057B2 (en) 2010-12-22 2011-12-22 Histone acetyltransferase modulators and uses thereof
CN201180066968.9A CN103347392B (en) 2010-12-22 2011-12-22 Histone acetyltransferase regulator and its purposes
CA2822621A CA2822621C (en) 2010-12-22 2011-12-22 Histone acetyltransferase modulators and uses thereof
EP11850544.5A EP2654428B1 (en) 2010-12-22 2011-12-22 Histone acetyltransferase modulators and usese thereof
US13/996,483 US9969677B2 (en) 2010-12-22 2011-12-22 Histone acetyltransferase modulators and uses thereof
EP17207865.1A EP3323813B1 (en) 2010-12-22 2011-12-22 Histone acetyltransferase modulators and uses thereof
US15/968,524 US20180244603A1 (en) 2010-12-22 2018-05-01 Histone acetyltransferase modulators and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201061426033P 2010-12-22 2010-12-22
US61/426,033 2010-12-22
US201161539697P 2011-09-27 2011-09-27
US61/539,697 2011-09-27
US201161541706P 2011-09-30 2011-09-30
US61/541,706 2011-09-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/996,483 A-371-Of-International US9969677B2 (en) 2010-12-22 2011-12-22 Histone acetyltransferase modulators and uses thereof
US15/968,524 Division US20180244603A1 (en) 2010-12-22 2018-05-01 Histone acetyltransferase modulators and uses thereof

Publications (1)

Publication Number Publication Date
WO2012088420A1 true WO2012088420A1 (en) 2012-06-28

Family

ID=46314479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/066851 WO2012088420A1 (en) 2010-12-22 2011-12-22 Histone acetyltransferase modulators and usese thereof

Country Status (7)

Country Link
US (2) US9969677B2 (en)
EP (2) EP3323813B1 (en)
JP (2) JP6616057B2 (en)
CN (2) CN103347392B (en)
CA (1) CA2822621C (en)
ES (1) ES2820863T3 (en)
WO (1) WO2012088420A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116663A1 (en) 2012-02-01 2013-08-08 The Trustees Of Columbia University In The City Of New York Novel cysteine protease inhibitors and uses thereof
WO2014145485A2 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Map kinase modulators and uses thereof
WO2015009930A2 (en) 2013-07-17 2015-01-22 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2015153410A1 (en) * 2014-03-31 2015-10-08 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
JP2016514154A (en) * 2013-03-14 2016-05-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Mitochondrial aldehyde dehydrogenase-2 modulator and method of use thereof
KR101755530B1 (en) 2016-02-02 2017-07-10 한남대학교 산학협력단 A Marker for Detecting a Neuro-Degenerative Disease and a Method for Detecting the Neuro-Degenerative Disease by Using the Same
WO2018017858A1 (en) 2016-07-20 2018-01-25 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
EP3323813B1 (en) * 2010-12-22 2020-08-26 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and uses thereof
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
EP3920897A4 (en) * 2019-02-08 2022-11-16 The Trustees of Columbia University in the City of New York Histone acetyltransferase (hat) regulators and uses thereof
EP3920900A4 (en) * 2019-02-08 2022-11-16 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and compositions and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
CN108358894B (en) * 2018-04-26 2021-05-07 四川大学 Compound for inhibiting histone acetyltransferase as well as preparation method and application thereof
CN108957004B (en) * 2018-07-09 2021-10-19 东南大学 Application of reagent for detecting expression levels of H3K9me2 and H3K36me3 in preparation of gastric cancer prognosis evaluation kit
CN111249276B (en) * 2020-03-05 2021-07-13 南京巴傲得生物科技有限公司 Application of indoprofen in preparation of CBP (cubic boron phosphate) bromine region inhibition reagent

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004053140A2 (en) 2002-12-12 2004-06-24 Jawaharlal Nehru Centre For Advanced Scientific Research Modulators (inhibitors/activators) of histone acetyltransferases
WO2005121119A1 (en) 2004-06-14 2005-12-22 F. Hoffmann-La Roche Ag Hydroxamates, their manufacture and use as pharmaceutical agents
US20060167107A1 (en) 2002-12-12 2006-07-27 Kundu Tapas K Modulators (inhibitors/ activators) of histone acetyltransferases
WO2009115707A2 (en) 2008-03-07 2009-09-24 Catalys Sas Preparation of hydroquinone amide compounds with antioxidant properties.
US20100144885A1 (en) 2006-09-29 2010-06-10 The Board Of Trustees Of The University Of Illinois Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
US20100166781A1 (en) 2007-01-19 2010-07-01 Tapimmune, Inc. Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
WO2011072243A1 (en) 2009-12-10 2011-06-16 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB728098A (en) 1952-03-05 1955-04-13 Geigy Ag J R Improvements relating to salicylanilides and their use
BE639158A (en) 1961-12-05
US4118332A (en) 1965-10-22 1978-10-03 Colgate-Palmolive Company Synergistic antibacterial composition containing mixtures of certain halogenated diphenyl ethers and trichlorocarbanilides
US3497508A (en) 1966-09-22 1970-02-24 Sandoz Ag Alpha-(2-(morpholinomethyl)phenyl) benzyl alcohols
DE1642224B2 (en) 1967-04-28 1976-04-29 Basf Ag, 6700 Ludwigshafen USE OF SUBSTITUTED BENZOIC ANILIDES FOR CONTROL OF FUNGI FROM THE CLASS OF BASIDIOMYCETS
US3591684A (en) 1968-05-29 1971-07-06 Monsanto Co Controlling southern armyworm with 3-iodo-3',4',5-trichlorosalicylanilide
US3671630A (en) * 1970-08-17 1972-06-20 Lever Brothers Ltd Halogenated phenolic germicidal compositions containing terpene color stabilizers
US4088770A (en) 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
JPS5541202Y2 (en) 1971-10-07 1980-09-26
CH609558A5 (en) 1973-09-18 1979-03-15 Givaudan & Cie Sa Antibacterial composition
JPS5920686B2 (en) * 1975-01-11 1984-05-15 日立電線株式会社 Method for producing flame retardant resin
JPS55129256A (en) 1979-02-28 1980-10-06 Isao Ozawa Antifungal compound
JPS5687501A (en) 1979-12-19 1981-07-16 Nissan Chem Ind Ltd Agricultural and horticultural germicide containing salicylic acid anilide as active constituent
JPS5687502A (en) 1979-12-19 1981-07-16 Nissan Chem Ind Ltd Agricultural and horticultural germicide of salicylic acid anilide
ATE168416T1 (en) 1989-10-05 1998-08-15 Optein Inc CELL-FREE SYNTHESIS AND ISOLATION OF GENES AND POLYPEPTIDES
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
GB9015658D0 (en) * 1990-07-17 1990-09-05 Shell Int Research Herbicidal compounds
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5565325A (en) 1992-10-30 1996-10-15 Bristol-Myers Squibb Company Iterative methods for screening peptide libraries
JPH09507487A (en) 1994-01-05 1997-07-29 アーキュール，インコーポレーテッド Systematic modular production of amine-imide and oxazolone-based molecules with selected properties
DE4428380A1 (en) * 1994-08-11 1996-02-15 Bayer Ag 4-trifluoromethylbenzamide
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5814646A (en) * 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
AU2962297A (en) 1996-05-24 1998-01-05 Neurosearch A/S Phenyl derivatives useful as blockers of chloride channels
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU3665199A (en) * 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
PL215901B1 (en) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
EE200100708A (en) * 1999-06-25 2003-02-17 The Institutes For Pharmaceutical Discovery, Llc Substituted phenoxyacetic acids
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6369030B1 (en) * 1999-11-29 2002-04-09 The Rockfeller University Inhibitors of histone acetyltransferases (HATs) and uses thereof
US20020042394A1 (en) * 2000-05-31 2002-04-11 Hogenkamp Henricus P.C. Cobalamin compounds useful as antibiotic agents and as imaging agents
JP4083422B2 (en) * 2000-12-22 2008-04-30 石原産業株式会社 Aniline derivatives or salts thereof, and cytokine production inhibitors containing them
US20050227915A1 (en) 2001-05-02 2005-10-13 Steffan Joan S Methods and reagents for treating neurodegenerative diseases and motor deficit disorders
WO2003103658A1 (en) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 Immunity-related protein kinase inhibitors
EP1535610A4 (en) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc Therapeutic agent for cancer
TWI280127B (en) * 2002-06-11 2007-05-01 Inst Med Molecular Design Inc Remedies for neurodegenerative diseases
EP1542699A4 (en) * 2002-07-15 2009-03-25 Myriad Genetics Inc Compounds, compositions, and methods employing same
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
AU2003275939A1 (en) * 2002-11-08 2004-06-07 Novo Nordisk A/S Safe chemical uncouplers for the treatment of obesity
AU2003289222A1 (en) 2002-12-06 2004-06-30 Toray Industries, Inc. Benzomorpholine derivatives
US7884189B2 (en) 2003-01-10 2011-02-08 The Trustees Of Columbia University In The City Of New York Carboxyltransferase domain of acetyl-CoA carboxylase
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
CA2532313A1 (en) 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. Medicament for treatment of dermal pigmentation
TW200538120A (en) * 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
WO2006132583A1 (en) 2005-06-07 2006-12-14 Innate Pharmaceuticals Ab Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
WO2007101710A1 (en) 2006-03-09 2007-09-13 Cenix Bioscience Gmbh Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
KR20100039429A (en) * 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 The use of benzamide derivatives for the treatment of cns disorders
US9034387B2 (en) 2007-10-03 2015-05-19 Jawaharlal Nehru Centre For Advanced Scientific Research Intrinsically fluorescent carbon nanospheres and a process thereof
US20100311616A1 (en) 2007-10-26 2010-12-09 Tomoyuki Ozawa Reaction chip and method of manufacturing the same
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926463B1 (en) * 2008-01-22 2010-08-13 Centre Nat Rech Scient USE OF AMINOPEPTIDASE INHIBITORS OR AZAINDOLE COMPOUNDS FOR PREVENTING OR TREATING CANCER METASTASES OF EPITHELIAL ORIGIN
RU2370484C1 (en) 2008-04-02 2009-10-20 Государственное образовательное учреждение высшего профессионального образования САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ ХИМИКО-ФАРМАЦЕВТИЧЕСКАЯ АКАДЕМИЯ (ГОУ ВПО СПХФА Росздрава) Vermicide medication based on n-(3-chloro-4-methylphenyl)-3,5-dibromosalicylamide
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
US20110081403A1 (en) 2009-10-01 2011-04-07 Gradalis, Inc. Histone octamers for increased nucleic acid transfer
CN101698651A (en) 2009-10-23 2010-04-28 南京大学中国医药城研发中心 Salicylanilide derivatives, preparation method thereof and application thereof
US10640457B2 (en) * 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US9969677B2 (en) * 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
JP5541202B2 (en) 2011-03-16 2014-07-09 コニカミノルタ株式会社 Spreadsheet data generation apparatus and program

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004053140A2 (en) 2002-12-12 2004-06-24 Jawaharlal Nehru Centre For Advanced Scientific Research Modulators (inhibitors/activators) of histone acetyltransferases
US20060167107A1 (en) 2002-12-12 2006-07-27 Kundu Tapas K Modulators (inhibitors/ activators) of histone acetyltransferases
US20090076155A1 (en) 2002-12-12 2009-03-19 Tapas Kumar Kundu Modulators (inhibitors/activators) of histone acetyltransferases
WO2005121119A1 (en) 2004-06-14 2005-12-22 F. Hoffmann-La Roche Ag Hydroxamates, their manufacture and use as pharmaceutical agents
US20100144885A1 (en) 2006-09-29 2010-06-10 The Board Of Trustees Of The University Of Illinois Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
US20100166781A1 (en) 2007-01-19 2010-07-01 Tapimmune, Inc. Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
WO2009115707A2 (en) 2008-03-07 2009-09-24 Catalys Sas Preparation of hydroquinone amide compounds with antioxidant properties.
WO2011072243A1 (en) 2009-12-10 2011-06-16 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof

Non-Patent Citations (162)

* Cited by examiner, † Cited by third party
Title
"Biochemistry", 2008, VANDERBILT: NASHVILLE, pages: 167
ABEL; ZUKIN, CURRENT OPINION IN PHARMACOLOGY, vol. 8, 2008, pages 57 - 64
ANGEW CHERN INT ED ENGL, vol. 44, no. 21, 2005, pages 3186 - 216
ANN NEUROL, vol. 55, no. 6, 2004, pages 801 - 14
ANN NEUROL,, vol. 55, no. 6, 2004, pages 801 - 14
BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, no. 1, January 1977 (1977-01-01), pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104
BIOCHEM BIOPHYS RES COMMUN, vol. 205, no. 3, 1994, pages 1829 - 35
BIOCHEM J, vol. 356, 2001, pages 1 - 10
BIOCHEM J, vol. 370, 2003, pages 737 - 49
BIOCHIM BIOPHYS ACTA, vol. 1789, no. 1, 2009, pages 58 - 68
BIOESSAYS, vol. 27, no. 2, 2005, pages 164 - 75
BIOSCI REP, vol. 21, no. 5, 2001, pages 565 - 611
BOLDEN ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 5, 2006, pages 769 - 84
BR J PHARMACOL,, vol. 137, no. 5, 2002, pages 676 - 82
BRAIN RES, vol. 840, no. 1-2, 1999, pages 23 - 35
BRAIN RES, vol. 920, no. 1-2, 2001, pages 32 - 40
CELL, vol. 126, no. 4, 2006, pages 775 - 88
CELL, vol. 79, no. 1, 1994, pages 49 - 58
CELL, vol. 79, no. 1, 1994, pages 59 - 68
CELL, vol. 98, no. 3, 1999, pages 285 - 94
CHEMBIOCHEM., vol. 11, no. 6, pages 818 - 27
CLEMENTS ET AL.: "Crystal structure of the histone acetyltransferase domain of the human PCAF transcriptional regulator bound to coenzyme A", THE EMBO JOURNAL, vol. 18, 1999, pages 3521 - 3532, XP055068959 *
CURR ALZHEIMER RES, vol. 2, no. 2, 2005, pages 171 - 82
CURR BIOL,, vol. 14, no. 14, 2004, pages R546 - 5
CURR DRUG TARGETS CNS NEUROL DISORD, vol. 4, no. 1, 2005, pages 41 - 50
CURR MED CHEM, vol. 10, no. 20, 2003, pages 2147 - 74
EMBO J, vol. 22, no. 24, 2003, pages 6537 - 49
EMBO J, vol. 26, no. 13, 2007, pages 3169 - 79
EMBORG, JOURNAL OF NEUROSCIENCE METHODS, vol. 139, 2004, pages 121 - 143
EUR J PHARMACOL, vol. 284, no. 3, 1995, pages Rl-3
EUR J PHARMACOL, vol. 382, no. 3, 1999, pages 167 - 75
EUR JPHARMACOL, vol. 382, 1999, pages 167 - 75
EUR. J. ORG. CHEM., 2008, pages 655 - 672
EXP GERONTOL, vol. 32, no. 4-5, 1997, pages 431 - 40
FASEB J, vol. 15, no. 8, 2001, pages 1407 - 9
FASEB J, vol. 16, no. 14, 2002, pages 1970 - 2
FLEMING ET AL., THE JOURNAL OF NEUROSCIENCE, vol. 24, no. 42, 2004, pages 9434 - 9440
H., B.A.; ZIPURSKY LS.; MATSUDAIRA P.; BALTIMORE D.; DARNELL J.: "Molecular Cell Biology. 4 ed.", 2000, W. H. FREEMAN AND COMPANY
HISTOL HISTOPATHOL, vol. 10, no. 2, 1995, pages 509 - 19
HODGSON ET AL., NEURON, vol. 23, May 1999 (1999-05-01), pages 181 - 192
HWANG ET AL., THE JOURNAL OF NEUROSCIENCE, vol. 25, no. 8, 2005, pages 2132 - 2137
J ALZHEIMERS DIS, vol. 18, no. 1, 2009, pages 131 - 9
J CLIN INVEST, vol. 114, no. 11, 2004, pages 1624 - 34
J IMMUNOL, vol. 171, no. 5, 2003, pages 2216 - 24
J MO I BIOL,, vol. 338, no. 1, 2004, pages 17 - 31
J NEUROPHYSIOL, vol. 85, no. 2, 2001, pages 708 - 13
J NEUROSCI RES, vol. 60, 2000, pages 65 - 72
J NEUROSCI, vol. 20, no. 4, 2000, pages 1386 - 92
J NEUROSCI, vol. 21, no. 12, 2001, pages 4125 - 33
J NEUROSCI, vol. 21, no. 15, 2001, pages 5703 - 14
J NEUROSCI, vol. 21, no. 4, 2001, pages 1327 - 33
J NEUROSCI, vol. 28, no. 53, 2008, pages 14537 - 45
J NEUROSCI,, vol. 25, no. 29, 2005, pages 6887 - 97
J PHARMACOL TOXICOL METHODS, vol. 31, no. 4, 1994, pages 177 - 86
J VIROL, vol. 77, no. 21, 2003, pages 11425 - 35
J VIROL,, vol. 75, no. 4, 2001, pages 1909 - 17
J. CLIN. INVEST., vol. 114, 2004, pages 1624 - 1634
J. ORG. CHEM., vol. 42, 1977, pages 2082 - 2087
J. ORG. CHEM., vol. 71, 2006, pages 4992 - 4995
J. PHYS. CHEM B, vol. 111, no. 17, 2007, pages 4527 - 4534
JALZHEIMERS DIS, vol. 18, no. 1, 2009, pages 131 - 9
JBIOCHEM, vol. 138, no. 6, 2005, pages 647 - 62
JBIOCHEM., vol. 138, no. 6, 2005, pages 647 - 662
JBIOL CHEM, vol. 274, no. 10, 1999, pages 6483 - 92
JBIOL CHEM, vol. 277, no. 25, 2002, pages 22768 - 80
JBIOL CHEM, vol. 278, no. 21, 2003, pages 19134 - 40
JBIOL CHEM, vol. 279, no. 39, 2004, pages 40545 - 59
JBIOL CHERN, vol. 279, no. 39, 2004, pages 40545 - 59
JMOL NEUROSCI, vol. 19, no. 1-2, 2002, pages 135 - 41
JNEUROCHEM, vol. 73, no. 2, 1999, pages 532 - 7
JNEUROSCI RES, vol. 60, no. 1, 2000, pages 65 - 72
JNEUROSCI, vol. 20, no. 4, 2000, pages 1386 - 92
JNEUROSCI, vol. 21, no. 13, 2001, pages 4691 - 8
JNEUROSCI, vol. 22, no. 9, 2002, pages 3484 - 92
JNEUROSCI, vol. 24, no. 27, 2004, pages 6049 - 56
JNEUROSCI, vol. 25, 2005, pages 6887 - 6897
JNEUROSCI, vol. 25, 2005, pages 6887 - 97
JNEUROSCI, vol. 25, no. 10, 2005, pages 2455 - 62
JNEUROSCI, vol. 25, no. 29, 2005, pages 6887 - 97
JNEUROSCI, vol. 28, no. 53, 2008, pages 14537 - 45
JPHYS CHEM B, vol. 111, no. 17, 2007, pages 4527 - 34
K. MANTELINGU ET AL., J. PHYS. CHEM. B, vol. 111, no. 17, 2007, pages 4527 - 4534
LANE, PSYCHOPHARMACOLOGY, vol. 199, 2008, pages 303 - 312
LANE; CHABNER, J CLIN ONCOL., vol. 27, no. 32, 2009, pages 5459 - 68
LEE; WORKMAN, NAT REV MOL CELL BIOL, vol. 8, 2007, pages 284 - 295
LEE; WORKMAN, NAT REV MOL CELL BIOL., vol. 8, no. 4, 2007, pages 284 - 95
LEVENSON ET AL., JBIOL CHEM, vol. 279, no. 39, 2004, pages 40545 - 59
MARMORSTEIN, JMOLEC BIOL., vol. 311, 2001, pages 433 - 444
MARMORSTEIN; ROTH, CURR OPIN IN GENET AND DEVELOP., vol. 11, 2001, pages 155 - 161
MED HYPOTHESES, vol. 51, no. 6, 1998, pages 465 - 76
MED RES REV, vol. 21, no. 5, 2001, pages 412 - 49
MEREDITH ET AL., ACTA NEUROPATHOL, vol. 115, 2008, pages 385 - 398
NAT BIOTECHNOL, vol. 19, no. 8, 2001, pages 722 - 6
NAT NEUROSCI, vol. 2, no. 3, 1999, pages 271 - 6
NAT NEUROSCI, vol. 8, 2005, pages 79 - 84
NAT NEUROSCI, vol. 8, no. 1, 2005, pages 79 - 84
NAT PROTOC, vol. 1, no. 4, 2006, pages 1671 - 9
NAT REV NEUROSCI, vol. 6, no. 2, 2005, pages 108 - 18
NAT REV NEUROSCI,, vol. 6, no. 2, 2005, pages 108 - 18
NATURE, vol. 325, 1987, pages 733 - 6
NATURE, vol. 345, no. 6277, 1990, pages 718 - 21
NATURE, vol. 375, 1995, pages 754 - 60
NATURE, vol. 375, no. 6534, 1995, pages 754 - 60
NATURE, vol. 383, no. 6602, 1996, pages 710 - 3
NATURE, vol. 387, no. 6632, 1997, pages 500 - 5
NATURE, vol. 400, no. 6740, 1999, pages 173 - 7
NATURE, vol. 403, no. 6765, 2000, pages 41 - 5
NATURE, vol. 409, no. 6822, 2001, pages 860 - 921
NATURE, vol. 416, 2002, pages 535 - 9
NATURE, vol. 416, no. 6880, 2002, pages 535 - 9
NATURE, vol. 447, no. 7141, 2007, pages 178 - 82
NATURE, vol. 459, 7 May 2009 (2009-05-07), pages 55 - 60
NATURE, vol. 459, no. 7243, 2009, pages 55 - 60
NEUROBIOL AGING, vol. 24, no. 3, 2003, pages 437 - 51
NEUROBIOL DIS, vol. 11, no. 3, 2002, pages 394 - 409
NEUROCHEM RES, vol. 28, no. 7, 2003, pages 1009 - 15
NEURON, vol. 42, 2004, pages 961 - 72
NEURON, vol. 42, no. 1, 2004, pages 129 - 41
NEURON, vol. 42, no. 1, 2004, pages 23 - 36
NEURON, vol. 42, no. 6, 2004, pages 947 - 59
NEURON, vol. 42, no. 6, 2004, pages 961 - 72
NEUROREPORT, vol. 17, no. 9, 2006, pages 917 - 21
NEUROREPORT, vol. 8, 1997, pages 3213 - 7
NEUROREPORT, vol. 8, no. 15, 1997, pages 3213 - 7
NEUROSCI LETT, vol. 260, 1999, pages 121 - 4
NEUROSCI LETT, vol. 322, no. 2, 2002, pages 121 - 5
NEUROSCI LETT, vol. 413, no. 2, 2007, pages 137 - 40
NEUROSCIENCE, vol. 147, no. 1, 2007, pages 28 - 36
NEUROSCIENCE, vol. 194, 2011, pages 272 - 281
NEUROSCIENCE, vol. 99, no. 4, 2000, pages 737 - 50
ONCOGENE, vol. 26, no. 37, 2007, pages 5310 - 8
ORG. PROC. RES. & DEV, vol. 13, 2009, pages 1407 - 1412
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 13, 2009, pages 1407 - 1412
PHILOS TRANS R SOC LOND B BIOL SCI, vol. 358, no. 1432, 2003, pages 757 - 63
PLOS ONE, vol. 4, no. 8, 2009, pages e6612
PROC NATL ACAD SCI US A, vol. 100, no. 4, 2003, pages 2041 - 6
PROC NATL ACAD SCI US A, vol. 96, no. 6, 1999, pages 3228 - 33
PROC NATL ACAD SCI USA, vol. 103, 2006, pages 8852 - 7
PROC NATL ACAD SCI USA, vol. 103, no. 23, 2006, pages 8852 - 7
PROC NATL ACAD SCI USA, vol. 103, no. 34, 2006, pages 12867 - 72
PROC NATL ACAD SCI USA, vol. 95, 1998, pages 6448 - 53
PROC NATL ACAD SCI USA, vol. 95, no. 11, 1998, pages 6448 - 53
PROC NATL ACAD SCI USA, vol. 99, 2002, pages 13217 - 21
PROC NATL ACAD SCI USA, vol. 99, no. 20, 2002, pages 13217 - 21
PROC NATL ACADSCI USA, vol. 99, no. 20, 2002, pages 13217 - 21
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 103, 2006, pages 12867 - 12872
PROG NEUROBIOL, vol. 60, 2000, pages 363 - 84
PUZZO ET AL., SOC NEUROSCI. ABSTR., 2006
PUZZO, D. ET AL.: "Sildenafil rescues synaptic and cognitive impairment in a mouse model of Alzheimer's disease", SOC NEUROSCI. ABSTR, 2006
SCIENCE, vol. 220, no. 4592, 1983, pages 91 - 3
SCIENCE, vol. 234, no. 4781, 1986, pages 1249 - 54
SCIENCE, vol. 269, 1995, pages 970 - 3
SCIENCE, vol. 269, no. 5226, 1995, pages 970 - 3
SCIENCE, vol. 274, no. 5284, 1996, pages 99 - 102
SCIENCE, vol. 298, 2002, pages 789 - 791
SCIENCE, vol. 298, no. 5594, 2002, pages 789 - 91
SCIENCE, vol. 328, no. 5979, 2010, pages 701 - 702
See also references of EP2654428A4
SYNTHETIC COMMUNICATIONS, vol. 40, 2010, pages 666 - 676
TETRAHEDRON LETTERS, vol. 51, 2010, pages 495 - 498
TRENDS BIOCHEM SCI, vol. 25, no. 3, 2000, pages 121 - 6
XENOBIOTICA, vol. 15, no. 12, 1985, pages 1111 - 9

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323813B1 (en) * 2010-12-22 2020-08-26 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and uses thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US10647709B2 (en) 2012-02-01 2020-05-12 The Trustees Of Columbia University In The City Of New York Cysteine protease inhibitors and uses thereof
WO2013116663A1 (en) 2012-02-01 2013-08-08 The Trustees Of Columbia University In The City Of New York Novel cysteine protease inhibitors and uses thereof
US10227304B2 (en) 2013-03-14 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
JP2016514154A (en) * 2013-03-14 2016-05-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Mitochondrial aldehyde dehydrogenase-2 modulator and method of use thereof
EP3521284A1 (en) 2013-03-15 2019-08-07 The Trustees of Columbia University in the City of New York Pyrazine compounds as map kinase modulators and uses thereof
US10428047B2 (en) 2013-03-15 2019-10-01 The Trustees Of Columbia University In The City Of New York MAP kinase modulators and uses thereof
US11566016B2 (en) 2013-03-15 2023-01-31 The Trustees Of Columbia University In The City Of New York MAP kinase modulators and uses thereof
US11149020B2 (en) 2013-03-15 2021-10-19 The Trustees Of Columbia University In The City Of New York MAP kinase modulators and uses thereof
WO2014145485A2 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Map kinase modulators and uses thereof
US9783525B2 (en) 2013-03-15 2017-10-10 The Trustees Of Columbia University In The City Of New York Map kinase modulators and uses thereof
WO2015009930A2 (en) 2013-07-17 2015-01-22 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
EP3126332A4 (en) * 2014-03-31 2017-09-06 The Trustees of Columbia University in the City of New York Histone acetyltransferase activators and uses thereof
AU2015241177B2 (en) * 2014-03-31 2019-09-26 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
WO2015153410A1 (en) * 2014-03-31 2015-10-08 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP3398937A1 (en) 2014-03-31 2018-11-07 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US11191768B2 (en) 2014-03-31 2021-12-07 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
KR101755530B1 (en) 2016-02-02 2017-07-10 한남대학교 산학협력단 A Marker for Detecting a Neuro-Degenerative Disease and a Method for Detecting the Neuro-Degenerative Disease by Using the Same
US10653648B2 (en) 2016-07-20 2020-05-19 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof
IL264310A (en) * 2016-07-20 2019-02-28 Univ Columbia Histone acetyltransferase activators and compositions and uses thereof
US11406608B2 (en) 2016-07-20 2022-08-09 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof
WO2018017858A1 (en) 2016-07-20 2018-01-25 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and compositions and uses thereof
EP3920897A4 (en) * 2019-02-08 2022-11-16 The Trustees of Columbia University in the City of New York Histone acetyltransferase (hat) regulators and uses thereof
EP3920900A4 (en) * 2019-02-08 2022-11-16 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and compositions and uses thereof

Also Published As

Publication number Publication date
CN103347392A (en) 2013-10-09
JP2017193578A (en) 2017-10-26
US20170121276A1 (en) 2017-05-04
CA2822621C (en) 2020-12-15
CA2822621A1 (en) 2012-06-28
US9969677B2 (en) 2018-05-15
US20180244603A1 (en) 2018-08-30
JP2014501763A (en) 2014-01-23
EP3323813A1 (en) 2018-05-23
EP3323813B1 (en) 2020-08-26
ES2820863T3 (en) 2021-04-22
CN106432137A (en) 2017-02-22
EP2654428A4 (en) 2014-08-27
JP6616057B2 (en) 2019-12-04
EP2654428B1 (en) 2018-02-14
CN103347392B (en) 2016-10-12
EP2654428A1 (en) 2013-10-30
CN106432137B (en) 2020-11-06
JP6629797B2 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
EP3323813B1 (en) Histone acetyltransferase modulators and uses thereof
US11406608B2 (en) Histone acetyltransferase activators and compositions and uses thereof
US11034647B2 (en) Histone acetyltransferase activators and uses thereof
US11191768B2 (en) Histone acetyltransferase activators and uses thereof
EP2509590B1 (en) Histone acetyltransferase activators and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11850544

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2822621

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013546423

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13996483

Country of ref document: US